ZEEVESTROVZEEV ESTROV8622ESTROV, ZEEVProfessorprns:coAuthorOfcoauthor ofFaculty Rankprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:positionInDivisionposition in divisionprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:similarTosimilar toprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierAddressvivo:address1address line 1vivo:addressCitycityvivo:addressPostalCodepostal codevivo:addressStatestate or provincevivo:authorInAuthorshipselected publicationsvivo:authorRankauthor rank in publicationAuthorshipDepartmentDivisionvivo:hasResearchArearesearch areasvivo:hrJobTitleHR job titleInformation Resourcevivo:linkedAuthorlinked authorvivo:linkedInformationResourcelinked information resourcevivo:mailingAddressmailing addressvivo:personInPositionpositionsPositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlerdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPerson1400 Holcombe BlvdHouston77030-4008TXAuthorship 1633941Authorship 1642251Authorship 1644531Authorship 1645382Authorship 1654844Authorship 1655475Authorship 1656482Authorship 1656751Authorship 1657192Authorship 1657541Authorship 1657782Authorship 1659001Authorship 1660036Authorship 1660332Authorship 1661601Authorship 1664905Authorship 1672542Authorship 1673831Authorship 1674207Authorship 1675686Authorship 1678871Authorship 1679765Authorship 1680201Authorship 1681059Authorship 1681818Authorship 1682652Authorship 1684831Authorship 1686832Authorship 1687563Authorship 1688633Authorship 1693008Authorship 1694865Authorship 170323Authorship 1706003Authorship 1720066Authorship 1722743Authorship 1724052Authorship 1732003Authorship 1733913Authorship 1738153Authorship 1742045Authorship 1744296Authorship 1755882Authorship 1758325Authorship 1772973Authorship 17909311Authorship 1793036Authorship 1794474Authorship 1797426Authorship 1798788Authorship 18095212Authorship 1810939Authorship 1812154Authorship 1820569Authorship 1824753Authorship 1827525Authorship 1832814Authorship 1839292Authorship 1841605Authorship 18417510Authorship 1842272Authorship 1846039Authorship 1870595Authorship 1871722Authorship 1875416Authorship 18799715Authorship 1882566Authorship 1882856Authorship 1891572Authorship 1899924Authorship 1900033Authorship 19036211Authorship 19077815Authorship 1921899Authorship 19310017Authorship 19315413Authorship 19366510Authorship 19579141311195Freedman MH, Cohen A, Grunberger T, Bunin N, Luddy RE, Saunders EF, Shahidi N, Lau A, Estrov ZBritish journal of haematologyCentral role of tumour necrosis factor, GM-CSF, and interleukin 1 in the pathogenesis of juvenile chronic myelogenous leukaemia. Br J Haematol. 1992 Jan; 80(1):40-8.Br J Haematol1992-01-01T00:00:001992Central role of tumour necrosis factor, GM-CSF, and interleukin 1 in the pathogenesis of juvenile chronic myelogenous leukaemia.2020193Estrov Z, Talpaz M, Chou TC, Kurzrock R, Blake M, Gutterman JULeukemiaSynergistic antiproliferative effect of interferon alpha and azidothymidine in chronic myelogenous leukemia. Leukemia. 1991 Feb; 5(2):101-7.Leukemia1991-02-01T00:00:001991Synergistic antiproliferative effect of interferon alpha and azidothymidine in chronic myelogenous leukemia.3052147Freedman MH, Estrov Z, Chan HSThe American journal of pediatric hematology/oncologyJuvenile chronic myelogenous leukemia. Am J Pediatr Hematol Oncol. 1988; 10(3):261-7.Am J Pediatr Hematol Oncol1988-01-01T00:00:001988Juvenile chronic myelogenous leukemia.3488505Estrov Z, Grunberger T, Dub? ID, Wang YP, Freedman MHThe New England journal of medicineDetection of residual acute lymphoblastic leukemia cells in cultures of bone marrow obtained during remission. N Engl J Med. 1986 Aug 28; 315(9):538-42.N Engl J Med1986-08-28T00:00:001986Detection of residual acute lymphoblastic leukemia cells in cultures of bone marrow obtained during remission.3493042Estrov Z, Tawa A, Wang XH, Dub? ID, Sulh H, Cohen A, Gelfand EW, Freedman MHBloodIn vitro and in vivo effects of deferoxamine in neonatal acute leukemia. Blood. 1987 Mar; 69(3):757-61.Blood1987-03-01T00:00:001987In vitro and in vivo effects of deferoxamine in neonatal acute leukemia.6404700Estrov Z, Berrebi A, Hazani E, Resnitzky PHaematologicaPleural effusion and ascites as presenting signs of IgA myeloma. Haematologica. 1983 Jan-Feb; 68(1):104-9.Haematologica1983-01-01T00:00:001983Pleural effusion and ascites as presenting signs of IgA myeloma.7506581Ferrajoli A, Zipf TF, Talpaz M, Felix EA, Estrov ZAnnals of hematologyGrowth factors controlling interleukin-4 action on hematopoietic progenitors. Ann Hematol. 1993 Dec; 67(6):277-84.Ann Hematol1993-12-01T00:00:001993Growth factors controlling interleukin-4 action on hematopoietic progenitors.7769852Attias D, Grunberger T, Vanek W, Estrov Z, Cohen A, Lau R, Freedman MHLeukemiaB-lineage lymphoid blast crisis in juvenile chronic myelogenous leukemia: II. Interleukin-1-mediated autocrine growth regulation of the lymphoblasts. Leukemia. 1995 May; 9(5):884-8.Leukemia1995-05-01T00:00:001995B-lineage lymphoid blast crisis in juvenile chronic myelogenous leukemia: II. Interleukin-1-mediated autocrine growth regulation of the lymphoblasts.8374694Zadik Z, Estrov Z, Karov Y, Hahn T, Barak YThe Journal of pediatric endocrinologyThe effect of growth hormone and IGF-I on clonogenic growth of hematopoietic cells in leukemic patients during active disease and during remission--a preliminary report. J Pediatr Endocrinol. 1993 Jan-Mar; 6(1):79-83.J Pediatr Endocrinol1993-01-01T00:00:001993The effect of growth hormone and IGF-I on clonogenic growth of hematopoietic cells in leukemic patients during active disease and during remission--a preliminary report.8564713Estrov Z, Samal B, Lapushin R, Kellokumpu-Lehtinen P, Sahin AA, Kurzrock R, Talpaz M, Aggarwal BBJournal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine ResearchLeukemia inhibitory factor binds to human breast cancer cells and stimulates their proliferation. J Interferon Cytokine Res. 1995 Oct; 15(10):905-13.J Interferon Cytokine Res1995-10-01T00:00:001995Leukemia inhibitory factor binds to human breast cancer cells and stimulates their proliferation.8635867Kellokumpu-Lehtinen P, Talpaz M, Harris D, Van Q, Kurzrock R, Estrov ZInternational journal of cancerLeukemia-inhibitory factor stimulates breast, kidney and prostate cancer cell proliferation by paracrine and autocrine pathways. Int J Cancer. 1996 May 16; 66(4):515-9.Int J Cancer1996-05-16T00:00:001996Leukemia-inhibitory factor stimulates breast, kidney and prostate cancer cell proliferation by paracrine and autocrine pathways.9669839Estrov Z, Talpaz M, Ku S, Harris D, Van Q, Beran M, Hirsch-Ginsberg C, Huh Y, Yee G, Kurzrock RLeukemia researchZ-138: a new mature B-cell acute lymphoblastic leukemia cell line from a patient with transformed chronic lymphocytic leukemia. Leuk Res. 1998 Apr; 22(4):341-53.Leuk Res1998-04-01T00:00:001998Z-138: a new mature B-cell acute lymphoblastic leukemia cell line from a patient with transformed chronic lymphocytic leukemia.9681246Faderl S, Estrov ZCytokines, cellular & molecular therapyResidual disease in acute lymphoblastic leukemia of childhood: methods of detection and clinical relevance. Cytokines Cell Mol Ther. 1998 Jun; 4(2):73-85.Cytokines Cell Mol Ther1998-06-01T00:00:001998Residual disease in acute lymphoblastic leukemia of childhood: methods of detection and clinical relevance.9711920Wright-Browne V, Schnee AM, Jenkins MA, Thall PF, Aggarwal BB, Talpaz M, Estrov ZLeukemia & lymphomaSerum cytokine levels in infectious mononucleosis at diagnosis and convalescence. Leuk Lymphoma. 1998 Aug; 30(5-6):583-9.Leuk Lymphoma1998-08-01T00:00:001998Serum cytokine levels in infectious mononucleosis at diagnosis and convalescence.9787143Estrov Z, Thall PF, Talpaz M, Estey EH, Kantarjian HM, Andreeff M, Harris D, Van Q, Walterscheid M, Kornblau SMBloodCaspase 2 and caspase 3 protein levels as predictors of survival in acute myelogenous leukemia. Blood. 1998 Nov 01; 92(9):3090-7.Blood1998-11-01T00:00:001998Caspase 2 and caspase 3 protein levels as predictors of survival in acute myelogenous leukemia.9874668Lee BN, Duvic M, Tang CK, Bueso-Ramos C, Estrov Z, Reuben JMClinical and diagnostic laboratory immunologyDysregulated synthesis of intracellular type 1 and type 2 cytokines by T cells of patients with cutaneous T-cell lymphoma. Clin Diagn Lab Immunol. 1999 Jan; 6(1):79-84.Clin Diagn Lab Immunol1999-01-01T00:00:001999Dysregulated synthesis of intracellular type 1 and type 2 cytokines by T cells of patients with cutaneous T-cell lymphoma.10194120Estrov Z, Freedman MHLeukemia & lymphomaDetection of residual disease in acute lymphoblastic leukemia of childhood. Leuk Lymphoma. 1999 Mar; 33(1-2):47-52.Leuk Lymphoma1999-03-01T00:00:001999Detection of residual disease in acute lymphoblastic leukemia of childhood.10383163Beaupre DM, Talpaz M, Marini FC, Cristiano RJ, Roth JA, Estrov Z, Albitar M, Freedman MH, Kurzrock RCancer researchAutocrine interleukin-1beta production in leukemia: evidence for the involvement of mutated RAS. Cancer Res. 1999 Jun 15; 59(12):2971-80.Cancer Res1999-06-15T00:00:001999Autocrine interleukin-1beta production in leukemia: evidence for the involvement of mutated RAS.10403855Faderl S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R, Kantarjian HMThe New England journal of medicineThe biology of chronic myeloid leukemia. N Engl J Med. 1999 Jul 15; 341(3):164-72.N Engl J Med1999-07-15T00:00:001999The biology of chronic myeloid leukemia.10430092Faderl S, Kantarjian HM, Manshouri T, Chan CY, Pierce S, Hays KJ, Cortes J, Thomas D, Estrov Z, Albitar MClinical cancer research : an official journal of the American Association for Cancer ResearchThe prognostic significance of p16INK4a/p14ARF and p15INK4b deletions in adult acute lymphoblastic leukemia. Clin Cancer Res. 1999 Jul; 5(7):1855-61.Clin Cancer Res1999-07-01T00:00:001999The prognostic significance of p16INK4a/p14ARF and p15INK4b deletions in adult acute lymphoblastic leukemia.10484639Lion TBloodMonitoring of residual disease in chronic myelogenous leukemia by quantitative polymerase chain reaction and clinical decision making. Blood. 1999 Aug 15; 94(4):1486-8.Blood1999-08-15T00:00:001999Monitoring of residual disease in chronic myelogenous leukemia by quantitative polymerase chain reaction and clinical decision making.10572084Aguayo A, Estey E, Kantarjian H, Mansouri T, Gidel C, Keating M, Giles F, Estrov Z, Barlogie B, Albitar MBloodCellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. Blood. 1999 Dec 01; 94(11):3717-21.Blood1999-12-01T00:00:001999Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia.10632330Ravandi F, Estrov Z, Kurzrock R, Breitmeyer JB, Maschek BJ, Talpaz MClinical cancer research : an official journal of the American Association for Cancer ResearchA phase I study of recombinant interferon-beta in patients with advanced malignant disease. Clin Cancer Res. 1999 Dec; 5(12):3990-8.Clin Cancer Res1999-12-01T00:00:001999A phase I study of recombinant interferon-beta in patients with advanced malignant disease.10776987Mavligit GM, Estrov ZAmerican journal of clinical oncologyCA 125: a clinically useful tumor marker in the management of colorectal carcinoma metastatic to the liver in patients with normal carcinoembryonic antigen. Am J Clin Oncol. 2000 Apr; 23(2):213-5.Am J Clin Oncol2000-04-01T00:00:002000CA 125: a clinically useful tumor marker in the management of colorectal carcinoma metastatic to the liver in patients with normal carcinoembryonic antigen.10845930Konopleva M, Tari AM, Estrov Z, Harris D, Xie Z, Zhao S, L?pez-Berestein G, Andreeff MBloodLiposomal Bcl-2 antisense oligonucleotides enhance proliferation, sensitize acute myeloid leukemia to cytosine-arabinoside, and induce apoptosis independent of other antiapoptotic proteins. Blood. 2000 Jun 15; 95(12):3929-38.Blood2000-06-15T00:00:002000Liposomal Bcl-2 antisense oligonucleotides enhance proliferation, sensitize acute myeloid leukemia to cytosine-arabinoside, and induce apoptosis independent of other antiapoptotic proteins.10979972Aguayo A, Kantarjian H, Manshouri T, Gidel C, Estey E, Thomas D, Koller C, Estrov Z, O'Brien S, Keating M, Freireich E, Albitar MBloodAngiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood. 2000 Sep 15; 96(6):2240-5.Blood2000-09-15T00:00:002000Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes.12124415Brouard M, Barrandon YThe New England journal of medicineMale cells in female recipients of hematopoietic-cell transplants. N Engl J Med. 2002 Jul 18; 347(3):218-20; author reply 218-20.N Engl J Med2002-07-18T00:00:002002Male cells in female recipients of hematopoietic-cell transplants.12537979Faderl S, Lotan R, Kantarjian HM, Harris D, Van Q, Estrov ZLeukemia researchN-(4-Hydroxylphenyl)retinamide (fenretinide, 4-HPR), a retinoid compound with antileukemic and proapoptotic activity in acute lymphoblastic leukemia (ALL). Leuk Res. 2003 Mar; 27(3):259-66.Leuk Res2003-03-01T00:00:002003N-(4-Hydroxylphenyl)retinamide (fenretinide, 4-HPR), a retinoid compound with antileukemic and proapoptotic activity in acute lymphoblastic leukemia (ALL).12576416Ravandi F, Talpaz M, Estrov ZClinical cancer research : an official journal of the American Association for Cancer ResearchModulation of cellular signaling pathways: prospects for targeted therapy in hematological malignancies. Clin Cancer Res. 2003 Feb; 9(2):535-50.Clin Cancer Res2003-02-01T00:00:002003Modulation of cellular signaling pathways: prospects for targeted therapy in hematological malignancies.12648504Faderl S, Estrov ZLeukemia researchCommentary: effect of flavonoids on normal and leukemic cells. Leuk Res. 2003 Jun; 27(6):471-3.Leuk Res2003-06-01T00:00:002003Commentary: effect of flavonoids on normal and leukemic cells.14506164Laurent E, Mitchell DL, Estrov Z, Lowery M, Tucker SL, Talpaz M, Kurzrock RClinical cancer research : an official journal of the American Association for Cancer ResearchImpact of p210(Bcr-Abl) on ultraviolet C wavelength-induced DNA damage and repair. Clin Cancer Res. 2003 Sep 01; 9(10 Pt 1):3722-30.Clin Cancer Res2003-09-01T00:00:002003Impact of p210(Bcr-Abl) on ultraviolet C wavelength-induced DNA damage and repair.15805291Contractor R, Samudio IJ, Estrov Z, Harris D, McCubrey JA, Safe SH, Andreeff M, Konopleva MCancer researchA novel ring-substituted diindolylmethane,1,1-bis[3'-(5-methoxyindolyl)]-1-(p-t-butylphenyl) methane, inhibits extracellular signal-regulated kinase activation and induces apoptosis in acute myelogenous leukemia. Cancer Res. 2005 Apr 01; 65(7):2890-8.Cancer Res2005-04-01T00:00:002005A novel ring-substituted diindolylmethane,1,1-bis[3'-(5-methoxyindolyl)]-1-(p-t-butylphenyl) methane, inhibits extracellular signal-regulated kinase activation and induces apoptosis in acute myelogenous leukemia.18056455Ferrajoli A, Faderl S, Van Q, Koch P, Harris D, Liu Z, Hazan-Halevy I, Wang Y, Kantarjian HM, Priebe W, Estrov ZCancer researchWP1066 disrupts Janus kinase-2 and induces caspase-dependent apoptosis in acute myelogenous leukemia cells. Cancer Res. 2007 Dec 01; 67(23):11291-9.Cancer Res2007-12-01T00:00:002007WP1066 disrupts Janus kinase-2 and induces caspase-dependent apoptosis in acute myelogenous leukemia cells.18224667Ma W, Kantarjian H, O'Brien S, Jilani I, Zhang X, Estrov Z, Ferrajoli A, Keating M, Giles F, Albitar MCancerEnzymatic activity of circulating proteasomes correlates with clinical behavior in patients with chronic lymphocytic leukemia. Cancer. 2008 Mar 15; 112(6):1306-12.Cancer2008-03-15T00:00:002008Enzymatic activity of circulating proteasomes correlates with clinical behavior in patients with chronic lymphocytic leukemia.18245540Verstovsek S, Manshouri T, Quint?s-Cardama A, Harris D, Cortes J, Giles FJ, Kantarjian H, Priebe W, Estrov ZClinical cancer research : an official journal of the American Association for Cancer ResearchWP1066, a novel JAK2 inhibitor, suppresses proliferation and induces apoptosis in erythroid human cells carrying the JAK2 V617F mutation. Clin Cancer Res. 2008 Feb 01; 14(3):788-96.Clin Cancer Res2008-02-01T00:00:002008WP1066, a novel JAK2 inhibitor, suppresses proliferation and induces apoptosis in erythroid human cells carrying the JAK2 V617F mutation.18495956Garcia-Manero G, Assouline S, Cortes J, Estrov Z, Kantarjian H, Yang H, Newsome WM, Miller WH, Rousseau C, Kalita A, Bonfils C, Dubay M, Patterson TA, Li Z, Besterman JM, Reid G, Laille E, Martell RE, Minden MBloodPhase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia. Blood. 2008 Aug 15; 112(4):981-9.Blood2008-05-21T00:00:002008Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia.19075265Ravandi F, Estey E, Jones D, Faderl S, O'Brien S, Fiorentino J, Pierce S, Blamble D, Estrov Z, Wierda W, Ferrajoli A, Verstovsek S, Garcia-Manero G, Cortes J, Kantarjian HJournal of clinical oncology : official journal of the American Society of Clinical OncologyEffective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. J Clin Oncol. 2009 Feb 01; 27(4):504-10.J Clin Oncol2008-12-15T00:00:002008Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin.19679351Bruey JM, Kantarjian H, Estrov Z, Zhang Z, Ma W, Albitar F, Abdool A, Thomas D, Yeh C, O'Brien S, Albitar MLeukemia researchCirculating Ki-67 protein in plasma as a biomarker and prognostic indicator of acute lymphoblastic leukemia. Leuk Res. 2010 Feb; 34(2):173-6.Leuk Res2009-08-12T00:00:002009Circulating Ki-67 protein in plasma as a biomarker and prognostic indicator of acute lymphoblastic leukemia.19728024Sever M, Kantarjian H, Pierce S, Jain N, Estrov Z, Cortes J, Verstovsek SInternational journal of hematologyCytogenetic abnormalities in essential thrombocythemia at presentation and transformation. Int J Hematol. 2009 Nov; 90(4):522-525.Int J Hematol2009-08-29T00:00:002009Cytogenetic abnormalities in essential thrombocythemia at presentation and transformation.19800118Yeh CH, Tseng R, Hannah A, Estrov Z, Estey E, Kantarjian H, Albitar MLeukemia researchClinical correlation of circulating heat shock protein 70 in acute leukemia. Leuk Res. 2010 May; 34(5):605-9.Leuk Res2009-10-01T00:00:002009Clinical correlation of circulating heat shock protein 70 in acute leukemia.20499401Verma D, Kantarjian H, Shan J, O'Brien S, Estrov Z, Garcia-Manero G, Koller C, Borthakur G, Cortes JCancerSurvival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy. Cancer. 2010 Jun 01; 116(11):2673-81.Cancer2010-06-01T00:00:002010Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy.20533075Tong WG, Estrov Z, Wang Y, O'Brien S, Faderl S, Harris DM, Van Pham Q, Hazan-Halevy I, Liu Z, Koch P, Kantarjian H, Keating MJ, Ferrajoli AInvestigational new drugsThe synthetic heat shock protein 90 (Hsp90) inhibitor EC141 induces degradation of Bcr-Abl p190 protein and apoptosis of Ph-positive acute lymphoblastic leukemia cells. Invest New Drugs. 2011 Dec; 29(6):1206-12.Invest New Drugs2010-06-09T00:00:002010The synthetic heat shock protein 90 (Hsp90) inhibitor EC141 induces degradation of Bcr-Abl p190 protein and apoptosis of Ph-positive acute lymphoblastic leukemia cells.20679526Kornblau SM, McCue D, Singh N, Chen W, Estrov Z, Coombes KRBloodRecurrent expression signatures of cytokines and chemokines are present and are independently prognostic in acute myelogenous leukemia and myelodysplasia. Blood. 2010 Nov 18; 116(20):4251-61.Blood2010-08-02T00:00:002010Recurrent expression signatures of cytokines and chemokines are present and are independently prognostic in acute myelogenous leukemia and myelodysplasia.21731684Harris DM, Hazan-Haley I, Coombes K, Bueso-Ramos C, Liu J, Liu Z, Li P, Ravoori M, Abruzzo L, Han L, Singh S, Sun M, Kundra V, Kurzrock R, Estrov ZPloS oneTransformation of human mesenchymal cells and skin fibroblasts into hematopoietic cells. PLoS One. 2011; 6(6):e21250.PLoS One2011-06-22T00:00:002011Transformation of human mesenchymal cells and skin fibroblasts into hematopoietic cells.21751197Faderl S, Garcia-Manero G, Jabbour E, Ravandi F, Borthakur G, Estrov Z, Gandhi V, Byrd AL, Kwari M, Cortes J, Kantarjian HMCancerA randomized study of 2 dose levels of intravenous clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome. Cancer. 2012 Feb 01; 118(3):722-8.Cancer2011-07-12T00:00:002011A randomized study of 2 dose levels of intravenous clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome.21858802Lee BN, Gao H, Cohen EN, Badoux X, Wierda WG, Estrov Z, Faderl SH, Keating MJ, Ferrajoli A, Reuben JMCancerTreatment with lenalidomide modulates T-cell immunophenotype and cytokine production in patients with chronic lymphocytic leukemia. Cancer. 2011 Sep 01; 117(17):3999-4008.Cancer2011-02-24T00:00:002011Treatment with lenalidomide modulates T-cell immunophenotype and cytokine production in patients with chronic lymphocytic leukemia.22303899Ohanian M, Leventaki V, Verstovsek S, Estrov Z, Lin P, Yin C, Kantarjian H, Huh Y, Ravandi FLeukemia & lymphomaAcute lymphoblastic leukemia arising in post-polycythemic myelofibrosis: a rare entity. Leuk Lymphoma. 2012 Sep; 53(9):1839-41.Leuk Lymphoma2012-03-13T00:00:002012Acute lymphoblastic leukemia arising in post-polycythemic myelofibrosis: a rare entity.22475363Quint?s-Cardama A, Kantarjian H, Estrov Z, Borthakur G, Cortes J, Verstovsek SLeukemia researchTherapy with the histone deacetylase inhibitor pracinostat for patients with myelofibrosis. Leuk Res. 2012 Sep; 36(9):1124-7.Leuk Res2012-04-02T00:00:002012Therapy with the histone deacetylase inhibitor pracinostat for patients with myelofibrosis.22579233Chen Y, Kantarjian H, Estrov Z, Faderl S, Ravandi F, Rey K, Cortes J, Borthakur GClinical lymphoma, myeloma & leukemiaA phase II study of lenalidomide alone in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes with chromosome 5 abnormalities. Clin Lymphoma Myeloma Leuk. 2012 Oct; 12(5):341-4.Clin Lymphoma Myeloma Leuk2012-05-10T00:00:002012A phase II study of lenalidomide alone in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes with chromosome 5 abnormalities.22665218Boumber Y, Kantarjian H, Jorgensen J, Wen S, Faderl S, Castoro R, Autry J, Garcia-Manero G, Borthakur G, Jabbour E, Estrov Z, Cortes J, Issa JP, Ravandi FLeukemiaA randomized study of decitabine versus conventional care for maintenance therapy in patients with acute myeloid leukemia in complete remission. Leukemia. 2012 Nov; 26(11):2428-31.Leukemia2012-06-05T00:00:002012A randomized study of decitabine versus conventional care for maintenance therapy in patients with acute myeloid leukemia in complete remission.22820254Koppikar P, Bhagwat N, Kilpivaara O, Manshouri T, Adli M, Hricik T, Liu F, Saunders LM, Mullally A, Abdel-Wahab O, Leung L, Weinstein A, Marubayashi S, Goel A, G?nen M, Estrov Z, Ebert BL, Chiosis G, Nimer SD, Bernstein BE, Verstovsek S, Levine RLNatureHeterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy. Nature. 2012 Sep 06; 489(7414):155-9.Nature2012-09-06T00:00:002012Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy.23701251Daver N, Vega-Ruiz A, Kantarjian HM, Estrov Z, Ferrajoli A, Kornblau S, Verstovsek S, Garcia-Manero G, Cortes JEEuropean journal of cancer careA phase II open-label study of the intravenous administration of homoharringtonine in the treatment of myelodysplastic syndrome. Eur J Cancer Care (Engl). 2013 Sep; 22(5):605-11.Eur J Cancer Care (Engl)2013-05-23T00:00:002013A phase II open-label study of the intravenous administration of homoharringtonine in the treatment of myelodysplastic syndrome.23774633Takahashi K, Jabbour E, Wang X, Luthra R, Bueso-Ramos C, Patel K, Pierce S, Yang H, Wei Y, Daver N, Faderl S, Ravandi F, Estrov Z, Cortes J, Kantarjian H, Garcia-Manero GLeukemiaDynamic acquisition of FLT3 or RAS alterations drive a subset of patients with lower risk MDS to secondary AML. Leukemia. 2013 Oct; 27(10):2081-3.Leukemia2013-06-07T00:00:002013Dynamic acquisition of FLT3 or RAS alterations drive a subset of patients with lower risk MDS to secondary AML.23936456Irwin ME, Nelson LD, Santiago-O'Farrill JM, Knouse PD, Miller CP, Palla SL, Siwak DR, Mills GB, Estrov Z, Li S, Kornblau SM, Hughes DP, Chandra JPloS oneSmall molecule ErbB inhibitors decrease proliferative signaling and promote apoptosis in philadelphia chromosome-positive acute lymphoblastic leukemia. PLoS One. 2013; 8(8):e70608.PLoS One2013-08-01T00:00:002013Small molecule ErbB inhibitors decrease proliferative signaling and promote apoptosis in philadelphia chromosome-positive acute lymphoblastic leukemia.LeukemiaMD AndersonJORGE ECORTESJORGE E CORTES8637CORTES, JORGE EProfessorWILLIAM GWIERDAWILLIAM G WIERDA8937WIERDA, WILLIAM GProfessorHAGOP MKANTARJIANHAGOP M KANTARJIAN8501KANTARJIAN, HAGOP MProfessor10.51340.002053511175research areas11.83970.0108681158coauthor of1028.8962.897560similar to11539selected publicationsSRDANVERSTOVSEKSRDAN VERSTOVSEK8781VERSTOVSEK, SRDANProfessorALESSANDRAFERRAJOLIALESSANDRA FERRAJOLI8776FERRAJOLI, ALESSANDRAProfessorGUILLERMOGARCIA-MANEROGUILLERMO GARCIA-MANERO8853GARCIA-MANERO, GUILLERMOProfessorAuthorship 2122263Authorship 2122475Authorship 2125351Authorship 2126441Authorship 2126673Authorship 2127551Authorship 2128361Authorship 2128451Authorship 2128571Authorship 2132173Authorship 2135641Authorship 2138912Authorship 2141101Authorship 2143651Authorship 2148712Authorship 2149181Authorship 2149453Authorship 2150162Authorship 2153992Authorship 2154492Authorship 2158104Authorship 2159227Authorship 2159272Authorship 2159331Authorship 2160654Authorship 2161573Authorship 2163604Authorship 2168535Authorship 2168623Authorship 2169442Authorship 217177Authorship 2173072Authorship 2173488Authorship 21788310Authorship 2179403Authorship 2179994Authorship 2186824Authorship 2187583Authorship 2197106Authorship 2199814Authorship 2205308Authorship 2206017Authorship 2207261Authorship 2209232Authorship 2217272Authorship 2218757Authorship 2220727Authorship 22248612Authorship 2225673Authorship 2228492Authorship 2228818Authorship 22314710Authorship 2232574Authorship 2233772Authorship 2234816Authorship 22358022Authorship 2236727Authorship 2236824Authorship 2249148Authorship 2263728Authorship 2267893Authorship 2270541Authorship 2276536Authorship 2280418Authorship 2284496Authorship 2289938Authorship 22913912Authorship 22923810Authorship 2292855Authorship 2311696Authorship 2320773Authorship 23252713Authorship 2327305Authorship 2327373Authorship 2329508Authorship 2331087Authorship 2332438Authorship 23325011Authorship 2332958Authorship 23336712Authorship 23368717Authorship 2340405Authorship 2343218Authorship 23433811Authorship 2351877Authorship 23542511373331Estrov Z, Kurzrock R, Estey E, Wetzler M, Ferrajoli A, Harris D, Blake M, Gutterman JU, Talpaz MBloodInhibition of acute myelogenous leukemia blast proliferation by interleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptors. Blood. 1992 Apr 15; 79(8):1938-45.Blood1992-04-15T00:00:001992Inhibition of acute myelogenous leukemia blast proliferation by interleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptors.1587302Estrov Z, Estey EH, Andreeff M, Talpaz M, Kurzrock R, Reading CL, Deisseroth AB, Gutterman JUExperimental hematologyComparison of in vivo and in vitro effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with acute myeloid leukemia. Exp Hematol. 1992 Jun; 20(5):558-64.Exp Hematol1992-06-01T00:00:001992Comparison of in vivo and in vitro effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with acute myeloid leukemia.1961041Kurzrock R, Talpaz M, Estey E, O'Brien S, Estrov Z, Gutterman JULeukemiaErythropoietin treatment in patients with myelodysplastic syndrome and anemia. Leukemia. 1991 Nov; 5(11):985-90.Leukemia1991-11-01T00:00:001991Erythropoietin treatment in patients with myelodysplastic syndrome and anemia.1965141Cohen A, Madrid-Marina V, Estrov Z, Freedman MH, Lingwood CA, Dosch HMInternational immunologyExpression of glycolipid receptors to Shiga-like toxin on human B lymphocytes: a mechanism for the failure of long-lived antibody response to dysenteric disease. Int Immunol. 1990; 2(1):1-8.Int Immunol1990-01-01T00:00:001990Expression of glycolipid receptors to Shiga-like toxin on human B lymphocytes: a mechanism for the failure of long-lived antibody response to dysenteric disease.1995313Estrov Z, Freedman MHExperimental hematologyAcute lymphoblastic leukemia blast cells do not inhibit bone marrow hematopoietic progenitor colony formation. Exp Hematol. 1991 Mar; 19(3):221-5.Exp Hematol1991-03-01T00:00:001991Acute lymphoblastic leukemia blast cells do not inhibit bone marrow hematopoietic progenitor colony formation.2045865Kurzrock R, Talpaz M, Estrov Z, Rosenblum MG, Gutterman JUJournal of clinical oncology : official journal of the American Society of Clinical OncologyPhase I study of recombinant human interleukin-3 in patients with bone marrow failure. J Clin Oncol. 1991 Jul; 9(7):1241-50.J Clin Oncol1991-07-01T00:00:001991Phase I study of recombinant human interleukin-3 in patients with bone marrow failure.3102273Estrov Z, Lau AS, Williams BR, Freedman MHExperimental hematologyRecombinant human interferon alpha-2 and juvenile chronic myelogenous leukemia: cell receptor binding, enzymatic induction, and growth suppression in vitro. Exp Hematol. 1987 Feb; 15(2):127-32.Exp Hematol1987-02-01T00:00:001987Recombinant human interferon alpha-2 and juvenile chronic myelogenous leukemia: cell receptor binding, enzymatic induction, and growth suppression in vitro.3239704Estrov Z, Cohen A, Gelfand EW, Freedman MHThe American journal of pediatric hematology/oncologySynergistic antiproliferative effects on HL-60 cells: deferoxamine enhances cytosine arabinoside, methotrexate, and daunorubicin cytotoxicity. Am J Pediatr Hematol Oncol. 1988; 10(4):288-91.Am J Pediatr Hematol Oncol1988-01-01T00:00:001988Synergistic antiproliferative effects on HL-60 cells: deferoxamine enhances cytosine arabinoside, methotrexate, and daunorubicin cytotoxicity.3461711Estrov Z, Grunberger T, Freedman MHAmerican journal of hematologyClinical utility of marrow cell tissue cultures in acute leukemia of childhood. Am J Hematol. 1986 Sep; 23(1):51-8.Am J Hematol1986-09-01T00:00:001986Clinical utility of marrow cell tissue cultures in acute leukemia of childhood.3486010Estrov Z, Grunberger T, Chan HS, Freedman MHBloodJuvenile chronic myelogenous leukemia: characterization of the disease using cell cultures. Blood. 1986 May; 67(5):1382-7.Blood1986-05-01T00:00:001986Juvenile chronic myelogenous leukemia: characterization of the disease using cell cultures.3742712Kaplinsky C, Yeger H, Estrov Z, Barankiewicz J, Pawlin G, Freedman MH, Cohen ACancer chemotherapy and pharmacologySelective protection of tubercidin toxicity by nitrobenzyl thioinosine in normal tissues but not in human neuroblastoma cells. Cancer Chemother Pharmacol. 1986; 17(3):264-8.Cancer Chemother Pharmacol1986-01-01T00:00:001986Selective protection of tubercidin toxicity by nitrobenzyl thioinosine in normal tissues but not in human neuroblastoma cells.3766908Freedman MH, Estrov Z, Williams BR, Gelfand EWThe American journal of pediatric hematology/oncologyClinical and in vitro antiproliferative properties of recombinant DNA-derived human interferon-alpha 2. Am J Pediatr Hematol Oncol. 1986; 8(3):178-82.Am J Pediatr Hematol Oncol1986-01-01T00:00:001986Clinical and in vitro antiproliferative properties of recombinant DNA-derived human interferon-alpha 2.6469595Estrov Z, Resnitzky P, Shenker Y, Berrebi A, Hurwitz NIsrael journal of medical sciencesCandidemia and sternal Candida albicans osteomyelitis in a patient with chronic lymphatic leukemia. Isr J Med Sci. 1984 Aug; 20(8):711-4.Isr J Med Sci1984-08-01T00:00:001984Candidemia and sternal Candida albicans osteomyelitis in a patient with chronic lymphatic leukemia.6800195Berrebi A, Estrov ZActa haematologicaTwenty years follow-up in a patient with multiple myeloma. Acta Haematol. 1981; 66(4):269-70.Acta Haematol1981-01-01T00:00:001981Twenty years follow-up in a patient with multiple myeloma.7535143Drach D, Estrov Z, Zhao S, Drach J, Cork A, Collins D, Kantarjian H, Andreeff MLeukemia & lymphomaGranulocyte-colony stimulating factor, granulocyte-macrophage colony stimulating factor, PIXY-321, stem cell factor, interleukin-3, and interleukin-7: receptor binding and effects on clonogenic proliferation in acute lymphoblastic leukemia. Leuk Lymphoma. 1994 Dec; 16(1-2):79-88.Leuk Lymphoma1994-12-01T00:00:001994Granulocyte-colony stimulating factor, granulocyte-macrophage colony stimulating factor, PIXY-321, stem cell factor, interleukin-3, and interleukin-7: receptor binding and effects on clonogenic proliferation in acute lymphoblastic leukemia.7539977Estrov Z, Talpaz M, Mavligit G, Pazdur R, Harris D, Greenberg SM, Kurzrock RThe American journal of medicineElevated plasma thrombopoietic activity in patients with metastatic cancer-related thrombocytosis. Am J Med. 1995 Jun; 98(6):551-8.Am J Med1995-06-01T00:00:001995Elevated plasma thrombopoietic activity in patients with metastatic cancer-related thrombocytosis.7570065Estrov Z, Kurzrock R, Talpaz MSeminars in hematologyCytokines and their antagonists in myeloid disorders. Semin Hematol. 1995 Jul; 32(3):220-31.Semin Hematol1995-07-01T00:00:001995Cytokines and their antagonists in myeloid disorders.7691980Wetzler M, Estrov Z, Talpaz M, Markowitz A, Gutterman JU, Kurzrock RJournal of internal medicineGranulocyte-macrophage colony-stimulating factor as a cause of paraneoplastic leukaemoid reaction in advanced transitional cell carcinoma. J Intern Med. 1993 Oct; 234(4):417-20.J Intern Med1993-10-01T00:00:001993Granulocyte-macrophage colony-stimulating factor as a cause of paraneoplastic leukaemoid reaction in advanced transitional cell carcinoma.7908106Estrov Z, Ouspenskaia MV, Zipf TF, Tubergen DG, Roberts WMLancet (London, England)Minimal residual leukaemia. Lancet. 1994 Apr 02; 343(8901):858-9.Lancet1994-04-02T00:00:001994Minimal residual leukaemia.7949186Wetzler M, Kurzrock R, Estrov Z, Kantarjian H, Gisslinger H, Underbrink MP, Talpaz MBloodAltered levels of interleukin-1 beta and interleukin-1 receptor antagonist in chronic myelogenous leukemia: clinical and prognostic correlates. Blood. 1994 Nov 01; 84(9):3142-7.Blood1994-11-01T00:00:001994Altered levels of interleukin-1 beta and interleukin-1 receptor antagonist in chronic myelogenous leukemia: clinical and prognostic correlates.8182937Ferrajoli A, Talpaz M, Zipf TF, Hirsch-Ginsberg C, Estey E, Wolpe SD, Estrov ZLeukemiaInhibition of acute myelogenous leukemia progenitor proliferation by macrophage inflammatory protein 1-alpha. Leukemia. 1994 May; 8(5):798-805.Leukemia1994-05-01T00:00:001994Inhibition of acute myelogenous leukemia progenitor proliferation by macrophage inflammatory protein 1-alpha.8251916Wetzler M, Talpaz M, Estrov Z, Kurzrock RLeukemia & lymphomaCML: mechanisms of disease initiation and progression. Leuk Lymphoma. 1993; 11 Suppl 1:47-50.Leuk Lymphoma1993-01-01T00:00:001993CML: mechanisms of disease initiation and progression.8624456Roberts WM, Estrov Z, Kitchingman GR, Zipf TFLeukemia & lymphomaThe clinical significance of residual disease in childhood acute lymphoblastic leukemia as detected by polymerase chain reaction amplification by antigen-receptor gene sequences. Leuk Lymphoma. 1996 Jan; 20(3-4):181-97.Leuk Lymphoma1996-01-01T00:00:001996The clinical significance of residual disease in childhood acute lymphoblastic leukemia as detected by polymerase chain reaction amplification by antigen-receptor gene sequences.8724630Roberts WM, Estrov Z, Kitchingman GR, Zipf TFCancer treatment and researchDetection of minimal residual disease in all: biology, methods, and applications. Cancer Treat Res. 1996; 84:149-66.Cancer Treat Res1996-01-01T00:00:001996Detection of minimal residual disease in all: biology, methods, and applications.8751477Estrov Z, Talpaz M, Ku S, Harris D, LaPushin R, Koller CA, Hirsh-Ginsberg C, Huh Y, Yee G, Kurzrock RLeukemiaMolecular and biologic characterization of a newly established Philadelphia-positive acute lymphoblastic leukemia cell line (Z-33) with an autocrine response to GM-CSF. Leukemia. 1996 Sep; 10(9):1534-43.Leukemia1996-09-01T00:00:001996Molecular and biologic characterization of a newly established Philadelphia-positive acute lymphoblastic leukemia cell line (Z-33) with an autocrine response to GM-CSF.8839860Lapidot T, Grunberger T, Vormoor J, Estrov Z, Kollet O, Bunin N, Zaizov R, Williams DE, Freedman MHBloodIdentification of human juvenile chronic myelogenous leukemia stem cells capable of initiating the disease in primary and secondary SCID mice. Blood. 1996 Oct 01; 88(7):2655-64.Blood1996-10-01T00:00:001996Identification of human juvenile chronic myelogenous leukemia stem cells capable of initiating the disease in primary and secondary SCID mice.9384665Roberts WM, Zipf TF, Kitchingman GR, Tubergen DG, Estrov ZCytokines and molecular therapyMonitoring residual disease in acute lymphoblastic leukemia: therapeutic implications. Cytokines Mol Ther. 1995 Mar; 1(1):65-9.Cytokines Mol Ther1995-03-01T00:00:001995Monitoring residual disease in acute lymphoblastic leukemia: therapeutic implications.9384674Kurzrock R, Wetzler M, Estrov Z, Talpaz MCytokines and molecular therapyInterleukin-1 and its inhibitors: a biologic and therapeutic model for the role of growth regulatory factors in leukemias. Cytokines Mol Ther. 1995 Sep; 1(3):177-84.Cytokines Mol Ther1995-09-01T00:00:001995Interleukin-1 and its inhibitors: a biologic and therapeutic model for the role of growth regulatory factors in leukemias.9552062Kurzrock R, Estrov Z, Kantarjian H, Talpaz MJournal of clinical oncology : official journal of the American Society of Clinical OncologyConversion of interferon-induced, long-term cytogenetic remissions in chronic myelogenous leukemia to polymerase chain reaction negativity. J Clin Oncol. 1998 Apr; 16(4):1526-31.J Clin Oncol1998-04-01T00:00:001998Conversion of interferon-induced, long-term cytogenetic remissions in chronic myelogenous leukemia to polymerase chain reaction negativity.9596644Faderl S, Kantarjian HM, Talpaz M, Estrov ZBloodClinical significance of cytogenetic abnormalities in adult acute lymphoblastic leukemia. Blood. 1998 Jun 01; 91(11):3995-4019.Blood1998-06-01T00:00:001998Clinical significance of cytogenetic abnormalities in adult acute lymphoblastic leukemia.10216068Faderl S, Talpaz M, Kantarjian HM, Estrov ZBloodShould polymerase chain reaction analysis to detect minimal residual disease in patients with chronic myelogenous leukemia be used in clinical decision making? Blood. 1999 May 01; 93(9):2755-9.Blood1999-05-01T00:00:001999Should polymerase chain reaction analysis to detect minimal residual disease in patients with chronic myelogenous leukemia be used in clinical decision making?10539902Faderl S, Kurzrock R, Estrov ZArchives of pathology & laboratory medicineMinimal residual disease in hematologic disorders. Arch Pathol Lab Med. 1999 Nov; 123(11):1030-4.Arch Pathol Lab Med1999-11-01T00:00:001999Minimal residual disease in hematologic disorders.10610116Moravcov? J, N?dvorn?kov? S, Luk?sov? M, Klamov? HBloodPolymerase chain reaction analyses should be used as a basis for clinical decision making in patients with chronic myelogenous leukemia. Blood. 1999 Nov 15; 94(10):3609-11.Blood1999-11-15T00:00:001999Polymerase chain reaction analyses should be used as a basis for clinical decision making in patients with chronic myelogenous leukemia.10656456Ueno NT, Bartholomeusz C, Herrmann JL, Estrov Z, Shao R, Andreeff M, Price J, Paul RW, Anklesaria P, Yu D, Hung MCClinical cancer research : an official journal of the American Association for Cancer ResearchE1A-mediated paclitaxel sensitization in HER-2/neu-overexpressing ovarian cancer SKOV3.ip1 through apoptosis involving the caspase-3 pathway. Clin Cancer Res. 2000 Jan; 6(1):250-9.Clin Cancer Res2000-01-01T00:00:002000E1A-mediated paclitaxel sensitization in HER-2/neu-overexpressing ovarian cancer SKOV3.ip1 through apoptosis involving the caspase-3 pathway.10674898Faderl S, Kantarjian HM, Thomas DA, Cortes J, Giles F, Pierce S, Albitar M, Estrov ZLeukemia & lymphomaOutcome of Philadelphia chromosome-positive adult acute lymphoblastic leukemia. Leuk Lymphoma. 2000 Jan; 36(3-4):263-73.Leuk Lymphoma2000-01-01T00:00:002000Outcome of Philadelphia chromosome-positive adult acute lymphoblastic leukemia.11078816Faderl S, Kantarjian HM, Talpaz M, Estrov ZInternational journal of oncologyClinical significance of minimal residual disease in leukemia. Int J Oncol. 2000 Dec; 17(6):1277-87.Int J Oncol2000-12-01T00:00:002000Clinical significance of minimal residual disease in leukemia.11391574Ravandi F, Kantarjian HM, Talpaz M, O'Brien S, Faderl S, Giles FJ, Thomas D, Cortes J, Andreeff M, Estrov Z, Rios MB, Albitar MCancerExpression of apoptosis proteins in chronic myelogenous leukemia: associations and significance. Cancer. 2001 Jun 01; 91(11):1964-72.Cancer2001-06-01T00:00:002001Expression of apoptosis proteins in chronic myelogenous leukemia: associations and significance.11560954Milella M, Kornblau SM, Estrov Z, Carter BZ, Lapillonne H, Harris D, Konopleva M, Zhao S, Estey E, Andreeff MThe Journal of clinical investigationTherapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia. J Clin Invest. 2001 Sep; 108(6):851-9.J Clin Invest2001-09-01T00:00:002001Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia.11734298Faderl S, Estrov ZLeukemia researchShift of immunoglobulin phenotypes in B-cell precursor cell lines. Leuk Res. 2002 Jan; 26(1):11-2.Leuk Res2002-01-01T00:00:002002Shift of immunoglobulin phenotypes in B-cell precursor cell lines.12124845Cheng K, Kurzrock R, Qiu X, Estrov Z, Ku S, Dulski KM, Wang JY, Talpaz MCancerReduced focal adhesion kinase and paxillin phosphorylation in BCR-ABL-transfected cells. Cancer. 2002 Jul 15; 95(2):440-50.Cancer2002-07-15T00:00:002002Reduced focal adhesion kinase and paxillin phosphorylation in BCR-ABL-transfected cells.12497210Alvarado Y, Cortes J, Verstovsek S, Thomas D, Faderl S, Estrov Z, Kantarjian H, Giles FJCancer chemotherapy and pharmacologyPilot study of pegylated interferon-alpha 2b in patients with essential thrombocythemia. Cancer Chemother Pharmacol. 2003 Jan; 51(1):81-6.Cancer Chemother Pharmacol2002-11-21T00:00:002002Pilot study of pegylated interferon-alpha 2b in patients with essential thrombocythemia.12730116Amin HM, Jilani I, Estey EH, Keating MJ, Dey AL, Manshouri T, Kantarjian HM, Estrov Z, Cortes JE, Thomas DA, Giles FJ, Albitar MBloodIncreased apoptosis in bone marrow B lymphocytes but not T lymphocytes in myelodysplastic syndrome. Blood. 2003 Sep 01; 102(5):1866-8.Blood2003-05-01T00:00:002003Increased apoptosis in bone marrow B lymphocytes but not T lymphocytes in myelodysplastic syndrome.12904523K?rbling M, Estrov ZThe New England journal of medicineAdult stem cells for tissue repair - a new therapeutic concept? N Engl J Med. 2003 Aug 07; 349(6):570-82.N Engl J Med2003-08-07T00:00:002003Adult stem cells for tissue repair - a new therapeutic concept?14628071Zhao S, Konopleva M, Cabreira-Hansen M, Xie Z, Hu W, Milella M, Estrov Z, Mills GB, Andreeff MLeukemiaInhibition of phosphatidylinositol 3-kinase dephosphorylates BAD and promotes apoptosis in myeloid leukemias. Leukemia. 2004 Feb; 18(2):267-75.Leukemia2004-02-01T00:00:002004Inhibition of phosphatidylinositol 3-kinase dephosphorylates BAD and promotes apoptosis in myeloid leukemias.15070700Bharti AC, Shishodia S, Reuben JM, Weber D, Alexanian R, Raj-Vadhan S, Estrov Z, Talpaz M, Aggarwal BBBloodNuclear factor-kappaB and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis. Blood. 2004 Apr 15; 103(8):3175-84.Blood2003-12-18T00:00:002003Nuclear factor-kappaB and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis.15234564Verstovsek S, Estrov ZLeukemia researchArsenic derivatives as therapeutic agents for hematologic malignancies. Leuk Res. 2004 Sep; 28(9):901-3.Leuk Res2004-09-01T00:00:002004Arsenic derivatives as therapeutic agents for hematologic malignancies.15543623Guikema JE, Fenton JA, de Boer C, Kleiverda K, Brink AA, Raap AK, Estrov Z, Schuuring E, Kluin PMGenes, chromosomes & cancerComplex biallelic IGH rearrangements in IgM-expressing Z-138 cell line: Involvement of downstream immunoglobulin class switch recombination. Genes Chromosomes Cancer. 2005 Feb; 42(2):164-9.Genes Chromosomes Cancer2005-02-01T00:00:002005Complex biallelic IGH rearrangements in IgM-expressing Z-138 cell line: Involvement of downstream immunoglobulin class switch recombination.16081352K?rbling M, Robinson S, Estrov Z, Champlin R, Shpall ECytotherapyUmbilical cord blood-derived cells for tissue repair. Cytotherapy. 2005; 7(3):258-61.Cytotherapy2005-01-01T00:00:002005Umbilical cord blood-derived cells for tissue repair.16293603Sampath D, Cortes J, Estrov Z, Du M, Shi Z, Andreeff M, Gandhi V, Plunkett WBloodPharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial. Blood. 2006 Mar 15; 107(6):2517-24.Blood2005-11-17T00:00:002005Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial.16333034Zhou Y, Garcia-Prieto C, Carney DA, Xu RH, Pelicano H, Kang Y, Yu W, Lou C, Kondo S, Liu J, Harris DM, Estrov Z, Keating MJ, Jin Z, Huang PJournal of the National Cancer InstituteOSW-1: a natural compound with potent anticancer activity and a novel mechanism of action. J Natl Cancer Inst. 2005 Dec 07; 97(23):1781-5.J Natl Cancer Inst2005-12-07T00:00:002005OSW-1: a natural compound with potent anticancer activity and a novel mechanism of action.16403905Faderl S, Verstovsek S, Cortes J, Ravandi F, Beran M, Garcia-Manero G, Ferrajoli A, Estrov Z, O'Brien S, Koller C, Giles FJ, Wierda W, Kwari M, Kantarjian HMBloodClofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older. Blood. 2006 Jul 01; 108(1):45-51.Blood2006-01-10T00:00:002006Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older.16428470Ravandi F, Estrov ZClinical cancer research : an official journal of the American Association for Cancer ResearchEradication of leukemia stem cells as a new goal of therapy in leukemia. Clin Cancer Res. 2006 Jan 15; 12(2):340-4.Clin Cancer Res2006-01-15T00:00:002006Eradication of leukemia stem cells as a new goal of therapy in leukemia.16828865Faderl S, Ferrajoli A, Harris D, Van Q, Kantarjian HM, Estrov ZLeukemia researchAtiprimod blocks phosphorylation of JAK-STAT and inhibits proliferation of acute myeloid leukemia (AML) cells. Leuk Res. 2007 Jan; 31(1):91-5.Leuk Res2006-07-07T00:00:002006Atiprimod blocks phosphorylation of JAK-STAT and inhibits proliferation of acute myeloid leukemia (AML) cells.16882708Kantarjian H, Oki Y, Garcia-Manero G, Huang X, O'Brien S, Cortes J, Faderl S, Bueso-Ramos C, Ravandi F, Estrov Z, Ferrajoli A, Wierda W, Shan J, Davis J, Giles F, Saba HI, Issa JPBloodResults of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood. 2007 Jan 01; 109(1):52-7.Blood2006-08-01T00:00:002006Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia.16966279Kurzrock R, Talpaz M, Li L, Estrov ZLeukemia & lymphomaDistinct biological impact of dephosphorylation vs. downregulation of p210Bcr-Abl: implications for imatinib mesylate response and resistance. Leuk Lymphoma. 2006 Aug; 47(8):1651-64.Leuk Lymphoma2006-08-01T00:00:002006Distinct biological impact of dephosphorylation vs. downregulation of p210Bcr-Abl: implications for imatinib mesylate response and resistance.17071475Montero AJ, Estrov Z, Freireich EJ, Khouri IF, Koller CA, Kurzrock RLeukemia & lymphomaPhase II study of low-dose interleukin-11 in patients with myelodysplastic syndrome. Leuk Lymphoma. 2006 Oct; 47(10):2049-54.Leuk Lymphoma2006-10-01T00:00:002006Phase II study of low-dose interleukin-11 in patients with myelodysplastic syndrome.17097560Konopleva M, Contractor R, Tsao T, Samudio I, Ruvolo PP, Kitada S, Deng X, Zhai D, Shi YX, Sneed T, Verhaegen M, Soengas M, Ruvolo VR, McQueen T, Schober WD, Watt JC, Jiffar T, Ling X, Marini FC, Harris D, Dietrich M, Estrov Z, McCubrey J, May WS, Reed JC, Andreeff MCancer cellMechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell. 2006 Nov; 10(5):375-88.Cancer Cell2006-11-01T00:00:002006Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia.17158228Kornblau SM, Banker DE, Stirewalt D, Shen D, Lemker E, Verstovsek S, Estrov Z, Faderl S, Cortes J, Beran M, Jackson CE, Chen W, Estey E, Appelbaum FRBloodBlockade of adaptive defensive changes in cholesterol uptake and synthesis in AML by the addition of pravastatin to idarubicin + high-dose Ara-C: a phase 1 study. Blood. 2007 Apr 01; 109(7):2999-3006.Blood2007-04-01T00:00:002007Blockade of adaptive defensive changes in cholesterol uptake and synthesis in AML by the addition of pravastatin to idarubicin + high-dose Ara-C: a phase 1 study.17168672Ferrajoli A, Faderl S, Ravandi F, Estrov ZCurrent cancer drug targetsThe JAK-STAT pathway: a therapeutic target in hematological malignancies. Curr Cancer Drug Targets. 2006 Dec; 6(8):671-9.Curr Cancer Drug Targets2006-12-01T00:00:002006The JAK-STAT pathway: a therapeutic target in hematological malignancies.18190591Jilani I, Wei C, Bekele BN, Zhang ZJ, Keating M, Wierda W, Ferrajoli A, Estrov Z, Kantarjian H, O'Brien SM, Giles FJ, Albitar MInternational journal of laboratory hematologySoluble syndecan-1 (sCD138) as a prognostic factor independent of mutation status in patients with chronic lymphocytic leukemia. Int J Lab Hematol. 2009 Feb; 31(1):97-105.Int J Lab Hematol2008-01-07T00:00:002008Soluble syndecan-1 (sCD138) as a prognostic factor independent of mutation status in patients with chronic lymphocytic leukemia.18715642Yeh CH, Tseng R, Zhang Z, Cortes J, O'Brien S, Giles F, Hannah A, Estrov Z, Keating M, Kantarjian H, Albitar MLeukemia researchCirculating heat shock protein 70 and progression in patients with chronic myeloid leukemia. Leuk Res. 2009 Feb; 33(2):212-7.Leuk Res2008-08-19T00:00:002008Circulating heat shock protein 70 and progression in patients with chronic myeloid leukemia.19340529Vega-Ruiz A, Faderl S, Estrov Z, Pierce S, Cortes J, Kantarjian H, Ravandi FInternational journal of hematologyIncidence of extramedullary disease in patients with acute promyelocytic leukemia: a single-institution experience. Int J Hematol. 2009 May; 89(4):489-496.Int J Hematol2009-04-02T00:00:002009Incidence of extramedullary disease in patients with acute promyelocytic leukemia: a single-institution experience.19778860Estrov ZClinical lymphoma & myelomaStem cells and somatic cells: reprogramming and plasticity. Clin Lymphoma Myeloma. 2009; 9 Suppl 3:S319-28.Clin Lymphoma Myeloma2009-01-01T00:00:002009Stem cells and somatic cells: reprogramming and plasticity.20154216Hazan-Halevy I, Harris D, Liu Z, Liu J, Li P, Chen X, Shanker S, Ferrajoli A, Keating MJ, Estrov ZBloodSTAT3 is constitutively phosphorylated on serine 727 residues, binds DNA, and activates transcription in CLL cells. Blood. 2010 Apr 08; 115(14):2852-63.Blood2010-02-12T00:00:002010STAT3 is constitutively phosphorylated on serine 727 residues, binds DNA, and activates transcription in CLL cells.20212254Ravandi F, Cortes JE, Jones D, Faderl S, Garcia-Manero G, Konopleva MY, O'Brien S, Estrov Z, Borthakur G, Thomas D, Pierce SR, Brandt M, Byrd A, Bekele BN, Pratz K, Luthra R, Levis M, Andreeff M, Kantarjian HMJournal of clinical oncology : official journal of the American Society of Clinical OncologyPhase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. J Clin Oncol. 2010 Apr 10; 28(11):1856-62.J Clin Oncol2010-03-08T00:00:002010Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia.20479284Liu X, Wang Y, Benaissa S, Matsuda A, Kantarjian H, Estrov Z, Plunkett WBloodHomologous recombination as a resistance mechanism to replication-induced double-strand breaks caused by the antileukemia agent CNDAC. Blood. 2010 Sep 09; 116(10):1737-46.Blood2010-05-17T00:00:002010Homologous recombination as a resistance mechanism to replication-induced double-strand breaks caused by the antileukemia agent CNDAC.20484983Tong WG, Wierda WG, Lin E, Kuang SQ, Bekele BN, Estrov Z, Wei Y, Yang H, Keating MJ, Garcia-Manero GEpigeneticsGenome-wide DNA methylation profiling of chronic lymphocytic leukemia allows identification of epigenetically repressed molecular pathways with clinical impact. Epigenetics. 2010 Aug 16; 5(6):499-508.Epigenetics2010-08-16T00:00:002010Genome-wide DNA methylation profiling of chronic lymphocytic leukemia allows identification of epigenetically repressed molecular pathways with clinical impact.20960519Jabbour E, Kantarjian H, Ravandi F, Garcia-Manero G, Estrov Z, Verstovsek S, O'Brien S, Faderl S, Thomas DA, Wright JJ, Cortes JCancerA phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome. Cancer. 2011 Mar 15; 117(6):1236-44.Cancer2010-10-19T00:00:002010A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome.21364020Liu Z, Hazan-Halevy I, Harris DM, Li P, Ferrajoli A, Faderl S, Keating MJ, Estrov ZMolecular cancer research : MCRSTAT-3 activates NF-kappaB in chronic lymphocytic leukemia cells. Mol Cancer Res. 2011 Apr; 9(4):507-15.Mol Cancer Res2011-03-01T00:00:002011STAT-3 activates NF-kappaB in chronic lymphocytic leukemia cells.21480207Mesa RA, Kantarjian H, Tefferi A, Dueck A, Levy R, Vaddi K, Erickson-Viitanen S, Thomas DA, Cortes J, Borthakur G, Pardanani AD, Estrov Z, Verstovsek SCancerEvaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial. Cancer. 2011 Nov 01; 117(21):4869-4877.Cancer2011-04-08T00:00:002011Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial.22360602Kadia TM, Borthakur G, Garcia-Manero G, Faderl S, Jabbour E, Estrov Z, York S, Huang X, Pierce S, Brandt M, Koller C, Kantarjian HM, Ravandi FBritish journal of haematologyFinal results of the phase II study of rabbit anti-thymocyte globulin, ciclosporin, methylprednisone, and granulocyte colony-stimulating factor in patients with aplastic anaemia and myelodysplastic syndrome. Br J Haematol. 2012 May; 157(3):312-20.Br J Haematol2012-02-24T00:00:002012Final results of the phase II study of rabbit anti-thymocyte globulin, ciclosporin, methylprednisone, and granulocyte colony-stimulating factor in patients with aplastic anaemia and myelodysplastic syndrome.22422826Eghtedar A, Verstovsek S, Estrov Z, Burger J, Cortes J, Bivins C, Faderl S, Ferrajoli A, Borthakur G, George S, Scherle PA, Newton RC, Kantarjian HM, Ravandi FBloodPhase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia. Blood. 2012 May 17; 119(20):4614-8.Blood2012-03-15T00:00:002012Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia.23017332Ohanian M, Borthakur G, Quintas-Cardama A, Mathisen M, Cort?s JE, Estrov Z, Pemmaraju NClinical lymphoma, myeloma & leukemiaOcular granulocytic sarcoma: a case report and literature review of ocular extramedullary acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2013 Feb; 13(1):93-6.Clin Lymphoma Myeloma Leuk2012-09-25T00:00:002012Ocular granulocytic sarcoma: a case report and literature review of ocular extramedullary acute myeloid leukemia.23019204Benjamini O, Jain P, Estrov Z, Kantarjian HM, Verstovsek SBloodTherapeutic effects of ruxolitinib in patients with myelofibrosis without clinically significant splenomegaly. Blood. 2012 Sep 27; 120(13):2768-9.Blood2012-09-27T00:00:002012Therapeutic effects of ruxolitinib in patients with myelofibrosis without clinically significant splenomegaly.23135353Chen Y, Kantarjian H, Pierce S, Faderl S, O'Brien S, Qiao W, Abruzzo L, de Lima M, Kebriaei P, Jabbour E, Daver N, Kadia T, Estrov Z, Garcia-Manero G, Cortes J, Ravandi FLeukemiaPrognostic significance of 11q23 aberrations in adult acute myeloid leukemia and the role of allogeneic stem cell transplantation. Leukemia. 2013 Apr; 27(4):836-42.Leukemia2012-11-08T00:00:002012Prognostic significance of 11q23 aberrations in adult acute myeloid leukemia and the role of allogeneic stem cell transplantation.23280377Ohanian M, Faderl S, Ravandi F, Pemmaraju N, Garcia-Manero G, Cortes J, Estrov ZInternational journal of cancerIs acute myeloid leukemia a liquid tumor? Int J Cancer. 2013 Aug 01; 133(3):534-43.Int J Cancer2013-02-04T00:00:002013Is acute myeloid leukemia a liquid tumor?23320889Jain P, Benjamini O, Pei L, Caraway NP, Landon G, Kim S, Shivaprasad S, Woodman K, O'Brien S, Ferrajoli A, Kadia T, Estrov ZLeukemia & lymphomaCentral nervous system Richter's transformation and parvovirus B19 infection. Leuk Lymphoma. 2013 Sep; 54(9):2070-2.Leuk Lymphoma2013-03-04T00:00:002013Central nervous system Richter's transformation and parvovirus B19 infection.23530930Takahashi K, Kantarjian H, Pemmaraju N, Andreeff M, Borthakur G, Faderl S, Garcia-Manero G, Pierce S, Luthra R, Cardenas-Turanzas M, Estrov Z, Ravandi F, Cortes JBritish journal of haematologySalvage therapy using FLT3 inhibitors may improve long-term outcome of relapsed or refractory AML in patients with FLT3-ITD. Br J Haematol. 2013 Jun; 161(5):659-666.Br J Haematol2013-03-27T00:00:002013Salvage therapy using FLT3 inhibitors may improve long-term outcome of relapsed or refractory AML in patients with FLT3-ITD.23733767Garcia-Manero G, Jabbour E, Borthakur G, Faderl S, Estrov Z, Yang H, Maddipoti S, Godley LA, Gabrail N, Berdeja JG, Nadeem A, Kassalow L, Kantarjian HJournal of clinical oncology : official journal of the American Society of Clinical OncologyRandomized open-label phase II study of decitabine in patients with low- or intermediate-risk myelodysplastic syndromes. J Clin Oncol. 2013 Jul 10; 31(20):2548-53.J Clin Oncol2013-06-03T00:00:002013Randomized open-label phase II study of decitabine in patients with low- or intermediate-risk myelodysplastic syndromes.23750211Li P, Grgurevic S, Liu Z, Harris D, Rozovski U, Calin GA, Keating MJ, Estrov ZPloS oneSignal transducer and activator of transcription-3 induces microRNA-155 expression in chronic lymphocytic leukemia. PLoS One. 2013; 8(6):e64678.PLoS One2013-06-04T00:00:002013Signal transducer and activator of transcription-3 induces microRNA-155 expression in chronic lymphocytic leukemia.23760779Jabbour E, Takahashi K, Wang X, Cornelison AM, Abruzzo L, Kadia T, Borthakur G, Estrov Z, O'Brien S, Mallo M, Wierda W, Pierce S, Wei Y, Sole F, Chen R, Kantarjian H, Garcia-Manero GAmerican journal of hematologyAcquisition of cytogenetic abnormalities in patients with IPSS defined lower-risk myelodysplastic syndrome is associated with poor prognosis and transformation to acute myelogenous leukemia. Am J Hematol. 2013 Oct; 88(10):831-7.Am J Hematol2013-07-23T00:00:002013Acquisition of cytogenetic abnormalities in patients with IPSS defined lower-risk myelodysplastic syndrome is associated with poor prognosis and transformation to acute myelogenous leukemia.23782935Quint?s-Cardama A, Abdel-Wahab O, Manshouri T, Kilpivaara O, Cortes J, Roupie AL, Zhang SJ, Harris D, Estrov Z, Kantarjian H, Levine RL, Verstovsek SBloodMolecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon a-2a. Blood. 2013 Aug 08; 122(6):893-901.Blood2013-06-19T00:00:002013Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon a-2a.23877926Nazha A, Kantarjian H, Ravandi F, Huang X, Choi S, Garcia-Manero G, Jabbour E, Borthakur G, Kadia T, Konopleva M, Cortes J, Ferrajoli A, Kornblau S, Daver N, Pemmaraju N, Andreeff M, Estrov Z, Du M, Brandt M, Faderl SAmerican journal of hematologyClofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients =60 years with newly diagnosed acute myeloid leukemia. Am J Hematol. 2013 Nov; 88(11):961-6.Am J Hematol2013-09-09T00:00:002013Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients =60 years with newly diagnosed acute myeloid leukemia.24578497Chae YK, Trinh L, Jain P, Wang X, Rozovski U, Wierda WG, Keating MJ, Estrov ZBloodStatin and aspirin use is associated with improved outcome of FCR therapy in relapsed/refractory chronic lymphocytic leukemia. Blood. 2014 Feb 27; 123(9):1424-6.Blood2014-02-27T00:00:002014Statin and aspirin use is associated with improved outcome of FCR therapy in relapsed/refractory chronic lymphocytic leukemia.24615780Falchi L, Keating MJ, Marom EM, Truong MT, Schlette EJ, Sargent RL, Trinh L, Wang X, Smith SC, Jain N, Estrov Z, O'Brien S, Wierda WG, Lerner S, Ferrajoli ABloodCorrelation between FDG/PET, histology, characteristics, and survival in 332 patients with chronic lymphoid leukemia. Blood. 2014 May 01; 123(18):2783-90.Blood2014-03-10T00:00:002014Correlation between FDG/PET, histology, characteristics, and survival in 332 patients with chronic lymphoid leukemia.24705492Strati P, Keating MJ, O'Brien SM, Burger J, Ferrajoli A, Jain N, Tambaro FP, Estrov Z, Jorgensen J, Challagundla P, Faderl SH, Wierda WGBloodEradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL. Blood. 2014 Jun 12; 123(24):3727-32.Blood2014-04-04T00:00:002014Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL.Authorship 2356941Authorship 2357681Authorship 2358251Authorship 2358492Authorship 2358631Authorship 2360362Authorship 2364231Authorship 2366531Authorship 2367122Authorship 2368182Authorship 2368371Authorship 2369271Authorship 2369891Authorship 2372271Authorship 2374341Authorship 2375363Authorship 2375812Authorship 2377344Authorship 2378342Authorship 2379971Authorship 2383354Authorship 2386271Authorship 2390851Authorship 2392909Authorship 2395351Authorship 2402505Authorship 2402794Authorship 2404505Authorship 2405103Authorship 2405487Authorship 2408792Authorship 2411643Authorship 2413192Authorship 24135210Authorship 2413783Authorship 2414322Authorship 2420927Authorship 2423911Authorship 24243312Authorship 2425772Authorship 2426542Authorship 2427173Authorship 24284210Authorship 2431262Authorship 2435532Authorship 2435903Authorship 2443331Authorship 2444936Authorship 2448745Authorship 2450244Authorship 2450556Authorship 2456305Authorship 2464172Authorship 2467946Authorship 24710710Authorship 24789411Authorship 24825413Authorship 2484438Authorship 2488888Authorship 2499256Authorship 2500944Authorship 25012710Authorship 2503694Authorship 2509096Authorship 2514925Authorship 2519916Authorship 2526132Authorship 2530535Authorship 2531909Authorship 2534566Authorship 2537154Authorship 2540533Authorship 2541597Authorship 2551224Authorship 2556783Authorship 2561786Authorship 2582226Authorship 2589184Authorship 2590246Authorship 2592348Authorship 2594435Authorship 2599873Authorship 2600959Authorship 2602037Authorship 2603254Authorship 26088918Authorship 2609284Authorship 2614213Authorship 26160214Authorship 2623911Authorship 2625774Authorship 26258911493463Estrov Z, Talpaz M, Wetzler M, Kurzrock RLeukemia & lymphomaThe modulatory hematopoietic activities of leukemia inhibitory factor. Leuk Lymphoma. 1992 Sep; 8(1-2):1-7.Leuk Lymphoma1992-09-01T00:00:001992The modulatory hematopoietic activities of leukemia inhibitory factor.1628706Estrov Z, Park CH, Reading CL, Estey EH, Talpaz M, Kurzrock R, Deisseroth AB, Gutterman JUExperimental hematologyThe effect of granulocyte-macrophage colony-stimulating factor on undifferentiated and mature acute myelogenous leukemia blast progenitors. Exp Hematol. 1992 Aug; 20(7):886-90.Exp Hematol1992-08-01T00:00:001992The effect of granulocyte-macrophage colony-stimulating factor on undifferentiated and mature acute myelogenous leukemia blast progenitors.1713508Re GG, Estrov Z, Antoun GR, Felix EA, Pinkel DP, Zipf TFBloodDifferentiation in B-precursor acute lymphoblastic leukemia cell populations with CD34-positive subpopulations. Blood. 1991 Aug 01; 78(3):575-80.Blood1991-08-01T00:00:001991Differentiation in B-precursor acute lymphoblastic leukemia cell populations with CD34-positive subpopulations.1715791Estrov Z, Kurzrock R, Wetzler M, Kantarjian H, Blake M, Harris D, Gutterman JU, Talpaz MBloodSuppression of chronic myelogenous leukemia colony growth by interleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptors: a novel application for inhibitors of IL-1 activity. Blood. 1991 Sep 15; 78(6):1476-84.Blood1991-09-15T00:00:001991Suppression of chronic myelogenous leukemia colony growth by interleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptors: a novel application for inhibitors of IL-1 activity.1756190Estrov Z, Kurzrock R, Talpaz M, Blake M, Gutterman JUAnnals of hematologyGranulocyte-macrophage colony-stimulating factor and interleukin-3 in combination: a potent and consistent myelodysplastic syndrome bone marrow stimulant in vitro. Ann Hematol. 1991 Dec; 63(6):297-301.Ann Hematol1991-12-01T00:00:001991Granulocyte-macrophage colony-stimulating factor and interleukin-3 in combination: a potent and consistent myelodysplastic syndrome bone marrow stimulant in vitro.1999709Estrov Z, Meir R, Barak Y, Zaizov R, Zadik ZJournal of clinical oncology : official journal of the American Society of Clinical OncologyHuman growth hormone and insulin-like growth factor-1 enhance the proliferation of human leukemic blasts. J Clin Oncol. 1991 Mar; 9(3):394-9.J Clin Oncol1991-03-01T00:00:001991Human growth hormone and insulin-like growth factor-1 enhance the proliferation of human leukemic blasts.2048564Kurzrock R, Estrov Z, Talpaz M, Gutterman JUAmerican journal of clinical oncologyCytokines in tumor therapy. Interleukin-3. Am J Clin Oncol. 1991; 14 Suppl 1:S45-50.Am J Clin Oncol1991-01-01T00:00:001991Cytokines in tumor therapy. Interleukin-3.2445935Chan HS, Estrov Z, Weitzman SS, Freedman MHJournal of clinical oncology : official journal of the American Society of Clinical OncologyThe value of intensive combination chemotherapy for juvenile chronic myelogenous leukemia. J Clin Oncol. 1987 Dec; 5(12):1960-7.J Clin Oncol1987-12-01T00:00:001987The value of intensive combination chemotherapy for juvenile chronic myelogenous leukemia.2502895Estrov Z, Berrebi A, Kusminsky G, Resnitzky PActa haematologicaCirculating mononuclear cells from pure red cell aplasia of chronic lymphocytic leukemia suppress in vitro erythropoiesis. Acta Haematol. 1989; 81(4):213-6.Acta Haematol1989-01-01T00:00:001989Circulating mononuclear cells from pure red cell aplasia of chronic lymphocytic leukemia suppress in vitro erythropoiesis.2649168Halperin DS, Estrov Z, Freedman MHBloodDiamond-Blackfan anemia: promotion of marrow erythropoiesis in vitro by recombinant interleukin-3. Blood. 1989 Apr; 73(5):1168-74.Blood1989-04-01T00:00:001989Diamond-Blackfan anemia: promotion of marrow erythropoiesis in vitro by recombinant interleukin-3.2676769Estrov Z, Freedman MHHarefuah[Recent advances in juvenile chronic myelogenous leukemia]. Harefuah. 1989 May 10; 116(10):538-41.Harefuah1989-05-10T00:00:001989[Recent advances in juvenile chronic myelogenous leukemia].2841965Estrov Z, Halperin DS, Coceani F, Freedman MHBritish journal of haematologyModulation of human marrow haematopoiesis by leucotrienes in vitro. Br J Haematol. 1988 Jul; 69(3):321-7.Br J Haematol1988-07-01T00:00:001988Modulation of human marrow haematopoiesis by leucotrienes in vitro.3103713Estrov Z, Roifman C, Mills G, Grunberger T, Gelfand EW, Freedman MHBloodThe regulatory role of interleukin 2-responsive T lymphocytes on human marrow granulopoiesis. Blood. 1987 Apr; 69(4):1161-6.Blood1987-04-01T00:00:001987The regulatory role of interleukin 2-responsive T lymphocytes on human marrow granulopoiesis.3312841Kaplinsky C, Estrov Z, Freedman MH, Gelfand EW, Cohen ALeukemiaEffect of deferoxamine on DNA synthesis, DNA repair, cell proliferation, and differentiation of HL-60 cells. Leukemia. 1987 May; 1(5):437-41.Leukemia1987-05-01T00:00:001987Effect of deferoxamine on DNA synthesis, DNA repair, cell proliferation, and differentiation of HL-60 cells.3465439Estrov Z, Zimmerman B, Grunberger T, Chao J, Teshima IE, Chan HS, Freedman MHCancer researchCharacterization of malignant peripheral blood cells of juvenile chronic myelogenous leukemia. Cancer Res. 1986 Dec; 46(12 Pt 1):6456-61.Cancer Res1986-12-01T00:00:001986Characterization of malignant peripheral blood cells of juvenile chronic myelogenous leukemia.3478101Estrov Z, Dub? ID, Chan HS, Freedman MHBloodResidual juvenile chronic myelogenous leukemia cells detected in peripheral blood during clinical remission. Blood. 1987 Nov; 70(5):1466-9.Blood1987-11-01T00:00:001987Residual juvenile chronic myelogenous leukemia cells detected in peripheral blood during clinical remission.3862600Freedman MH, Fish E, Estrov Z, Grunberger T, Williams BRExperimental hematologyGrowth inhibitory effect of gene-cloned interferons on human myeloblast colonies. Exp Hematol. 1985 Oct; 13(9):932-6.Exp Hematol1985-10-01T00:00:001985Growth inhibitory effect of gene-cloned interferons on human myeloblast colonies.3866124Resnitzky P, Estrov Z, Haran-Ghera NLeukemia researchHigh incidence of acute myeloid leukemia in SJL/J mice after X-irradiation and corticosteroids. Leuk Res. 1985; 9(12):1519-28.Leuk Res1985-01-01T00:00:001985High incidence of acute myeloid leukemia in SJL/J mice after X-irradiation and corticosteroids.6139289Estrov Z, Resnitzky PExperimental hematologyEnhancement of hemopoietic stem cell proliferation by prostaglandin inhibitory drugs. Exp Hematol. 1983 Oct; 11(9):802-9.Exp Hematol1983-10-01T00:00:001983Enhancement of hemopoietic stem cell proliferation by prostaglandin inhibitory drugs.7013961Naparstek Y, Ben-Chetrit E, Okon E, Estrov Z, Eliakim MCancerAngioimmunoblastic lymphadenopathy in a patient with allergy to insulin: a case report. Cancer. 1981 Feb 01; 47(3):545-7.Cancer1981-02-01T00:00:001981Angioimmunoblastic lymphadenopathy in a patient with allergy to insulin: a case report.7497586Przepiorka D, Madden T, Ippoliti C, Estrov Z, Dimopoulos MCancer chemotherapy and pharmacologyDosing of thioTEPA for myeloablative therapy. Cancer Chemother Pharmacol. 1995; 37(1-2):155-60.Cancer Chemother Pharmacol1995-01-01T00:00:001995Dosing of thioTEPA for myeloablative therapy.7533582Ferrajoli A, Talpaz M, Ordonez NG, Stanley ER, Hirsch-Ginsberg C, Zipf TF, Wetzler M, Kurzrock R, Estrov ZStem cells (Dayton, Ohio)Interleukin 4 alters human bone marrow stroma and modulates its interaction with hematopoietic progenitors. Stem Cells. 1994 Nov; 12(6):638-49.Stem Cells1994-11-01T00:00:001994Interleukin 4 alters human bone marrow stroma and modulates its interaction with hematopoietic progenitors.7544738Estrov Z, Talpaz M, Estey EH, Strassmann GExperimental hematologyRole of suramin as an IL-1 inhibitor in suppression of acute myelogenous leukemia progenitor proliferation. Exp Hematol. 1995 Sep; 23(10):1080-7.Exp Hematol1995-09-01T00:00:001995Role of suramin as an IL-1 inhibitor in suppression of acute myelogenous leukemia progenitor proliferation.7694373Estrov ZSeminars in hematologyInterruption of autocrine and paracrine growth-stimulatory mechanisms: a new therapeutic strategy for chronic myelogenous leukemia. Semin Hematol. 1993 Jul; 30(3 Suppl 3):35-6.Semin Hematol1993-07-01T00:00:001993Interruption of autocrine and paracrine growth-stimulatory mechanisms: a new therapeutic strategy for chronic myelogenous leukemia.8338938Kantarjian HM, Deisseroth A, Kurzrock R, Estrov Z, Talpaz MBloodChronic myelogenous leukemia: a concise update. Blood. 1993 Aug 01; 82(3):691-703.Blood1993-08-01T00:00:001993Chronic myelogenous leukemia: a concise update.8382256Estrov Z, Kurzrock R, Pocsik E, Pathak S, Kantarjian HM, Zipf TF, Harris D, Talpaz M, Aggarwal BBThe Journal of experimental medicineLymphotoxin is an autocrine growth factor for Epstein-Barr virus-infected B cell lines. J Exp Med. 1993 Mar 01; 177(3):763-74.J Exp Med1993-03-01T00:00:001993Lymphotoxin is an autocrine growth factor for Epstein-Barr virus-infected B cell lines.8541550Estrov Z, Black RA, Sleath PR, Harris D, Van Q, LaPushin R, Estey EH, Talpaz MBloodEffect of interleukin-1 beta converting enzyme inhibitor on acute myelogenous leukemia progenitor proliferation. Blood. 1995 Dec 15; 86(12):4594-602.Blood1995-12-15T00:00:001995Effect of interleukin-1 beta converting enzyme inhibitor on acute myelogenous leukemia progenitor proliferation.9086432Estrov Z, Talpaz MLeukemia & lymphomaRole of interleukin-1 beta converting enzyme (ICE) in acute myelogenous leukemia cell proliferation and programmed cell death. Leuk Lymphoma. 1997 Feb; 24(5-6):379-91.Leuk Lymphoma1997-02-01T00:00:001997Role of interleukin-1 beta converting enzyme (ICE) in acute myelogenous leukemia cell proliferation and programmed cell death.9596488Dhingra K, Sahin A, Emami K, Hortobagyi GN, Estrov ZBreast cancer research and treatmentExpression of leukemia inhibitory factor and its receptor in breast cancer: a potential autocrine and paracrine growth regulatory mechanism. Breast Cancer Res Treat. 1998 Mar; 48(2):165-74.Breast Cancer Res Treat1998-03-01T00:00:001998Expression of leukemia inhibitory factor and its receptor in breast cancer: a potential autocrine and paracrine growth regulatory mechanism.9617575Liu J, Hadjokas N, Mosley B, Estrov Z, Spence MJ, Vestal RECytokineOncostatin M-specific receptor expression and function in regulating cell proliferation of normal and malignant mammary epithelial cells. Cytokine. 1998 Apr; 10(4):295-302.Cytokine1998-04-01T00:00:001998Oncostatin M-specific receptor expression and function in regulating cell proliferation of normal and malignant mammary epithelial cells.9676840Beran M, Cao X, Estrov Z, Jeha S, Jin G, O'Brien S, Talpaz M, Arlinghaus RB, Lydon NB, Kantarjian HClinical cancer research : an official journal of the American Association for Cancer ResearchSelective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148). Clin Cancer Res. 1998 Jul; 4(7):1661-72.Clin Cancer Res1998-07-01T00:00:001998Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148).9713960Ferrajoli A, Talpaz M, Kurzrock R, Harris D, Van Q, Estey EH, Estrov ZLeukemia & lymphomaThrombopoietin stimulates myelodysplastic syndrome granulocyte-macrophage and erythroid progenitor proliferation. Leuk Lymphoma. 1998 Jul; 30(3-4):279-92.Leuk Lymphoma1998-07-01T00:00:001998Thrombopoietin stimulates myelodysplastic syndrome granulocyte-macrophage and erythroid progenitor proliferation.9715769Faderl S, Estrov ZCritical reviews in oncology/hematologyThe clinical significance of detection of residual disease in childhood ALL. Crit Rev Oncol Hematol. 1998 Jun; 28(1):31-55.Crit Rev Oncol Hematol1998-06-01T00:00:001998The clinical significance of detection of residual disease in childhood ALL.9794400Konopleva M, Estrov Z, Zhao S, Andreeff M, Mehta KJournal of immunology (Baltimore, Md. : 1950)Ligation of cell surface CD38 protein with agonistic monoclonal antibody induces a cell growth signal in myeloid leukemia cells. J Immunol. 1998 Nov 01; 161(9):4702-8.J Immunol1998-11-01T00:00:001998Ligation of cell surface CD38 protein with agonistic monoclonal antibody induces a cell growth signal in myeloid leukemia cells.9933137Albitar M, Manshouri T, Kantarjian H, Keating M, Estrov Z, Faber J, Freireich EJ, Pierce S, Estey ELeukemia researchCorrelation between lower c-mpl protein expression and favorable cytogenetic groups in acute myeloid leukemia. Leuk Res. 1999 Jan; 23(1):63-9.Leuk Res1999-01-01T00:00:001999Correlation between lower c-mpl protein expression and favorable cytogenetic groups in acute myeloid leukemia.10029596Konopleva M, Mikhail A, Estrov Z, Zhao S, Harris D, Sanchez-Williams G, Kornblau SM, Dong J, Kliche KO, Jiang S, Snodgrass HR, Estey EH, Andreeff MBloodExpression and function of leptin receptor isoforms in myeloid leukemia and myelodysplastic syndromes: proliferative and anti-apoptotic activities. Blood. 1999 Mar 01; 93(5):1668-76.Blood1999-03-01T00:00:001999Expression and function of leptin receptor isoforms in myeloid leukemia and myelodysplastic syndromes: proliferative and anti-apoptotic activities.10428738Faderl S, Talpaz M, Estrov Z, Kantarjian HMAnnals of internal medicineChronic myelogenous leukemia: biology and therapy. Ann Intern Med. 1999 Aug 03; 131(3):207-19.Ann Intern Med1999-08-03T00:00:001999Chronic myelogenous leukemia: biology and therapy.10515888Estrov Z, Manna SK, Harris D, Van Q, Estey EH, Kantarjian HM, Talpaz M, Aggarwal BBBloodPhenylarsine oxide blocks interleukin-1beta-induced activation of the nuclear transcription factor NF-kappaB, inhibits proliferation, and induces apoptosis of acute myelogenous leukemia cells. Blood. 1999 Oct 15; 94(8):2844-53.Blood1999-10-15T00:00:001999Phenylarsine oxide blocks interleukin-1beta-induced activation of the nuclear transcription factor NF-kappaB, inhibits proliferation, and induces apoptosis of acute myelogenous leukemia cells.10632337Faderl S, Thall PF, Kantarjian HM, Talpaz M, Harris D, Van Q, Beran M, Kornblau SM, Pierce S, Estrov ZClinical cancer research : an official journal of the American Association for Cancer ResearchCaspase 2 and caspase 3 as predictors of complete remission and survival in adults with acute lymphoblastic leukemia. Clin Cancer Res. 1999 Dec; 5(12):4041-7.Clin Cancer Res1999-12-01T00:00:001999Caspase 2 and caspase 3 as predictors of complete remission and survival in adults with acute lymphoblastic leukemia.10641574Faderl S, Estrov Z, Kantarjian HM, Thomas D, Cortes J, Manshouri T, Chan CC, Hays KJ, Pierce S, Albitar MCytokines, cellular & molecular therapyThe incidence of chromosome 9p21 abnormalities and deletions of tumor suppressor genes p15(INK4b)/p16(INK4a)/p14(ARF) in patients with acute lymphoblastic leukemia. Cytokines Cell Mol Ther. 1999 Sep; 5(3):159-63.Cytokines Cell Mol Ther1999-09-01T00:00:001999The incidence of chromosome 9p21 abnormalities and deletions of tumor suppressor genes p15(INK4b)/p16(INK4a)/p14(ARF) in patients with acute lymphoblastic leukemia.10928987Kardinal C, Konkol B, Schulz A, Posern G, Lin H, Adermann K, Eulitz M, Estrov Z, Talpaz M, Arlinghaus RB, Feller SMFASEB journal : official publication of the Federation of American Societies for Experimental BiologyCell-penetrating SH3 domain blocker peptides inhibit proliferation of primary blast cells from CML patients. FASEB J. 2000 Aug; 14(11):1529-38.FASEB J2000-08-01T00:00:002000Cell-penetrating SH3 domain blocker peptides inhibit proliferation of primary blast cells from CML patients.11064355Faderl S, Kantarjian HM, Estey E, Manshouri T, Chan CY, Rahman Elsaied A, Kornblau SM, Cortes J, Thomas DA, Pierce S, Keating MJ, Estrov Z, Albitar MCancerThe prognostic significance of p16(INK4a)/p14(ARF) locus deletion and MDM-2 protein expression in adult acute myelogenous leukemia. Cancer. 2000 Nov 01; 89(9):1976-82.Cancer2000-11-01T00:00:002000The prognostic significance of p16(INK4a)/p14(ARF) locus deletion and MDM-2 protein expression in adult acute myelogenous leukemia.11147224Stock W, Estrov ZHematology/oncology clinics of North AmericaStudies of minimal residual disease in acute lymphocytic leukemia. Hematol Oncol Clin North Am. 2000 Dec; 14(6):1289-305, viii-ix.Hematol Oncol Clin North Am2000-12-01T00:00:002000Studies of minimal residual disease in acute lymphocytic leukemia.11196151Wang Y, Liu J, Wu Y, Luo W, Lin SH, Lin H, Hawk N, Sun T, Guo JQ, Estrov Z, Talpaz M, Champlin R, Arlinghaus RBCancer researchExpression of a truncated first exon BCR sequence in chronic myelogenous leukemia cells blocks cell growth and induces cell death. Cancer Res. 2001 Jan 01; 61(1):138-44.Cancer Res2001-01-01T00:00:002001Expression of a truncated first exon BCR sequence in chronic myelogenous leukemia cells blocks cell growth and induces cell death.11243400Sarriera JE, Albitar M, Estrov Z, Gidel C, Aboul-Nasr R, Manshouri T, Kornblau S, Chang KS, Kantarjian H, Estey ELeukemiaComparison of outcome in acute myelogenous leukemia patients with translocation (8;21) found by standard cytogenetic analysis and patients with AML1/ETO fusion transcript found only by PCR testing. Leukemia. 2001 Jan; 15(1):57-61.Leukemia2001-01-01T00:00:002001Comparison of outcome in acute myelogenous leukemia patients with translocation (8;21) found by standard cytogenetic analysis and patients with AML1/ETO fusion transcript found only by PCR testing.11426520Faderl S, Estrov ZLeukemia & lymphomaThe clinical significance of caspase regulation in acute leukemia. Leuk Lymphoma. 2001 Feb; 40(5-6):471-81.Leuk Lymphoma2001-02-01T00:00:002001The clinical significance of caspase regulation in acute leukemia.11756188Konopleva M, Tsao T, Ruvolo P, Stiouf I, Estrov Z, Leysath CE, Zhao S, Harris D, Chang S, Jackson CE, Munsell M, Suh N, Gribble G, Honda T, May WS, Sporn MB, Andreeff MBloodNovel triterpenoid CDDO-Me is a potent inducer of apoptosis and differentiation in acute myelogenous leukemia. Blood. 2002 Jan 01; 99(1):326-35.Blood2002-01-01T00:00:002002Novel triterpenoid CDDO-Me is a potent inducer of apoptosis and differentiation in acute myelogenous leukemia.11911247Faderl S, Estrov Z, Kantarjian HM, Harris D, Van Q, Fokt I, Przewloka T, Godlewski C, Woynarowski JM, Priebe WAnticancer researchWP744, a novel anthracycline with enhanced proapoptotic and antileukemic activity. Anticancer Res. 2001 Nov-Dec; 21(6A):3777-84.Anticancer Res2001-11-01T00:00:002001WP744, a novel anthracycline with enhanced proapoptotic and antileukemic activity.11964319Milella M, Estrov Z, Kornblau SM, Carter BZ, Konopleva M, Tari A, Schober WD, Harris D, Leysath CE, Lopez-Berestein G, Huang Z, Andreeff MBloodSynergistic induction of apoptosis by simultaneous disruption of the Bcl-2 and MEK/MAPK pathways in acute myelogenous leukemia. Blood. 2002 May 01; 99(9):3461-4.Blood2002-05-01T00:00:002002Synergistic induction of apoptosis by simultaneous disruption of the Bcl-2 and MEK/MAPK pathways in acute myelogenous leukemia.12008081Ravandi F, Cortes J, Estrov Z, Thomas D, Giles FJ, Huh YO, Pierce S, O'Brien S, Faderl S, Kantarjian HMLeukemia researchCD56 expression predicts occurrence of CNS disease in acute lymphoblastic leukemia. Leuk Res. 2002 Jul; 26(7):643-9.Leuk Res2002-07-01T00:00:002002CD56 expression predicts occurrence of CNS disease in acute lymphoblastic leukemia.12149200Ferrajoli A, Keating MJ, Manshouri T, Giles FJ, Dey A, Estrov Z, Koller CA, Kurzrock R, Thomas DA, Faderl S, Lerner S, O'Brien S, Albitar MBloodThe clinical significance of tumor necrosis factor-alpha plasma level in patients having chronic lymphocytic leukemia. Blood. 2002 Aug 15; 100(4):1215-9.Blood2002-08-15T00:00:002002The clinical significance of tumor necrosis factor-alpha plasma level in patients having chronic lymphocytic leukemia.12663443Faderl S, Harris D, Van Q, Kantarjian HM, Talpaz M, Estrov ZBloodGranulocyte-macrophage colony-stimulating factor (GM-CSF) induces antiapoptotic and proapoptotic signals in acute myeloid leukemia. Blood. 2003 Jul 15; 102(2):630-7.Blood2003-03-27T00:00:002003Granulocyte-macrophage colony-stimulating factor (GM-CSF) induces antiapoptotic and proapoptotic signals in acute myeloid leukemia.12931235K?rbling M, Estrov Z, Champlin RBone marrow transplantationAdult stem cells and tissue repair. Bone Marrow Transplant. 2003 Aug; 32 Suppl 1:S23-4.Bone Marrow Transplant2003-08-01T00:00:002003Adult stem cells and tissue repair.14523478Thompson MP, Aggarwal BB, Shishodia S, Estrov Z, Kurzrock RLeukemiaAutocrine lymphotoxin production in Epstein-Barr virus-immortalized B cells: induction via NF-kappaB activation mediated by EBV-derived latent membrane protein 1. Leukemia. 2003 Nov; 17(11):2196-201.Leukemia2003-11-01T00:00:002003Autocrine lymphotoxin production in Epstein-Barr virus-immortalized B cells: induction via NF-kappaB activation mediated by EBV-derived latent membrane protein 1.15061199Faderl S, Estrov ZLeukemia & lymphomaHematopoietic recovery following induction therapy of acute leukemias: prognostic implications and a new look at the definition of remission. Leuk Lymphoma. 2004 Jan; 45(1):67-71.Leuk Lymphoma2004-01-01T00:00:002004Hematopoietic recovery following induction therapy of acute leukemias: prognostic implications and a new look at the definition of remission.15621735Bueso-Ramos CE, Ferrajoli A, Medeiros LJ, Keating MJ, Estrov ZHematology (Amsterdam, Netherlands)Aberrant morphology, proliferation, and apoptosis of B-cell chronic lymphocytic leukemia cells. Hematology. 2004 Aug; 9(4):279-86.Hematology2004-08-01T00:00:002004Aberrant morphology, proliferation, and apoptosis of B-cell chronic lymphocytic leukemia cells.15970928Amit-Vazina M, Shishodia S, Harris D, Van Q, Wang M, Weber D, Alexanian R, Talpaz M, Aggarwal BB, Estrov ZBritish journal of cancerAtiprimod blocks STAT3 phosphorylation and induces apoptosis in multiple myeloma cells. Br J Cancer. 2005 Jul 11; 93(1):70-80.Br J Cancer2005-07-11T00:00:002005Atiprimod blocks STAT3 phosphorylation and induces apoptosis in multiple myeloma cells.16158916Faderl S, Ferrajoli A, Harris D, Van Q, Priebe W, Estrov ZAnticancer researchWP-1034, a novel JAK-STAT inhibitor, with proapoptotic and antileukemic activity in acute myeloid leukemia (AML). Anticancer Res. 2005 May-Jun; 25(3B):1841-50.Anticancer Res2005-05-01T00:00:002005WP-1034, a novel JAK-STAT inhibitor, with proapoptotic and antileukemic activity in acute myeloid leukemia (AML).16291594Chandra J, Tracy J, Loegering D, Flatten K, Verstovsek S, Beran M, Gorre M, Estrov Z, Donato N, Talpaz M, Sawyers C, Bhalla K, Karp J, Sausville E, Kaufmann SHBloodAdaphostin-induced oxidative stress overcomes BCR/ABL mutation-dependent and -independent imatinib resistance. Blood. 2006 Mar 15; 107(6):2501-6.Blood2005-11-15T00:00:002005Adaphostin-induced oxidative stress overcomes BCR/ABL mutation-dependent and -independent imatinib resistance.16882711Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B, Yang H, Rosner G, Verstovsek S, Rytting M, Wierda WG, Ravandi F, Koller C, Xiao L, Faderl S, Estrov Z, Cortes J, O'brien S, Estey E, Bueso-Ramos C, Fiorentino J, Jabbour E, Issa JPBloodPhase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. Blood. 2006 Nov 15; 108(10):3271-9.Blood2006-08-01T00:00:002006Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia.17002637K?rbling M, Reuben JM, Gao H, Lee BN, Harris DM, Cogdell D, Giralt SA, Khouri IF, Saliba RM, Champlin RE, Zhang W, Estrov ZTransfusionRecombinant human granulocyte-colony-stimulating factor-mobilized and apheresis-collected endothelial progenitor cells: a novel blood cell component for therapeutic vasculogenesis. Transfusion. 2006 Oct; 46(10):1795-802.Transfusion2006-10-01T00:00:002006Recombinant human granulocyte-colony-stimulating factor-mobilized and apheresis-collected endothelial progenitor cells: a novel blood cell component for therapeutic vasculogenesis.17172852Kornblau SM, Qiu YH, Bekele BN, Cade JS, Zhou X, Harris D, Jackson CE, Estrov Z, Andreeff MCell cycle (Georgetown, Tex.)Studying the right cell in acute myelogenous leukemia: dynamic changes of apoptosis and signal transduction pathway protein expression in chemotherapy resistant ex-vivo selected "survivor cells". Cell Cycle. 2006 Dec; 5(23):2769-77.Cell Cycle2006-12-01T00:00:002006Studying the right cell in acute myelogenous leukemia: dynamic changes of apoptosis and signal transduction pathway protein expression in chemotherapy resistant ex-vivo selected "survivor cells".17202319Bartholomeusz GA, Talpaz M, Kapuria V, Kong LY, Wang S, Estrov Z, Priebe W, Wu J, Donato NJBloodActivation of a novel Bcr/Abl destruction pathway by WP1130 induces apoptosis of chronic myelogenous leukemia cells. Blood. 2007 Apr 15; 109(8):3470-8.Blood2007-01-03T00:00:002007Activation of a novel Bcr/Abl destruction pathway by WP1130 induces apoptosis of chronic myelogenous leukemia cells.17593028Aribi A, Bueso-Ramos C, Estey E, Estrov Z, O'Brien S, Giles F, Faderl S, Thomas D, Kebriaei P, Garcia-Manero G, Pierce S, Cortes J, Kantarjian H, Ravandi FBritish journal of haematologyBiphenotypic acute leukaemia: a case series. Br J Haematol. 2007 Jul; 138(2):213-6.Br J Haematol2007-07-01T00:00:002007Biphenotypic acute leukaemia: a case series.17596541Soriano AO, Yang H, Faderl S, Estrov Z, Giles F, Ravandi F, Cortes J, Wierda WG, Ouzounian S, Quezada A, Pierce S, Estey EH, Issa JP, Kantarjian HM, Garcia-Manero GBloodSafety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood. 2007 Oct 01; 110(7):2302-8.Blood2007-06-27T00:00:002007Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome.18182662Tsimberidou AM, Wierda WG, Plunkett W, Kurzrock R, O'Brien S, Wen S, Ferrajoli A, Ravandi-Kashani F, Garcia-Manero G, Estrov Z, Kipps TJ, Brown JR, Fiorentino A, Lerner S, Kantarjian HM, Keating MJJournal of clinical oncology : official journal of the American Society of Clinical OncologyPhase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol. 2008 Jan 10; 26(2):196-203.J Clin Oncol2008-01-10T00:00:002008Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia.18347134Sun M, Estrov Z, Ji Y, Coombes KR, Harris DH, Kurzrock RMolecular cancer therapeuticsCurcumin (diferuloylmethane) alters the expression profiles of microRNAs in human pancreatic cancer cells. Mol Cancer Ther. 2008 Mar; 7(3):464-73.Mol Cancer Ther2008-03-01T00:00:002008Curcumin (diferuloylmethane) alters the expression profiles of microRNAs in human pancreatic cancer cells.18473351Borthakur G, Alvarado Y, Ravandi-Kashani F, Cortes J, Estrov Z, Faderl S, Ivy P, Bueso-Ramos C, Nebiyou Bekele B, Giles FCancerPhase 1 study of XL119, a rebeccamycin analog, in patients with refractory hematologic malignancies. Cancer. 2008 Jul 15; 113(2):360-6.Cancer2008-07-15T00:00:002008Phase 1 study of XL119, a rebeccamycin analog, in patients with refractory hematologic malignancies.18565853Faderl S, Ravandi F, Huang X, Garcia-Manero G, Ferrajoli A, Estrov Z, Borthakur G, Verstovsek S, Thomas DA, Kwari M, Kantarjian HMBloodA randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood. 2008 Sep 01; 112(5):1638-45.Blood2008-06-18T00:00:002008A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome.19458051Ma W, Kantarjian H, Bekele B, Donahue AC, Zhang X, Zhang ZJ, O'Brien S, Estey E, Estrov Z, Cortes J, Keating M, Giles F, Albitar MClinical cancer research : an official journal of the American Association for Cancer ResearchProteasome enzymatic activities in plasma as risk stratification of patients with acute myeloid leukemia and advanced-stage myelodysplastic syndrome. Clin Cancer Res. 2009 Jun 01; 15(11):3820-6.Clin Cancer Res2009-05-19T00:00:002009Proteasome enzymatic activities in plasma as risk stratification of patients with acute myeloid leukemia and advanced-stage myelodysplastic syndrome.19458629Carter BZ, Mak DH, Woessner R, Gross S, Schober WD, Estrov Z, Kantarjian H, Andreeff MLeukemiaInhibition of KSP by ARRY-520 induces cell cycle block and cell death via the mitochondrial pathway in AML cells. Leukemia. 2009 Oct; 23(10):1755-62.Leukemia2009-05-21T00:00:002009Inhibition of KSP by ARRY-520 induces cell cycle block and cell death via the mitochondrial pathway in AML cells.19729517Garg RJ, Kantarjian H, O'Brien S, Quint?s-Cardama A, Faderl S, Estrov Z, Cortes JBloodThe use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up. Blood. 2009 Nov 12; 114(20):4361-8.Blood2009-09-03T00:00:002009The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up.19826111Quint?s-Cardama A, Kantarjian H, Manshouri T, Luthra R, Estrov Z, Pierce S, Richie MA, Borthakur G, Konopleva M, Cortes J, Verstovsek SJournal of clinical oncology : official journal of the American Society of Clinical OncologyPegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol. 2009 Nov 10; 27(32):5418-24.J Clin Oncol2009-10-13T00:00:002009Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera.20348955Wang Y, Klumpp S, Amin HM, Liang H, Li J, Estrov Z, Zweidler-McKay P, Brandt SJ, Agulnick A, Nagarajan LOncogeneSSBP2 is an in vivo tumor suppressor and regulator of LDB1 stability. Oncogene. 2010 May 27; 29(21):3044-53.Oncogene2010-03-29T00:00:002010SSBP2 is an in vivo tumor suppressor and regulator of LDB1 stability.20362333Bruey JM, Kantarjian H, Ma W, Estrov Z, Yeh C, Donahue A, Sanders H, O'Brien S, Keating M, Albitar MLeukemia researchCirculating Ki-67 index in plasma as a biomarker and prognostic indicator in chronic lymphocytic leukemia. Leuk Res. 2010 Oct; 34(10):1320-4.Leuk Res2010-04-01T00:00:002010Circulating Ki-67 index in plasma as a biomarker and prognostic indicator in chronic lymphocytic leukemia.20421540Faderl S, Garcia-Manero G, Estrov Z, Ravandi F, Borthakur G, Cortes JE, O'Brien S, Gandhi V, Plunkett W, Byrd A, Kwari M, Kantarjian HMJournal of clinical oncology : official journal of the American Society of Clinical OncologyOral clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome. J Clin Oncol. 2010 Jun 01; 28(16):2755-60.J Clin Oncol2010-04-26T00:00:002010Oral clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome.20686606Li P, Harris D, Liu Z, Liu J, Keating M, Estrov ZPloS oneStat3 activates the receptor tyrosine kinase like orphan receptor-1 gene in chronic lymphocytic leukemia cells. PLoS One. 2010 Jul 29; 5(7):e11859.PLoS One2010-07-29T00:00:002010Stat3 activates the receptor tyrosine kinase like orphan receptor-1 gene in chronic lymphocytic leukemia cells.20843246Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, Thomas DA, Estrov Z, Fridman JS, Bradley EC, Erickson-Viitanen S, Vaddi K, Levy R, Tefferi AThe New England journal of medicineSafety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med. 2010 Sep 16; 363(12):1117-27.N Engl J Med2010-09-16T00:00:002010Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.21555694Chen Y, Cortes J, Estrov Z, Faderl S, Qiao W, Abruzzo L, Garcia-Manero G, Pierce S, Huang X, Kebriaei P, Kadia T, De Lima M, Kantarjian H, Ravandi FJournal of clinical oncology : official journal of the American Society of Clinical OncologyPersistence of cytogenetic abnormalities at complete remission after induction in patients with acute myeloid leukemia: prognostic significance and the potential role of allogeneic stem-cell transplantation. J Clin Oncol. 2011 Jun 20; 29(18):2507-13.J Clin Oncol2011-05-09T00:00:002011Persistence of cytogenetic abnormalities at complete remission after induction in patients with acute myeloid leukemia: prognostic significance and the potential role of allogeneic stem-cell transplantation.22072492Dimicoli S, Jabbour E, Borthakur G, Kadia T, Estrov Z, Yang H, Kelly M, Pierce S, Kantarjian H, Garcia-Manero GAmerican journal of hematologyPhase II study of the histone deacetylase inhibitor panobinostat (LBH589) in patients with low or intermediate-1 risk myelodysplastic syndrome. Am J Hematol. 2012 Jan; 87(1):127-9.Am J Hematol2011-11-10T00:00:002011Phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in patients with low or intermediate-1 risk myelodysplastic syndrome.22578814Chacar C, Jabbour E, Ravandi F, Borthakur G, Kadia T, Estrov Z, Rios MB, Cortes J, Kantarjian HClinical lymphoma, myeloma & leukemiaPhase I-II study of bendamustine in patients with acute leukemia and high risk myelodysplastic syndrome. Clin Lymphoma Myeloma Leuk. 2012 Jun; 12(3):197-200.Clin Lymphoma Myeloma Leuk2012-06-01T00:00:002012Phase I-II study of bendamustine in patients with acute leukemia and high risk myelodysplastic syndrome.23246163Bhamidipati PK, Jabbour E, Konoplev S, Estrov Z, Cortes J, Daver NClinical lymphoma, myeloma & leukemiaEpstein-Barr virus-induced CD30-positive diffuse large B-cell lymphoma in a patient with mixed-phenotypic leukemia treated with clofarabine. Clin Lymphoma Myeloma Leuk. 2013 Jun; 13(3):342-6.Clin Lymphoma Myeloma Leuk2012-12-14T00:00:002012Epstein-Barr virus-induced CD30-positive diffuse large B-cell lymphoma in a patient with mixed-phenotypic leukemia treated with clofarabine.23265768Malik A, Shoukier M, Garcia-Manero G, Wierda W, Cortes J, Bickel S, Keating MJ, Estrov ZClinical lymphoma, myeloma & leukemiaAzacitidine in fludarabine-refractory chronic lymphocytic leukemia: a phase II study. Clin Lymphoma Myeloma Leuk. 2013 Jun; 13(3):292-5.Clin Lymphoma Myeloma Leuk2012-12-21T00:00:002012Azacitidine in fludarabine-refractory chronic lymphocytic leukemia: a phase II study.23270583Rozovski U, Keating M, Estrov ZLeukemia & lymphomaThe significance of spliceosome mutations in chronic lymphocytic leukemia. Leuk Lymphoma. 2013 Jul; 54(7):1364-6.Leuk Lymphoma2013-01-10T00:00:002013The significance of spliceosome mutations in chronic lymphocytic leukemia.23387894Jain P, Benjamini O, Konoplev S, Mohamed MS, Romo CG, Estrov ZLeukemia & lymphomaSpontaneous remission of chemo-immunotherapy related, non-transplant Epstein-Barr virus-associated lymphoproliferative disorder in a patient with chronic lymphocytic leukemia. Leuk Lymphoma. 2013 Nov; 54(11):2540-2.Leuk Lymphoma2013-03-08T00:00:002013Spontaneous remission of chemo-immunotherapy related, non-transplant Epstein-Barr virus-associated lymphoproliferative disorder in a patient with chronic lymphocytic leukemia.23512829Al-Kali A, Quint?s-Cardama A, Luthra R, Bueso-Ramos C, Pierce S, Kadia T, Borthakur G, Estrov Z, Jabbour E, Faderl S, Ravandi F, Cortes J, Tefferi A, Kantarjian H, Garcia-Manero GAmerican journal of hematologyPrognostic impact of RAS mutations in patients with myelodysplastic syndrome. Am J Hematol. 2013 May; 88(5):365-9.Am J Hematol2013-03-20T00:00:002013Prognostic impact of RAS mutations in patients with myelodysplastic syndrome.23800602Benjamini O, Jain P, Konoplev SN, Yin CC, Abruzzo L, Wotherspoon AC, Dearden C, Shpall EJ, Estrov Z, Keating MJClinical lymphoma, myeloma & leukemiaCD4(-)/CD8(-) variant of T-cell large granular lymphocytic leukemia or hepatosplenic T-cell lymphoma: a clinicopathologic dilemma. Clin Lymphoma Myeloma Leuk. 2013 Oct; 13(5):610-3.Clin Lymphoma Myeloma Leuk2013-06-22T00:00:002013CD4(-)/CD8(-) variant of T-cell large granular lymphocytic leukemia or hepatosplenic T-cell lymphoma: a clinicopathologic dilemma.23821659Ferrajoli A, Shanafelt TD, Ivan C, Shimizu M, Rabe KG, Nouraee N, Ikuo M, Ghosh AK, Lerner S, Rassenti LZ, Xiao L, Hu J, Reuben JM, Calin S, You MJ, Manning JT, Wierda WG, Estrov Z, O'Brien S, Kipps TJ, Keating MJ, Kay NE, Calin GABloodPrognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia. Blood. 2013 Sep 12; 122(11):1891-9.Blood2013-07-02T00:00:002013Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia.23879961Rozovski U, Hazan-Halevy I, Keating MJ, Estrov ZCancer lettersPersonalized medicine in CLL: current status and future perspectives. Cancer Lett. 2014 Sep 28; 352(1):4-14.Cancer Lett2013-07-20T00:00:002013Personalized medicine in CLL: current status and future perspectives.24060288Quint?s-Cardama A, Grgurevic S, Rozovski U, Li P, Estrov Z, Cortes JClinical lymphoma, myeloma & leukemiaDetection of dormant chronic myeloid leukemia clones in the bone marrow of patients in complete molecular remission. Clin Lymphoma Myeloma Leuk. 2013 Dec; 13(6):681-5.Clin Lymphoma Myeloma Leuk2013-09-20T00:00:002013Detection of dormant chronic myeloid leukemia clones in the bone marrow of patients in complete molecular remission.24778152Rozovski U, Wu JY, Harris DM, Liu Z, Li P, Hazan-Halevy I, Ferrajoli A, Burger JA, O'Brien S, Jain N, Verstovsek S, Wierda WG, Keating MJ, Estrov ZBloodStimulation of the B-cell receptor activates the JAK2/STAT3 signaling pathway in chronic lymphocytic leukemia cells. Blood. 2014 Jun 12; 123(24):3797-802.Blood2014-04-28T00:00:002014Stimulation of the B-cell receptor activates the JAK2/STAT3 signaling pathway in chronic lymphocytic leukemia cells.25217891Strati P, Pemmaraju N, Estrov Z, Cardenas-Turanzas M, Pierce S, Newberry KJ, Daver N, Cortes J, Kantarjian H, Verstovsek SLeukemia researchClinical significance of microcytosis in patients with primary myelofibrosis. Leuk Res. 2014 Oct; 38(10):1212-6.Leuk Res2014-08-28T00:00:002014Clinical significance of microcytosis in patients with primary myelofibrosis.Authorship 2631561Authorship 2637892Authorship 2638264Authorship 2639464Authorship 2639754Authorship 2639864Authorship 2640918Authorship 2641841Authorship 2642862Authorship 2643512Authorship 2645515Authorship 2645532Authorship 2646397Authorship 2652548Authorship 2656121Authorship 2665733Authorship 26674311Authorship 2669366Authorship 2674905Authorship 2675345Authorship 2682797Authorship 26876110Authorship 2695811Authorship 2699729Authorship 2712252Authorship 27175313Authorship 2722432Authorship 2723171Authorship 2724192Authorship 27245523048651Estrov Z, Freedman MHCancer researchGrowth requirements for human acute lymphoblastic leukemia cells: refinement of a clonogenic assay. Cancer Res. 1988 Oct 15; 48(20):5901-7.Cancer Res1988-10-15T00:00:001988Growth requirements for human acute lymphoblastic leukemia cells: refinement of a clonogenic assay.3486684Estrov Z, Roifman C, Wang YP, Grunberger T, Gelfand EW, Freedman MHBloodThe regulatory role of interleukin 2-responsive T lymphocytes on early and mature erythroid progenitor proliferation. Blood. 1986 Jun; 67(6):1607-10.Blood1986-06-01T00:00:001986The regulatory role of interleukin 2-responsive T lymphocytes on early and mature erythroid progenitor proliferation.6576990Berrebi A, Estrov Z, Chemke JIsrael journal of medical sciencesChronic myeloid leukemia following radiotherapy for breast cancer. Isr J Med Sci. 1983 Jul; 19(7):653-4.Isr J Med Sci1983-07-01T00:00:001983Chronic myeloid leukemia following radiotherapy for breast cancer.7620179Roberts WM, Estrov Z, Zipf TFBloodDetection of minimal residual disease in acute lymphoblastic leukemia. Blood. 1995 Aug 01; 86(3):1237-9.Blood1995-08-01T00:00:001995Detection of minimal residual disease in acute lymphoblastic leukemia.7869771Ouspenskaia MV, Johnston DA, Roberts WM, Estrov Z, Zipf TFLeukemiaAccurate quantitation of residual B-precursor acute lymphoblastic leukemia by limiting dilution and a PCR-based detection system: a description of the method and the principles involved. Leukemia. 1995 Feb; 9(2):321-8.Leukemia1995-02-01T00:00:001995Accurate quantitation of residual B-precursor acute lymphoblastic leukemia by limiting dilution and a PCR-based detection system: a description of the method and the principles involved.7929813Talpaz M, Estrov Z, Kantarjian H, Ku S, Foteh A, Kurzrock RThe Journal of clinical investigationPersistence of dormant leukemic progenitors during interferon-induced remission in chronic myelogenous leukemia. Analysis by polymerase chain reaction of individual colonies. J Clin Invest. 1994 Oct; 94(4):1383-9.J Clin Invest1994-10-01T00:00:001994Persistence of dormant leukemic progenitors during interferon-induced remission in chronic myelogenous leukemia. Analysis by polymerase chain reaction of individual colonies.8137298Wetzler M, Estrov Z, Talpaz M, Kim KJ, Alphonso M, Srinivasan R, Kurzrock RCancer researchLeukemia inhibitory factor in long-term adherent layer cultures: increased levels of bioactive protein in leukemia and modulation by IL-4, IL-1 beta, and TNF-alpha. Cancer Res. 1994 Apr 01; 54(7):1837-42.Cancer Res1994-04-01T00:00:001994Leukemia inhibitory factor in long-term adherent layer cultures: increased levels of bioactive protein in leukemia and modulation by IL-4, IL-1 beta, and TNF-alpha.8384506Ferrajoli A, Talpaz M, Kurzrock R, Estrov ZStem cells (Dayton, Ohio)Analysis of the effects of tumor necrosis factor inhibitors on human hematopoiesis. Stem Cells. 1993 Mar; 11(2):112-9.Stem Cells1993-03-01T00:00:001993Analysis of the effects of tumor necrosis factor inhibitors on human hematopoiesis.8417962Kurzrock R, Kantarjian H, Wetzler M, Estrov Z, Estey E, Troutman-Worden K, Gutterman JU, Talpaz MExperimental hematologyUbiquitous expression of cytokines in diverse leukemias of lymphoid and myeloid lineage. Exp Hematol. 1993 Jan; 21(1):80-5.Exp Hematol1993-01-01T00:00:001993Ubiquitous expression of cytokines in diverse leukemias of lymphoid and myeloid lineage.8426475Estrov Z, Markowitz AB, Kurzrock R, Wetzler M, Kantarjian HM, Ferrajoli A, Gutterman JU, Talpaz MLeukemiaSuppression of chronic myelogenous leukemia colony growth by interleukin-4. Leukemia. 1993 Feb; 7(2):214-20.Leukemia1993-02-01T00:00:001993Suppression of chronic myelogenous leukemia colony growth by interleukin-4.8656668Sarris AH, Talpaz M, Deisseroth AB, Estrov ZLeukemiaHuman recombinant interferon-inducible protein-10 inhibits the proliferation of normal and acute myelogenous leukemia progenitors. Leukemia. 1996 May; 10(5):757-65.Leukemia1996-05-01T00:00:001996Human recombinant interferon-inducible protein-10 inhibits the proliferation of normal and acute myelogenous leukemia progenitors.8916965Lisovsky M, Estrov Z, Zhang X, Consoli U, Sanchez-Williams G, Snell V, Munker R, Goodacre A, Savchenko V, Andreeff MBloodFlt3 ligand stimulates proliferation and inhibits apoptosis of acute myeloid leukemia cells: regulation of Bcl-2 and Bax. Blood. 1996 Nov 15; 88(10):3987-97.Blood1996-11-15T00:00:001996Flt3 ligand stimulates proliferation and inhibits apoptosis of acute myeloid leukemia cells: regulation of Bcl-2 and Bax.9312169Peleg S, Qiu H, Reddy S, Harris D, Van Q, Estey EH, Talpaz M, Estrov ZThe Journal of clinical investigation1,25-Dihydroxyvitamin D3 and its analogues inhibit acute myelogenous leukemia progenitor proliferation by suppressing interleukin-1beta production. J Clin Invest. 1997 Oct 01; 100(7):1716-24.J Clin Invest1997-10-01T00:00:0019971,25-Dihydroxyvitamin D3 and its analogues inhibit acute myelogenous leukemia progenitor proliferation by suppressing interleukin-1beta production.9519789Kurzrock R, Talpaz M, Beran M, Harris D, Estrov ZLeukemiaDNA in situ hybridization of individual colonies to determine lineage derivation in leukemia. Leukemia. 1998 Feb; 12(2):242-6.Leukemia1998-02-01T00:00:001998DNA in situ hybridization of individual colonies to determine lineage derivation in leukemia.9523851Kurzrock R, Estrov Z, Ku S, Leonard M, Talpaz MThe Journal of laboratory and clinical medicineInterleukin-1 increases expression of the LYT-10 (NFkappaB2) proto-oncogene/transcription factor in renal cell carcinoma lines. J Lab Clin Med. 1998 Mar; 131(3):261-8.J Lab Clin Med1998-03-01T00:00:001998Interleukin-1 increases expression of the LYT-10 (NFkappaB2) proto-oncogene/transcription factor in renal cell carcinoma lines.9917220Faderl S, Estrov ZThe New England journal of medicineDetection of residual disease in childhood acute lymphoblastic leukemia. N Engl J Med. 1999 Jan 14; 340(2):152-3; author reply 153-4.N Engl J Med1999-01-14T00:00:001999Detection of residual disease in childhood acute lymphoblastic leukemia.10500797Konopleva M, Zhao S, Xie Z, Segall H, Younes A, Claxton DF, Estrov Z, Kornblau SM, Andreeff MAdvances in experimental medicine and biologyApoptosis. Molecules and mechanisms. Adv Exp Med Biol. 1999; 457:217-36.Adv Exp Med Biol1999-01-01T00:00:001999Apoptosis. Molecules and mechanisms.11948708Hester JJournal of clinical apheresisRE: Therapeutic plasma exchange: a paired comparison of Fresenius AS104 vs. COBE Spectra. J Clin Apher. 2002; 17(1):49.J Clin Apher2002-01-01T00:00:002002RE: Therapeutic plasma exchange: a paired comparison of Fresenius AS104 vs. COBE Spectra.12881315Grunberger T, Demin P, Rounova O, Sharfe N, Cimpean L, Dadi H, Freywald A, Estrov Z, Roifman CMBloodInhibition of acute lymphoblastic and myeloid leukemias by a novel kinase inhibitor. Blood. 2003 Dec 01; 102(12):4153-8.Blood2003-07-24T00:00:002003Inhibition of acute lymphoblastic and myeloid leukemias by a novel kinase inhibitor.15486072Faderl S, Gandhi V, O'Brien S, Bonate P, Cortes J, Estey E, Beran M, Wierda W, Garcia-Manero G, Ferrajoli A, Estrov Z, Giles FJ, Du M, Kwari M, Keating M, Plunkett W, Kantarjian HBloodResults of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. Blood. 2005 Feb 01; 105(3):940-7.Blood2004-10-14T00:00:002004Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias.16332390Giles FJ, Bellamy WT, Estrov Z, O'Brien SM, Verstovsek S, Ravandi F, Beran M, Bycott P, Pithavala Y, Steinfeldt H, Reich SD, List AF, Yee KWLeukemia researchThe anti-angiogenesis agent, AG-013736, has minimal activity in elderly patients with poor prognosis acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Leuk Res. 2006 Jul; 30(7):801-11.Leuk Res2005-12-05T00:00:002005The anti-angiogenesis agent, AG-013736, has minimal activity in elderly patients with poor prognosis acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).16551975Koller C, Bekele BN, Zhou X, Park C, Estrov Z, O'Brien S, Keating M, Jilani I, Giles FJ, Kantarjian HM, Albitar MBloodPlasma thrombopoietin compared with immunoglobulin heavy-chain mutation status as a predictor of survival in chronic lymphocytic leukemia. Blood. 2006 Aug 01; 108(3):1001-6.Blood2006-03-21T00:00:002006Plasma thrombopoietin compared with immunoglobulin heavy-chain mutation status as a predictor of survival in chronic lymphocytic leukemia.16556893Carter BZ, Mak DH, Schober WD, McQueen T, Harris D, Estrov Z, Evans RL, Andreeff MBloodTriptolide induces caspase-dependent cell death mediated via the mitochondrial pathway in leukemic cells. Blood. 2006 Jul 15; 108(2):630-7.Blood2006-03-23T00:00:002006Triptolide induces caspase-dependent cell death mediated via the mitochondrial pathway in leukemic cells.17154172Quint?s-Cardama A, Kantarjian H, Garcia-Manero G, O'Brien S, Faderl S, Estrov Z, Giles F, Murgo A, Ladie N, Verstovsek S, Cortes JCancerPhase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy. Cancer. 2007 Jan 15; 109(2):248-55.Cancer2007-01-15T00:00:002007Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy.18756533Faderl S, Ferrajoli A, Wierda W, Huang X, Verstovsek S, Ravandi F, Estrov Z, Borthakur G, Kwari M, Kantarjian HMCancerClofarabine combinations as acute myeloid leukemia salvage therapy. Cancer. 2008 Oct 15; 113(8):2090-6.Cancer2008-10-15T00:00:002008Clofarabine combinations as acute myeloid leukemia salvage therapy.19439093Raza A, Galili N, Callander N, Ochoa L, Piro L, Emanuel P, Williams S, Burris H, Faderl S, Estrov Z, Curtin P, Larson RA, Keck JG, Jones M, Meng L, Brown GLJournal of hematology & oncologyPhase 1-2a multicenter dose-escalation study of ezatiostat hydrochloride liposomes for injection (Telintra, TLK199), a novel glutathione analog prodrug in patients with myelodysplastic syndrome. J Hematol Oncol. 2009 May 13; 2:20.J Hematol Oncol2009-05-13T00:00:002009Phase 1-2a multicenter dose-escalation study of ezatiostat hydrochloride liposomes for injection (Telintra, TLK199), a novel glutathione analog prodrug in patients with myelodysplastic syndrome.20306242Estrov ZCancer treatment and researchThe leukemia stem cell. Cancer Treat Res. 2010; 145:1-17.Cancer Treat Res2010-01-01T00:00:002010The leukemia stem cell.21750315Parikh SA, Keating MJ, O'Brien S, Wang X, Ferrajoli A, Faderl S, Burger J, Koller C, Estrov Z, Badoux X, Lerner S, Wierda WGBloodFrontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia. Blood. 2011 Aug 25; 118(8):2062-8.Blood2011-07-12T00:00:002011Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia.23343175Nazha A, Estrov Z, Cortes J, Bueso-Ramos CE, Kantarjian H, Verstovsek SLeukemia & lymphomaPrognostic implications and clinical characteristics associated with bone marrow fibrosis in patients with myelofibrosis. Leuk Lymphoma. 2013 Nov; 54(11):2537-9.Leuk Lymphoma2013-02-21T00:00:002013Prognostic implications and clinical characteristics associated with bone marrow fibrosis in patients with myelofibrosis.23836561Ravandi F, Jorgensen JL, Thomas DA, O'Brien S, Garris R, Faderl S, Huang X, Wen S, Burger JA, Ferrajoli A, Kebriaei P, Champlin RE, Estrov Z, Challagundla P, Wang SA, Luthra R, Cortes JE, Kantarjian HMBloodDetection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy. Blood. 2013 Aug 15; 122(7):1214-21.Blood2013-07-08T00:00:002013Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy.Authorship 2725402Authorship 2725924Authorship 2727802Authorship 2729773Authorship 2735728Authorship 2740178Authorship 2741855Authorship 2745585Authorship 27459110Authorship 2748953Authorship 27516615Authorship 2752643Authorship 2756362Authorship 2759292Authorship 2759411Authorship 2763021Authorship 2763511Authorship 2764453Authorship 2765303Authorship 2766143Authorship 2766571Authorship 2767134Authorship 2770151Authorship 2772262Authorship 2772947Authorship 2773821Authorship 2775468Authorship 2776637Authorship 27784271935819Kurzrock R, Estrov Z, Wetzler M, Gutterman JU, Talpaz MEndocrine reviewsLIF: not just a leukemia inhibitory factor. Endocr Rev. 1991 Aug; 12(3):208-17.Endocr Rev1991-08-01T00:00:001991LIF: not just a leukemia inhibitory factor.2378417Freedman MH, Estrov ZThe American journal of pediatric hematology/oncologyCongenital amegakaryocytic thrombocytopenia: an intrinsic hematopoietic stem cell defect. Am J Pediatr Hematol Oncol. 1990; 12(2):225-30.Am J Pediatr Hematol Oncol1990-01-01T00:00:001990Congenital amegakaryocytic thrombocytopenia: an intrinsic hematopoietic stem cell defect.7837815Wetzler M, Kurzrock R, Estrov Z, Estey E, Talpaz MLeukemia researchCytokine expression in adherent layers from patients with myelodysplastic syndrome and acute myelogenous leukemia. Leuk Res. 1995 Jan; 19(1):23-34.Leuk Res1995-01-01T00:00:001995Cytokine expression in adherent layers from patients with myelodysplastic syndrome and acute myelogenous leukemia.8220141Estrov Z, Re GG, Zipf TFLeukemia & lymphomaImmature and differentiated neoplastic populations in acute lymphoid leukemia of childhood: biological and clinical implications. Leuk Lymphoma. 1993 Sep; 11(1-2):1-7.Leuk Lymphoma1993-09-01T00:00:001993Immature and differentiated neoplastic populations in acute lymphoid leukemia of childhood: biological and clinical implications.8401177Estrov Z, Kurzrock R, Talpaz MLeukemia & lymphomaRole of interleukin-1 inhibitory molecules in therapy of acute and chronic myelogenous leukemia. Leuk Lymphoma. 1993 Aug; 10(6):407-18.Leuk Lymphoma1993-08-01T00:00:001993Role of interleukin-1 inhibitory molecules in therapy of acute and chronic myelogenous leukemia.8600166Estrov Z, Talpaz M, Zipf TF, Kantarjian HM, Ku S, Ouspenskaia MV, Hirsch-Ginsberg C, Huh Y, Yee G, Kurzrock RJournal of cellular physiologyRole of granulocyte-macrophage colony-stimulating factor in Philadelphia (Ph1)-positive acute lymphoblastic leukemia: studies on two newly established Ph1-positive acute lymphoblastic leukemia cell lines (Z-119 and Z-181). J Cell Physiol. 1996 Mar; 166(3):618-30.J Cell Physiol1996-03-01T00:00:001996Role of granulocyte-macrophage colony-stimulating factor in Philadelphia (Ph1)-positive acute lymphoblastic leukemia: studies on two newly established Ph1-positive acute lymphoblastic leukemia cell lines (Z-119 and Z-181).8821574Estrov Z, Kurzrock R, Talpaz MCancer treatment and researchInterleukin-1 and its inhibitors: implications for disease biology and therapy. Cancer Treat Res. 1995; 80:51-82.Cancer Treat Res1995-01-01T00:00:001995Interleukin-1 and its inhibitors: implications for disease biology and therapy.9279363Wetzler M, Kurzrock R, Estrov Z, Barone S, Estey E, Talpaz MLeukemia researchSuppressed formation of bone marrow adherent layers derived from acute myeloid leukemia patients after in vitro exposure to interleukin-4. Leuk Res. 1997 Jun; 21(6):519-27.Leuk Res1997-06-01T00:00:001997Suppressed formation of bone marrow adherent layers derived from acute myeloid leukemia patients after in vitro exposure to interleukin-4.9384684Estrov Z, Talpaz MCytokines and molecular therapyRole of interleukin-1 beta converting enzyme (ICE) in leukemia. Cytokines Mol Ther. 1996 Mar; 2(1):1-11.Cytokines Mol Ther1996-03-01T00:00:001996Role of interleukin-1 beta converting enzyme (ICE) in leukemia.10362346Mavligit GM, Estrov Z, Ayala AAmerican journal of clinical oncologyCarcinoma of the stomach metastatic to the liver that progressed after hepatic arterial infusion of cisplatin plus 5-floxuridine, and then dramatically regressed after chemoembolization based on positive chromogranin staining. Am J Clin Oncol. 1999 Jun; 22(3):320-2.Am J Clin Oncol1999-06-01T00:00:001999Carcinoma of the stomach metastatic to the liver that progressed after hepatic arterial infusion of cisplatin plus 5-floxuridine, and then dramatically regressed after chemoembolization based on positive chromogranin staining.10430080Kornblau SM, Thall PF, Estrov Z, Walterscheid M, Patel S, Theriault A, Keating MJ, Kantarjian H, Estey E, Andreeff MClinical cancer research : an official journal of the American Association for Cancer ResearchThe prognostic impact of BCL2 protein expression in acute myelogenous leukemia varies with cytogenetics. Clin Cancer Res. 1999 Jul; 5(7):1758-66.Clin Cancer Res1999-07-01T00:00:001999The prognostic impact of BCL2 protein expression in acute myelogenous leukemia varies with cytogenetics.10778970Kornblau SM, Vu HT, Ruvolo P, Estrov Z, O'Brien S, Cortes J, Kantarjian H, Andreeff M, May WSClinical cancer research : an official journal of the American Association for Cancer ResearchBAX and PKCalpha modulate the prognostic impact of BCL2 expression in acute myelogenous leukemia. Clin Cancer Res. 2000 Apr; 6(4):1401-9.Clin Cancer Res2000-04-01T00:00:002000BAX and PKCalpha modulate the prognostic impact of BCL2 expression in acute myelogenous leukemia.11882729K?rbling M, Katz RL, Khanna A, Ruifrok AC, Rondon G, Albitar M, Champlin RE, Estrov ZThe New England journal of medicineHepatocytes and epithelial cells of donor origin in recipients of peripheral-blood stem cells. N Engl J Med. 2002 Mar 07; 346(10):738-46.N Engl J Med2002-03-07T00:00:002002Hepatocytes and epithelial cells of donor origin in recipients of peripheral-blood stem cells.12007503Lin CW, Manshouri T, Jilani I, Neuberg D, Patel K, Kantarjian H, Andreeff M, Estrov Z, Beran M, Keating M, Estey E, Albitar MLeukemia researchProliferation and apoptosis in acute and chronic leukemias and myelodysplastic syndrome. Leuk Res. 2002 Jun; 26(6):551-9.Leuk Res2002-06-01T00:00:002002Proliferation and apoptosis in acute and chronic leukemias and myelodysplastic syndrome.12689943Estrov Z, Shishodia S, Faderl S, Harris D, Van Q, Kantarjian HM, Talpaz M, Aggarwal BBBloodResveratrol blocks interleukin-1beta-induced activation of the nuclear transcription factor NF-kappaB, inhibits proliferation, causes S-phase arrest, and induces apoptosis of acute myeloid leukemia cells. Blood. 2003 Aug 01; 102(3):987-95.Blood2003-04-10T00:00:002003Resveratrol blocks interleukin-1beta-induced activation of the nuclear transcription factor NF-kappaB, inhibits proliferation, causes S-phase arrest, and induces apoptosis of acute myeloid leukemia cells.14991544Bueso-Ramos CE, Rocha FC, Shishodia S, Medeiros LJ, Kantarjian HM, Vadhan-Raj S, Estrov Z, Smith TL, Nguyen MH, Aggarwal BBHuman pathologyExpression of constitutively active nuclear-kappa B RelA transcription factor in blasts of acute myeloid leukemia. Hum Pathol. 2004 Feb; 35(2):246-53.Hum Pathol2004-02-01T00:00:002004Expression of constitutively active nuclear-kappa B RelA transcription factor in blasts of acute myeloid leukemia.15238877Hennessy B, K?rbling M, Estrov ZPanminerva medicaCirculating stem cells and tissue repair. Panminerva Med. 2004 Mar; 46(1):1-11.Panminerva Med2004-03-01T00:00:002004Circulating stem cells and tissue repair.15739196Freireich EJ, Kurzrock R, Estrov ZCancerMetastasis--an alternative hypothesis. Cancer. 2005 Apr 15; 103(8):1537-9.Cancer2005-04-15T00:00:002005Metastasis--an alternative hypothesis.16203034Medeiros LJ, Estrov Z, Rassidakis GZLeukemia researchZ-138 cell line was derived from a patient with blastoid variant mantle cell lymphoma. Leuk Res. 2006 Apr; 30(4):497-501.Leuk Res2005-10-03T00:00:002005Z-138 cell line was derived from a patient with blastoid variant mantle cell lymphoma.16585200Zeng Z, Samudio IJ, Zhang W, Estrov Z, Pelicano H, Harris D, Frolova O, Hail N, Chen W, Kornblau SM, Huang P, Lu Y, Mills GB, Andreeff M, Konopleva MCancer researchSimultaneous inhibition of PDK1/AKT and Fms-like tyrosine kinase 3 signaling by a small-molecule KP372-1 induces mitochondrial dysfunction and apoptosis in acute myelogenous leukemia. Cancer Res. 2006 Apr 01; 66(7):3737-46.Cancer Res2006-04-01T00:00:002006Simultaneous inhibition of PDK1/AKT and Fms-like tyrosine kinase 3 signaling by a small-molecule KP372-1 induces mitochondrial dysfunction and apoptosis in acute myelogenous leukemia.18230792Zhang W, Konopleva M, Shi YX, McQueen T, Harris D, Ling X, Estrov Z, Quint?s-Cardama A, Small D, Cortes J, Andreeff MJournal of the National Cancer InstituteMutant FLT3: a direct target of sorafenib in acute myelogenous leukemia. J Natl Cancer Inst. 2008 Feb 06; 100(3):184-98.J Natl Cancer Inst2008-01-29T00:00:002008Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.18334676Ferrajoli A, Lee BN, Schlette EJ, O'Brien SM, Gao H, Wen S, Wierda WG, Estrov Z, Faderl S, Cohen EN, Li C, Reuben JM, Keating MJBloodLenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood. 2008 Jun 01; 111(11):5291-7.Blood2008-03-11T00:00:002008Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia.20008298Santos FP, Kantarjian HM, Jain N, Manshouri T, Thomas DA, Garcia-Manero G, Kennedy D, Estrov Z, Cortes J, Verstovsek SBloodPhase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. Blood. 2010 Feb 11; 115(6):1131-6.Blood2009-12-11T00:00:002009Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.20951430Ma W, Kantarjian H, Zhang X, Wang X, Estrov Z, O'Brien S, Albitar MLeukemia researchUbiquitin-proteasome system profiling in acute leukemias and its clinical relevance. Leuk Res. 2011 Apr; 35(4):526-33.Leuk Res2010-10-15T00:00:002010Ubiquitin-proteasome system profiling in acute leukemias and its clinical relevance.21733558Badoux X, Bueso-Ramos C, Harris D, Li P, Liu Z, Burger J, O'Brien S, Ferrajoli A, Keating MJ, Estrov ZHuman pathologyCross-talk between chronic lymphocytic leukemia cells and bone marrow endothelial cells: role of signal transducer and activator of transcription 3. Hum Pathol. 2011 Dec; 42(12):1989-2000.Hum Pathol2011-07-05T00:00:002011Cross-talk between chronic lymphocytic leukemia cells and bone marrow endothelial cells: role of signal transducer and activator of transcription 3.22718840Verstovsek S, Kantarjian HM, Estrov Z, Cortes JE, Thomas DA, Kadia T, Pierce S, Jabbour E, Borthakur G, Rumi E, Pungolino E, Morra E, Caramazza D, Cazzola M, Passamonti FBloodLong-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood. 2012 Aug 09; 120(6):1202-9.Blood2012-06-20T00:00:002012Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls.23332395Benjamini O, Jain P, Schlette E, Sciffman JS, Estrov Z, Keating MClinical lymphoma, myeloma & leukemiaChronic lymphocytic leukemia with central nervous system involvement: a high-risk disease? Clin Lymphoma Myeloma Leuk. 2013 Jun; 13(3):338-41.Clin Lymphoma Myeloma Leuk2013-01-16T00:00:002013Chronic lymphocytic leukemia with central nervous system involvement: a high-risk disease?23725032Rozovski U, Calin GA, Setoyama T, D'Abundo L, Harris DM, Li P, Liu Z, Grgurevic S, Ferrajoli A, Faderl S, Burger JA, O'Brien S, Wierda WG, Keating MJ, Estrov ZMolecular cancerSignal transducer and activator of transcription (STAT)-3 regulates microRNA gene expression in chronic lymphocytic leukemia cells. Mol Cancer. 2013 Jun 01; 12:50.Mol Cancer2013-06-01T00:00:002013Signal transducer and activator of transcription (STAT)-3 regulates microRNA gene expression in chronic lymphocytic leukemia cells.23941728Rozovski U, Keating MJ, Estrov ZCritical reviews in oncology/hematologyTargeting inflammatory pathways in chronic lymphocytic leukemia. Crit Rev Oncol Hematol. 2013 Dec; 88(3):655-66.Crit Rev Oncol Hematol2013-08-12T00:00:002013Targeting inflammatory pathways in chronic lymphocytic leukemia.Authorship 279367108289497Estrov Z, Ouspenskaia MV, Felix EA, McClain KL, Lee MS, Harris D, Pinkel DP, Zipf TFLeukemiaPersistence of self-renewing leukemia cell progenitors during remission in children with B-precursor acute lymphoblastic leukemia. Leukemia. 1994 Jan; 8(1):46-52.Leukemia1994-01-01T00:00:001994Persistence of self-renewing leukemia cell progenitors during remission in children with B-precursor acute lymphoblastic leukemia.8990093McClain K, Estrov Z, Raju U, Kelley PK, Aggarwal BBMethods (San Diego, Calif.)Epstein-Barr Virus EBNA-2 gene expression enhances lymphotoxin production by B lymphocytes. Methods. 1997 Jan; 11(1):83-7.Methods1997-01-01T00:00:001997Epstein-Barr Virus EBNA-2 gene expression enhances lymphotoxin production by B lymphocytes.9158705Wright-Browne V, McClain KL, Talpaz M, Ordonez N, Estrov ZHuman pathologyPhysiology and pathophysiology of dendritic cells. Hum Pathol. 1997 May; 28(5):563-79.Hum Pathol1997-05-01T00:00:001997Physiology and pathophysiology of dendritic cells.8251410McClain K, Estrov Z, Chen H, Mahoney DHBritish journal of haematologyChronic neutropenia of childhood: frequent association with parvovirus infection and correlations with bone marrow culture studies. Br J Haematol. 1993 Sep; 85(1):57-62.Br J Haematol1993-09-01T00:00:001993Chronic neutropenia of childhood: frequent association with parvovirus infection and correlations with bone marrow culture studies.8324740Estrov Z, Talpaz M, Kantarjian HM, Zipf TF, McClain KL, Kurzrock RCancer researchHeterogeneity in lineage derivation of Philadelphia-positive acute lymphoblastic leukemia expressing p190BCR-ABL or p210BCR-ABL: determination by analysis of individual colonies with the polymerase chain reaction. Cancer Res. 1993 Jul 15; 53(14):3289-93.Cancer Res1993-07-15T00:00:001993Heterogeneity in lineage derivation of Philadelphia-positive acute lymphoblastic leukemia expressing p190BCR-ABL or p210BCR-ABL: determination by analysis of individual colonies with the polymerase chain reaction.10557066Andreeff M, Jiang S, Zhang X, Konopleva M, Estrov Z, Snell VE, Xie Z, Okcu MF, Sanchez-Williams G, Dong J, Estey EH, Champlin RC, Kornblau SM, Reed JC, Zhao SLeukemiaExpression of Bcl-2-related genes in normal and AML progenitors: changes induced by chemotherapy and retinoic acid. Leukemia. 1999 Nov; 13(11):1881-92.Leukemia1999-11-01T00:00:001999Expression of Bcl-2-related genes in normal and AML progenitors: changes induced by chemotherapy and retinoic acid.Authorship 2877135Authorship 2881724Authorship 2892528Authorship 28945215Authorship 2895246Authorship 28973613Authorship 2904828Authorship 2904922Authorship 2906488Authorship 2912284Authorship 29148813Authorship 2917429Authorship 2919425Authorship 2920557Authorship 2932988Authorship 2938874Authorship 2942484Authorship 29441810Authorship 2949016Authorship 29507215Authorship 29543915Authorship 2964166Authorship 2966908Authorship 2970738Authorship 29760218Authorship 29891921Authorship 29918516Authorship 3000679Authorship 305006423987820Strati P, Manning JT, Ok CY, Garcia-Manero G, Estrov ZLeukemia & lymphomaInteraction between myelomonocytic and lymphoid cells in a patient with acute myelomonocytic leukemia and chronic lymphocytic leukemia. Leuk Lymphoma. 2014 Jun; 55(6):1425-7.Leuk Lymphoma2014-01-28T00:00:002014Interaction between myelomonocytic and lymphoid cells in a patient with acute myelomonocytic leukemia and chronic lymphocytic leukemia.24376763Fiorcari S, Brown WS, McIntyre BW, Estrov Z, Maffei R, O'Brien S, Sivina M, Hoellenriegel J, Wierda WG, Keating MJ, Ding W, Kay NE, Lannutti BJ, Marasca R, Burger JAPloS oneThe PI3-kinase delta inhibitor idelalisib (GS-1101) targets integrin-mediated adhesion of chronic lymphocytic leukemia (CLL) cell to endothelial and marrow stromal cells. PLoS One. 2013; 8(12):e83830.PLoS One2013-12-23T00:00:002013The PI3-kinase delta inhibitor idelalisib (GS-1101) targets integrin-mediated adhesion of chronic lymphocytic leukemia (CLL) cell to endothelial and marrow stromal cells.24678068Rozovski U, Li P, Harris D, Ohanian M, Kantarjian H, Estrov ZCancer medicineInterleukin-7 receptor-a gene mutations are not detected in adult T-cell acute lymphoblastic leukemia. Cancer Med. 2014 Jun; 3(3):550-4.Cancer Med2014-03-26T00:00:002014Interleukin-7 receptor-a gene mutations are not detected in adult T-cell acute lymphoblastic leukemia.24737502Alvarado Y, Kantarjian HM, Luthra R, Ravandi F, Borthakur G, Garcia-Manero G, Konopleva M, Estrov Z, Andreeff M, Cortes JECancerTreatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations. Cancer. 2014 Jul 15; 120(14):2142-9.Cancer2014-04-15T00:00:002014Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations.24836891Li P, Harris D, Liu Z, Rozovski U, Ferrajoli A, Wang Y, Bueso-Ramos C, Hazan-Halevy I, Grgurevic S, Wierda W, Burger J, O'Brien S, Faderl S, Keating M, Estrov ZMolecular cancer research : MCRSTAT3-activated GM-CSFRa translocates to the nucleus and protects CLL cells from apoptosis. Mol Cancer Res. 2014 Sep; 12(9):1267-82.Mol Cancer Res2014-05-16T00:00:002014STAT3-activated GM-CSFRa translocates to the nucleus and protects CLL cells from apoptosis.24875590Quint?s-Cardama A, Daver N, Kim H, Dinardo C, Jabbour E, Kadia T, Borthakur G, Pierce S, Shan J, Cardenas-Turanzas M, Cortes J, Ravandi F, Wierda W, Estrov Z, Faderl S, Wei Y, Kantarjian H, Garcia-Manero GClinical lymphoma, myeloma & leukemiaA prognostic model of therapy-related myelodysplastic syndrome for predicting survival and transformation to acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2014 Oct; 14(5):401-10.Clin Lymphoma Myeloma Leuk2014-05-06T00:00:002014A prognostic model of therapy-related myelodysplastic syndrome for predicting survival and transformation to acute myeloid leukemia.25043749Jain P, Lee HJ, Qiao W, Wierda W, Benjamini O, Burger J, Ferrajoli A, Estrov Z, Kantarjian H, Keating M, O'Brien SCancerFCR and bevacizumab treatment in patients with relapsed chronic lymphocytic leukemia. Cancer. 2014 Nov 15; 120(22):3494-501.Cancer2014-07-15T00:00:002014FCR and bevacizumab treatment in patients with relapsed chronic lymphocytic leukemia.25048874Chen Y, Estrov Z, Pierce S, Qiao W, Borthakur G, Ravandi F, Kadia T, Brandt M, O'Brien S, Jabbour E, Garcia-Manero G, Cortes J, Beran MLeukemia & lymphomaMyeloid neoplasms after breast cancer: "therapy-related" not an independent poor prognostic factor. Leuk Lymphoma. 2015 Apr; 56(4):1012-9.Leuk Lymphoma2014-08-13T00:00:002014Myeloid neoplasms after breast cancer: "therapy-related" not an independent poor prognostic factor.25110819Rozovski U, Ohanian M, Ravandi F, Garcia-Manero G, Faderl S, Pierce S, Cortes J, Estrov ZLeukemia & lymphomaIncidence of and risk factors for involvement of the central nervous system in acute myeloid leukemia. Leuk Lymphoma. 2015 May; 56(5):1392-7.Leuk Lymphoma2014-11-03T00:00:002014Incidence of and risk factors for involvement of the central nervous system in acute myeloid leukemia.25131853Ohanian M, Huang RS, Yakoushina TV, Estrov Z, Juneja H, Chen L, Idowu M, Abruzzo LVClinical lymphoma, myeloma & leukemiaIsolated mesenteric CD20-positive myeloid sarcoma. Clin Lymphoma Myeloma Leuk. 2014 Dec; 14(6):e217-20.Clin Lymphoma Myeloma Leuk2014-06-26T00:00:002014Isolated mesenteric CD20-positive myeloid sarcoma.25238756Li J, Kurasawa Y, Wang Y, Clise-Dwyer K, Klumpp SA, Liang H, Tailor RC, Raymond AC, Estrov Z, Brandt SJ, Davis RE, Zweidler-McKay P, Amin HM, Nagarajan LJournal of immunology (Baltimore, Md. : 1950)Requirement for ssbp2 in hematopoietic stem cell maintenance and stress response. J Immunol. 2014 Nov 01; 193(9):4654-62.J Immunol2014-09-19T00:00:002014Requirement for ssbp2 in hematopoietic stem cell maintenance and stress response.25308294Benjamini O, Jain P, Trinh L, Qiao W, Strom SS, Lerner S, Wang X, Burger J, Ferrajoli A, Kantarjian H, O'Brien S, Wierda W, Estrov Z, Keating MLeukemia & lymphomaSecond cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes. Leuk Lymphoma. 2015 Jun; 56(6):1643-50.Leuk Lymphoma2014-11-19T00:00:002014Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes.25368968Kadia TM, Kantarjian HM, Thomas DA, O'Brien S, Estrov Z, Ravandi F, Jabbour E, Pemmaraju N, Daver N, Wang X, Jain P, Pierce S, Brandt M, Garcia-Manero G, Cortes J, Borthakur GAmerican journal of hematologyPhase II study of methotrexate, vincristine, pegylated-asparaginase, and dexamethasone (MOpAD) in patients with relapsed/refractory acute lymphoblastic leukemia. Am J Hematol. 2015 Feb; 90(2):120-4.Am J Hematol2014-11-19T00:00:002014Phase II study of methotrexate, vincristine, pegylated-asparaginase, and dexamethasone (MOpAD) in patients with relapsed/refractory acute lymphoblastic leukemia.25413673Ohanian M, Rozovski U, Ravandi F, Garcia-Manero G, Jabbour E, Kantarjian HM, Estrov ZBritish journal of haematologyVery high levels of lactate dehydrogenase at diagnosis predict central nervous system relapse in acute promyelocytic leukaemia. Br J Haematol. 2015 May; 169(4):595-7.Br J Haematol2014-11-21T00:00:002014Very high levels of lactate dehydrogenase at diagnosis predict central nervous system relapse in acute promyelocytic leukaemia.25530214Strati P, Kantarjian H, Ravandi F, Nazha A, Borthakur G, Daver N, Kadia T, Estrov Z, Garcia-Manero G, Konopleva M, Rajkhowa T, Durand M, Andreeff M, Levis M, Cortes JAmerican journal of hematologyPhase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome. Am J Hematol. 2015 Apr; 90(4):276-81.Am J Hematol2015-03-02T00:00:002015Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome.25573991Jain P, Keating M, Wierda W, Estrov Z, Ferrajoli A, Jain N, George B, James D, Kantarjian H, Burger J, O'Brien SBloodOutcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib. Blood. 2015 Mar 26; 125(13):2062-7.Blood2015-01-08T00:00:002015Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib.25683856Jain P, Keating M, Thompson PA, Trinh L, Wang X, Wierda W, Ferrajoli A, Burger J, Kantarjian H, Estrov Z, Abruzzo L, O'Brien SAmerican journal of hematologyHigh fluorescence in situ hybridization percentage of deletion 11q in patients with chronic lymphocytic leukemia is an independent predictor of adverse outcome. Am J Hematol. 2015 Jun; 90(6):471-7.Am J Hematol2015-03-30T00:00:002015High fluorescence in situ hybridization percentage of deletion 11q in patients with chronic lymphocytic leukemia is an independent predictor of adverse outcome.25733697Rozovski U, Grgurevic S, Bueso-Ramos C, Harris DM, Li P, Liu Z, Wu JY, Jain P, Wierda W, Burger J, O'Brien S, Jain N, Ferrajoli A, Keating MJ, Estrov ZMolecular cancer research : MCRAberrant LPL Expression, Driven by STAT3, Mediates Free Fatty Acid Metabolism in CLL Cells. Mol Cancer Res. 2015 May; 13(5):944-53.Mol Cancer Res2015-03-02T00:00:002015Aberrant LPL Expression, Driven by STAT3, Mediates Free Fatty Acid Metabolism in CLL Cells.25808231Jain P, Verstovsek S, Loghavi S, Jorgensen JL, Patel KP, Estrov Z, Fayad L, Pemmaraju NAmerican journal of hematologyDurable remission with rituximab in a patient with an unusual variant of Castleman's disease with myelofibrosis-TAFRO syndrome. Am J Hematol. 2015 Nov; 90(11):1091-2.Am J Hematol2015-04-29T00:00:002015Durable remission with rituximab in a patient with an unusual variant of Castleman's disease with myelofibrosis-TAFRO syndrome.25847930Rozovski U, Benjamini O, Jain P, Thompson PA, Wierda WG, O'Brien S, Burger JA, Ferrajoli A, Faderl S, Shpall E, Hosing C, Khouri IF, Champlin R, Keating MJ, Estrov ZJournal of clinical oncology : official journal of the American Society of Clinical OncologyOutcomes of Patients With Chronic Lymphocytic Leukemia and Richter's Transformation After Transplantation Failure. J Clin Oncol. 2015 May 10; 33(14):1557-63.J Clin Oncol2015-04-06T00:00:002015Outcomes of Patients With Chronic Lymphocytic Leukemia and Richter's Transformation After Transplantation Failure.25850565Jain P, Hu S, Jabbour E, Takahashi K, Pemmaraju N, O'Brien S, Mulanovich VE, Estrov ZAmerican journal of hematologyDisseminated histoplasmosis as pseudo Richter's transformation in a patient with chronic lymphocytic leukemia. Am J Hematol. 2015 Aug; 90(8):752-3.Am J Hematol2015-08-01T00:00:002015Disseminated histoplasmosis as pseudo Richter's transformation in a patient with chronic lymphocytic leukemia.25904378Masarova L, Cherry M, Newberry KJ, Estrov Z, Cortes JE, Kantarjian HM, Verstovsek SLeukemia & lymphomaSecondary solid tumors and lymphoma in patients with essential thrombocythemia and polycythemia vera - single center experience. Leuk Lymphoma. 2016; 57(1):237-9.Leuk Lymphoma2015-09-25T00:00:002015Secondary solid tumors and lymphoma in patients with essential thrombocythemia and polycythemia vera - single center experience.26012362Masarova L, Newberry KJ, Pierce SA, Estrov Z, Cortes JE, Kantarjian HM, Verstovsek SLeukemia researchAssociation of lymphoid malignancies and Philadelphia-chromosome negative myeloproliferative neoplasms: Clinical characteristics, therapy and outcome. Leuk Res. 2015 Aug; 39(8):822-7.Leuk Res2015-05-12T00:00:002015Association of lymphoid malignancies and Philadelphia-chromosome negative myeloproliferative neoplasms: Clinical characteristics, therapy and outcome.26193999Thompson PA, O'Brien SM, Wierda WG, Ferrajoli A, Stingo F, Smith SC, Burger JA, Estrov Z, Jain N, Kantarjian HM, Keating MJCancerComplex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens. Cancer. 2015 Oct 15; 121(20):3612-21.Cancer2015-07-20T00:00:002015Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens.26218678Short NJ, Keating MJ, Wierda WG, Faderl S, Ferrajoli A, Estrov Z, Smith SC, O'Brien SMCancerFludarabine, cyclophosphamide, and multiple-dose rituximab as frontline therapy for chronic lymphocytic leukemia. Cancer. 2015 Nov 01; 121(21):3869-76.Cancer2015-07-28T00:00:002015Fludarabine, cyclophosphamide, and multiple-dose rituximab as frontline therapy for chronic lymphocytic leukemia.26288818Ferrajoli A, Ivan C, Ciccone M, Shimizu M, Kita Y, Ohtsuka M, D'Abundo L, Qiang J, Lerner S, Nouraee N, Rabe KG, Rassenti LZ, Van Roosbroeck K, Manning JT, Yuan Y, Zhang X, Shanafelt TD, Wierda WG, Sabbioni S, Tarrand JJ, Estrov Z, Radovich M, Liang H, Negrini M, Kipps TJ, Kay NE, Keating M, Calin GAEBioMedicineEpstein-Barr Virus MicroRNAs are Expressed in Patients with Chronic Lymphocytic Leukemia and Correlate with Overall Survival. EBioMedicine. 2015 Jun; 2(6):572-82.EBioMedicine2015-04-29T00:00:002015Epstein-Barr Virus MicroRNAs are Expressed in Patients with Chronic Lymphocytic Leukemia and Correlate with Overall Survival.26308885Ravandi F, O'Brien SM, Cortes JE, Thomas DM, Garris R, Faderl S, Burger JA, Rytting ME, Ferrajoli A, Wierda WG, Verstovsek S, Champlin R, Kebriaei P, McCue DA, Huang X, Jabbour E, Garcia-Manero G, Estrov Z, Kantarjian HMCancerLong-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer. 2015 Dec 01; 121(23):4158-64.Cancer2015-08-26T00:00:002015Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.26382622Ohanian M, Bueso-Ramos C, Ok CY, Lin P, Patel K, Alattar ML, Khoury JD, Rozovski U, Estrov Z, Huh YO, Cortes J, Abruzzo LVCancer geneticsAcute myeloid leukemia with MYC rearrangement and JAK2 V617F mutation. Cancer Genet. 2015 Nov; 208(11):571-4.Cancer Genet2015-06-25T00:00:002015Acute myeloid leukemia with MYC rearrangement and JAK2 V617F mutation.26432046Jabbour E, Kantarjian H, Ravandi F, Thomas D, Huang X, Faderl S, Pemmaraju N, Daver N, Garcia-Manero G, Sasaki K, Cortes J, Garris R, Yin CC, Khoury JD, Jorgensen J, Estrov Z, Bohannan Z, Konopleva M, Kadia T, Jain N, DiNardo C, Wierda W, Jeanis V, O'Brien SThe Lancet. OncologyCombination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study. Lancet Oncol. 2015 Nov; 16(15):1547-1555.Lancet Oncol2015-09-30T00:00:002015Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study.11309324Ferrajoli A, Manshouri T, Estrov Z, Keating MJ, O'Brien S, Lerner S, Beran M, Kantarjian HM, Freireich EJ, Albitar MClinical cancer research : an official journal of the American Association for Cancer ResearchHigh levels of vascular endothelial growth factor receptor-2 correlate with shortened survival in chronic lymphocytic leukemia. Clin Cancer Res. 2001 Apr; 7(4):795-9.Clin Cancer Res2001-04-01T00:00:002001High levels of vascular endothelial growth factor receptor-2 correlate with shortened survival in chronic lymphocytic leukemia.74Professor26492205Ravandi F, Jorgensen JL, O'Brien SM, Jabbour E, Thomas DA, Borthakur G, Garris R, Huang X, Garcia-Manero G, Burger JA, Ferrajoli A, Wierda W, Kadia T, Jain N, Wang SA, Konoplev S, Kebriaei P, Champlin RE, McCue D, Estrov Z, Cortes JE, Kantarjian HMBritish journal of haematologyMinimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia. Br J Haematol. 2016 Feb; 172(3):392-400.Br J Haematol2015-10-22T00:00:002015Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia.27481130Verstovsek S, Manshouri T, Pilling D, Bueso-Ramos CE, Newberry KJ, Prijic S, Knez L, Bozinovic K, Harris DM, Spaeth EL, Post SM, Multani AS, Rampal RK, Ahn J, Levine RL, Creighton CJ, Kantarjian HM, Estrov ZThe Journal of experimental medicineRole of neoplastic monocyte-derived fibrocytes in primary myelofibrosis. J Exp Med. 2016 08 22; 213(9):1723-40.J Exp Med2016-08-01T00:00:002016Role of neoplastic monocyte-derived fibrocytes in primary myelofibrosis.18451169Konopleva M, Watt J, Contractor R, Tsao T, Harris D, Estrov Z, Bornmann W, Kantarjian H, Viallet J, Samudio I, Andreeff MCancer researchMechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax). Cancer Res. 2008 May 01; 68(9):3413-20.Cancer Res2008-05-01T00:00:002008Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax).18482053Manshouri T, Quint?s-Cardama A, Nussenzveig RH, Gaikwad A, Estrov Z, Prchal J, Cortes JE, Kantarjian HM, Verstovsek SCancer scienceThe JAK kinase inhibitor CP-690,550 suppresses the growth of human polycythemia vera cells carrying the JAK2V617F mutation. Cancer Sci. 2008 Jun; 99(6):1265-73.Cancer Sci2008-06-01T00:00:002008The JAK kinase inhibitor CP-690,550 suppresses the growth of human polycythemia vera cells carrying the JAK2V617F mutation.14568894Yeh ET, Zhang S, Wu HD, K?rbling M, Willerson JT, Estrov ZCirculationTransdifferentiation of human peripheral blood CD34+-enriched cell population into cardiomyocytes, endothelial cells, and smooth muscle cells in vivo. Circulation. 2003 Oct 28; 108(17):2070-3.Circulation2003-10-20T00:00:002003Transdifferentiation of human peripheral blood CD34+-enriched cell population into cardiomyocytes, endothelial cells, and smooth muscle cells in vivo.15520199Konopleva M, Tsao T, Estrov Z, Lee RM, Wang RY, Jackson CE, McQueen T, Monaco G, Munsell M, Belmont J, Kantarjian H, Sporn MB, Andreeff MCancer researchThe synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces caspase-dependent and -independent apoptosis in acute myelogenous leukemia. Cancer Res. 2004 Nov 01; 64(21):7927-35.Cancer Res2004-11-01T00:00:002004The synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces caspase-dependent and -independent apoptosis in acute myelogenous leukemia.15596566Zhang S, Wang D, Estrov Z, Raj S, Willerson JT, Yeh ETCirculationBoth cell fusion and transdifferentiation account for the transformation of human peripheral blood CD34-positive cells into cardiomyocytes in vivo. Circulation. 2004 Dec 21; 110(25):3803-7.Circulation2004-12-13T00:00:002004Both cell fusion and transdifferentiation account for the transformation of human peripheral blood CD34-positive cells into cardiomyocytes in vivo.21512135Manshouri T, Estrov Z, Quint?s-Cardama A, Burger J, Zhang Y, Livun A, Knez L, Harris D, Creighton CJ, Kantarjian HM, Verstovsek SCancer researchBone marrow stroma-secreted cytokines protect JAK2(V617F)-mutated cells from the effects of a JAK2 inhibitor. Cancer Res. 2011 Jun 01; 71(11):3831-40.Cancer Res2011-04-21T00:00:002011Bone marrow stroma-secreted cytokines protect JAK2(V617F)-mutated cells from the effects of a JAK2 inhibitor.23251462Lamothe B, Lai Y, Hur L, Orozco NM, Wang J, Campos AD, Xie M, Schneider MD, Lockworth CR, Jakacky J, Tran D, Ho M, Dawud S, Dong C, Lin HK, Hu P, Estrov Z, Bueso-Ramos CE, Darnay BGPloS oneDeletion of TAK1 in the myeloid lineage results in the spontaneous development of myelomonocytic leukemia in mice. PLoS One. 2012; 7(12):e51228.PLoS One2012-12-10T00:00:002012Deletion of TAK1 in the myeloid lineage results in the spontaneous development of myelomonocytic leukemia in mice.19383925Faderl S, Pal A, Bornmann W, Albitar M, Maxwell D, Van Q, Peng Z, Harris D, Liu Z, Hazan-Halevy I, Kantarjian HM, Estrov ZCancer researchKit inhibitor APcK110 induces apoptosis and inhibits proliferation of acute myeloid leukemia cells. Cancer Res. 2009 May 01; 69(9):3910-7.Cancer Res2009-04-21T00:00:002009Kit inhibitor APcK110 induces apoptosis and inhibits proliferation of acute myeloid leukemia cells.20372971Quint?s-Cardama A, Manshouri T, Estrov Z, Harris D, Zhang Y, Gaikwad A, Kantarjian HM, Verstovsek SInvestigational new drugsPreclinical characterization of atiprimod, a novel JAK2 AND JAK3 inhibitor. Invest New Drugs. 2011 Oct; 29(5):818-26.Invest New Drugs2010-04-07T00:00:002010Preclinical characterization of atiprimod, a novel JAK2 AND JAK3 inhibitor.20517635Faderl S, Bueso-Ramos C, Liu Z, Pal A, Bornmann W, Ciurea DV, Harris D, Hazan-Halevy I, Kantarjian HM, Estrov ZInvestigational new drugsKit inhibitor APcK110 extends survival in an AML xenograft mouse model. Invest New Drugs. 2011 Oct; 29(5):1094-7.Invest New Drugs2010-06-03T00:00:002010Kit inhibitor APcK110 extends survival in an AML xenograft mouse model.Authorship 841118Authorship 841604Authorship 842884Authorship 843052Authorship 843386Authorship 844084Authorship 844899Authorship 845125Authorship 845299Authorship 846641Authorship 846796Authorship 847411Authorship 847732Authorship 849779Authorship 849885Authorship 850640Authorship 851567Authorship 851623Authorship 852246Authorship 852839Authorship 852956Authorship 853301Authorship 853506Authorship 853876Authorship 856009Authorship 856188Authorship 856328Authorship 857085Authorship 857794Authorship 858166Authorship 858776Authorship 858821Authorship 859536Authorship 859608Authorship 859934Authorship 860996Authorship 861807Authorship 861956Authorship 863066Authorship 863422Authorship 863743Authorship 864149Authorship 864206Authorship 865048Authorship 865563Authorship 865860Authorship 866488Authorship 867950Authorship 868161Authorship 868165CancerFludarabine, cyclophosphamide, and multiple-dose rituximab as frontline therapy for chronic lymphocytic leukemia. Cancer. Fludarabine, cyclophosphamide, and multiple-dose rituximab as frontline therapy for chronic lymphocytic leukemiaJournal of Clinical Ligand AssayHematopoietec growth factors and cytokines. Journal of Clinical Ligand Assay. 23:169-180.Hematopoietec growth factors and cytokinesAmerican Journal of HematologyClinical and molecular characteristics of XPO1 mutations in patients with chronic lymphocytic leukemia. American Journal of Hematology. 91:E478-E479.Clinical and molecular characteristics of XPO1 mutations in patients with chronic lymphocytic leukemiaHaematologicaAn accurate, simple prognostic model consisting of age, JAK2, CALR, and MPL mutation status for patients with primary myelofibrosis. Haematologica. 102:79-84.An accurate, simple prognostic model consisting of age, JAK2, CALR, and MPL mutation status for patients with primary myelofibrosisThe Lancet HaematologyRuxolitinib for symptom control in patients with chronic lymphocytic leukaemia. The Lancet Haematology. Ruxolitinib for symptom control in patients with chronic lymphocytic leukaemiaEBioMedicineEpstein-Barr Virus MicroRNAs are Expressed in Patients with Chronic Lymphocytic Leukemia and Correlate with Overall Survival. EBioMedicine. Epstein-Barr Virus MicroRNAs are Expressed in Patients with Chronic Lymphocytic Leukemia and Correlate with Overall SurvivalBritish Journal of HaematologyOcular extramedullary myeloid leukaemia. British Journal of Haematology. Ocular extramedullary myeloid leukaemiaFORUM - Trends in Experimental and Clinical MedicineInterruption of endogenous growth regulatory networks. FORUM - Trends in Experimental and Clinical Medicine. 3:306-318.Interruption of endogenous growth regulatory networksClinical Lymphoma, Myeloma and LeukemiaClofarabine Plus Low-Dose Cytarabine Is as Effective as and Less Toxic Than Intensive Chemotherapy in Elderly AML Patients. Clinical Lymphoma, Myeloma and Leukemia. 16:163-168.Clofarabine Plus Low-Dose Cytarabine Is as Effective as and Less Toxic Than Intensive Chemotherapy in Elderly AML PatientsAmerican Journal of HematologyDurable remission with rituximab in a patient with an unusual variant of Castleman's disease with myelofibrosis-TAFRO syndrome. American Journal of Hematology. 90:1091-1092.Durable remission with rituximab in a patient with an unusual variant of Castleman's disease with myelofibrosis-TAFRO syndromeLeukemia and LymphomaDNMT3A, TET2, and JAK2 mutations in polycythemia vera following long-term remission of secondary acute myeloid leukemia. Leukemia and Lymphoma. 1-5.DNMT3A, TET2, and JAK2 mutations in polycythemia vera following long-term remission of secondary acute myeloid leukemiaJournal of Experimental MedicineRole of neoplastic monocyte-derived fibrocytes in primary myelofibrosis. Journal of Experimental Medicine. 213:1723-1740.Role of neoplastic monocyte-derived fibrocytes in primary myelofibrosisJournal of Clinical OncologyRelapsed refractory BRAF-negative, IGHV4-34-positive variant of hairy cell leukemia. Journal of Clinical Oncology. 34:e57-e60.Relapsed refractory BRAF-negative, IGHV4-34-positive variant of hairy cell leukemiaHaematologicaAutoimmune cytopenias in patients with chronic lymphocytic leukemia treated with ibrutinib. Haematologica. 101:e254-e258.Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with ibrutinibToxicology in VitroIn vitro cytotoxicity of deferoxamine on human marrow haematopoietic progenitors. Toxicology in Vitro. 2:131-134.In vitro cytotoxicity of deferoxamine on human marrow haematopoietic progenitorsBritish Journal of HaematologyMinimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia. British Journal of Haematology. Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemiaTargeting signal transducer and activator of transcription (STAT) for anticancer therapy. 299-321.Targeting signal transducer and activator of transcription (STAT) for anticancer therapyOncogeneElimination of chronic lymphocytic leukemia cells in stromal microenvironment by targeting CPT with an antiangina drug perhexiline. Oncogene. Elimination of chronic lymphocytic leukemia cells in stromal microenvironment by targeting CPT with an antiangina drug perhexilineJournal of ImmunologyAt high levels, constitutively activated STAT3 induces apoptosis of chronic lymphocytic leukemia cells. Journal of Immunology. 196:4400-4409.At high levels, constitutively activated STAT3 induces apoptosis of chronic lymphocytic leukemia cellsLeukemia and LymphomaSecondary solid tumors and lymphoma in patients with essential thrombocythemia and polycythemia vera - Single center experience. Leukemia and Lymphoma. 57:237-239.Secondary solid tumors and lymphoma in patients with essential thrombocythemia and polycythemia vera - Single center experienceBritish Journal of HaematologyThe addition of CD20 monoclonal antibodies to lenalidomide improves response rates and survival in relapsed/refractory patients with chronic lymphocytic leukaemia relative to lenalidomide monotherapy - the MD Anderson Cancer Center experience. British Journal of Haematology. 171:281-284.The addition of CD20 monoclonal antibodies to lenalidomide improves response rates and survival in relapsed/refractory patients with chronic lymphocytic leukaemia relative to lenalidomide monotherapy - the MD Anderson Cancer Center experienceOncotargetClinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents. Oncotarget. 7:14172-14187.Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agentsLeukemiaA clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials. Leukemia. A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trialsCancerLong-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer. Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemiaMolecular Cancer ResearchAberrant LPL expression, driven by STAT3, Mediates free fatty acid metabolism in cll cells. Molecular Cancer Research. 13:944-953.Aberrant LPL expression, driven by STAT3, Mediates free fatty acid metabolism in cll cellsLeukemia and LymphomaMetabolism pathways in chronic lymphocytic leukemia. Leukemia and Lymphoma. 57:758-765.Metabolism pathways in chronic lymphocytic leukemiaLeukemia and LymphomaSecond cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy. Leukemia and Lymphoma. 56:1643-1650.Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapyCurrent Rheumatology ReviewsSignal transduction in rheumatology-from bench to bedside. Current Rheumatology Reviews. 7:273.Signal transduction in rheumatology-from bench to bedsideLeukemia and LymphomaIncidence of and risk factors for involvement of the central nervous system in acute myeloid leukemia. Leukemia and Lymphoma. 56:1392-1397.Incidence of and risk factors for involvement of the central nervous system in acute myeloid leukemiaInternational Journal of Pediatric Hematology/OncologyInterruption of autocrine/paracrine growth factor stimulatory mechanisms. International Journal of Pediatric Hematology/Oncology. 1:253-258.Interruption of autocrine/paracrine growth factor stimulatory mechanismsThe Lancet OncologyCombination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia. The Lancet Oncology. 16:1547-1555.Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemiaCancer geneticsAcute myeloid leukemia with MYC rearrangement and JAK2 V617F mutation. Cancer genetics. 208:571-574.Acute myeloid leukemia with MYC rearrangement and JAK2 V617F mutationCancerFCR and bevacizumab treatment in patients with relapsed chronic lymphocytic leukemia. Cancer. 120:3494-3501.FCR and bevacizumab treatment in patients with relapsed chronic lymphocytic leukemiaBloodResponse. Blood. 116:500.ResponseLeukemia and LymphomaMyeloid neoplasms after breast cancer. Leukemia and Lymphoma. 56:1012-1019.Myeloid neoplasms after breast cancerBloodImpact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors. Blood. 127:1269-1275.Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitorsInterferons and CytokinesGrowth factor inhibitory molecules. Interferons and Cytokines. 22-25.Growth factor inhibitory moleculesBBA ClinicalHemophagocytic lymphohistiocytosis in adults. BBA Clinical. 7:36-40.Hemophagocytic lymphohistiocytosis in adultsCancerMeir Wetzler, MD. Cancer. Meir Wetzler, MDCancerβ<sub>2</sub>-microglobulin normalization within 6 months of ibrutinib-based treatment is associated with superior progression-free survival in patients with chronic lymphocytic leukemia. Cancer. 122:565-573.β<sub>2</sub>-microglobulin normalization within 6 months of ibrutinib-based treatment is associated with superior progression-free survival in patients with chronic lymphocytic leukemiaAmerican Journal of HematologySynchronous del5q myelodysplastic syndrome (del5qMDS) and adult B-cell acute lymphoblastic leukemia (B-ALL) with TET2 and TP53 mutations. American Journal of Hematology. 91:354-355.Synchronous del5q myelodysplastic syndrome (del5qMDS) and adult B-cell acute lymphoblastic leukemia (B-ALL) with TET2 and TP53 mutationsDrug News and PerspectivesPotential therapeutic utility of ICE inhibitors in leukemia. Drug News and Perspectives. 9:5-12.Potential therapeutic utility of ICE inhibitors in leukemiaJournal of Visualized ExperimentsDescribing a transcription factor dependent regulation of the micro RNA transcriptome. Journal of Visualized Experiments. 2016.Describing a transcription factor dependent regulation of the micro RNA transcriptomeLeukemia and LymphomaChronic lymphocytic leukemia and myeloproliferative neoplasms concurrently diagnosed. Leukemia and Lymphoma. Chronic lymphocytic leukemia and myeloproliferative neoplasms concurrently diagnosedBloodInihibition of PI3K by LY294002 promotes apoptosis and dephosphorylates bad in myeloid leukemias. Blood. 96.Inihibition of PI3K by LY294002 promotes apoptosis and dephosphorylates bad in myeloid leukemiasCancerComplex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens. Cancer. 121:3612-3621.Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimensCancerTP53 mutations in newly diagnosed acute myeloid leukemia. Cancer. 122:3484-3491.TP53 mutations in newly diagnosed acute myeloid leukemiaInternational Journal of Pediatric Hematology/OncologyResidual disease in acute lymphoblastic leukemia of childhood. International Journal of Pediatric Hematology/Oncology. 5:251-266.Residual disease in acute lymphoblastic leukemia of childhoodAmerican Journal of HematologyPhiladelphia-positive dimorphic blasts in mixed-phenotype acute leukemia with TET2 mutation. American Journal of Hematology. Philadelphia-positive dimorphic blasts in mixed-phenotype acute leukemia with TET2 mutationJournal of ImmunologyFunctional differences between IgM and IgD signaling in chronic lymphocytic leukemia. Journal of Immunology. 197:2522-2531.Functional differences between IgM and IgD signaling in chronic lymphocytic leukemia9011783Roberts WM, Estrov Z, Ouspenskaia MV, Johnston DA, McClain KL, Zipf TFThe New England journal of medicineMeasurement of residual leukemia during remission in childhood acute lymphoblastic leukemia. N Engl J Med. 1997 Jan 30; 336(5):317-23.N Engl J Med1997-01-30T00:00:001997Measurement of residual leukemia during remission in childhood acute lymphoblastic leukemia.28338082Montalban-Bravo G, Huang X, Naqvi K, Jabbour E, Borthakur G, DiNardo CD, Pemmaraju N, Cortes J, Verstovsek S, Kadia T, Daver N, Wierda W, Alvarado Y, Konopleva M, Ravandi F, Estrov Z, Jain N, Alfonso A, Brandt M, Sneed T, Chen HC, Yang H, Bueso-Ramos C, Pierce S, Estey E, Bohannan Z, Kantarjian HM, Garcia-Manero GLeukemiaA clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials. Leukemia. 2017 07; 31(7):1659.Leukemia2017-03-24T00:00:002017A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials.27795561Montalban-Bravo G, Huang X, Naqvi K, Jabbour E, Borthakur G, DiNardo CD, Pemmaraju N, Cortes J, Verstovsek S, Kadia T, Daver N, Wierda W, Alvarado Y, Konopleva M, Ravandi F, Estrov Z, Jain N, Alfonso A, Brandt M, Sneed T, Chen HC, Yang H, Bueso-Ramos C, Pierce S, Estey E, Bohannan Z, Kantarjian HM, Garcia-Manero GLeukemiaA clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials. Leukemia. 2017 02; 31(2):318-324.Leukemia2016-10-31T00:00:002016A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials.16088214Lev EI, Kleiman NS, Birnbaum Y, Harris D, Korbling M, Estrov ZJournal of vascular researchCirculating endothelial progenitor cells and coronary collaterals in patients with non-ST segment elevation myocardial infarction. J Vasc Res. 2005 Sep-Oct; 42(5):408-14.J Vasc Res2005-08-08T00:00:002005Circulating endothelial progenitor cells and coronary collaterals in patients with non-ST segment elevation myocardial infarction.17003929Lev EI, Estrov Z, Aboulfatova K, Harris D, Granada JF, Alviar C, Kleiman NS, Dong JFThrombosis and haemostasisPotential role of activated platelets in homing of human endothelial progenitor cells to subendothelial matrix. Thromb Haemost. 2006 Oct; 96(4):498-504.Thromb Haemost2006-10-01T00:00:002006Potential role of activated platelets in homing of human endothelial progenitor cells to subendothelial matrix.Authorship 88792016Authorship 88807618Authorship 88826620Authorship 88914216D055728Disorders1248310.549493Primary MyelofibrosisD011720Chemicals & Drugs46814710.521737PyrazolesD050796Chemicals & Drugs38311200.601372STAT3 Transcription FactorD015470Disorders52668850.242997Leukemia, Myeloid, AcuteAuthorship 9035406Authorship 9037512Authorship 9038359Authorship 9041237Authorship 9042179Authorship 9043527Authorship 9044158Authorship 90505813Authorship 90513816Authorship 9053538Authorship 9055058Authorship 90609513Authorship 90702115Authorship 9087005Authorship 90876913Authorship 9095527Authorship 9104596Authorship 9110266Authorship 9111938Authorship 91132514Authorship 9121028Authorship 9129267Authorship 9129396Authorship 91304122Authorship 9136513Authorship 91367022Authorship 9139706Authorship 91413215Authorship 91439215Authorship 91477718Authorship 91528612Authorship 91531112Authorship 91564412Authorship 9169808Authorship 91721811Authorship 91739324Authorship 9174407Authorship 91746211Authorship 9176867Authorship 91803212Authorship 9183997Authorship 9186666Authorship 91928019Authorship 9202442Authorship 9203935Authorship 92111912Authorship 9211645Authorship 9215725Authorship 92205513Authorship 9222264Authorship 92330920Authorship 9240979Authorship 92425524Authorship 92438816Authorship 9250318Authorship 92578319Authorship 92593316Authorship 9259916Authorship 92608915Authorship 9263364Authorship 92679813Authorship 9269327Authorship 9271359Authorship 92745113Authorship 92768816Authorship 92821612Authorship 9287637Authorship 92876714Authorship 9288497Authorship 92917613Authorship 93004418Authorship 9306253Authorship 9310747Authorship 93136015Authorship 93272811Authorship 9327456Authorship 9328747Authorship 93378011Authorship 93439121Authorship 93465812Authorship 93488113Authorship 9350346Authorship 93568711Authorship 9368129Authorship 9376568Authorship 9377696Authorship 93931513Authorship 9400831324982452Jain P, Ok CY, Konoplev S, Patel KP, Jorgensen J, Estrov Z, Luthra R, Kantarjian H, Ravandi FJournal of clinical oncology : official journal of the American Society of Clinical OncologyRelapsed Refractory BRAF-Negative, IGHV4-34-Positive Variant of Hairy Cell Leukemia: A Distinct Entity? J Clin Oncol. 2016 Mar 01; 34(7):e57-60.J Clin Oncol2014-06-30T00:00:002014Relapsed Refractory BRAF-Negative, IGHV4-34-Positive Variant of Hairy Cell Leukemia: A Distinct Entity?25832851Kurzrock R, Estrov Z, Talpaz M, Kantarjian HMCancerMeir Wetzler, MD. Cancer. 2015 Jul 01; 121(13):2106-7.Cancer2015-04-01T00:00:002015Meir Wetzler, MD.25824652Thompson PA, Rozovski U, Keating MJ, Stingo F, Smith SC, Wierda WG, Falchi L, O'Brien SM, Estrov Z, Burger JA, Ferrajoli ABritish journal of haematologyThe addition of CD20 monoclonal antibodies to lenalidomide improves response rates and survival in relapsed/refractory patients with chronic lymphocytic leukaemia relative to lenalidomide monotherapy - the MD Anderson Cancer Center experience. Br J Haematol. 2015 Oct; 171(2):281-284.Br J Haematol2015-03-30T00:00:002015The addition of CD20 monoclonal antibodies to lenalidomide improves response rates and survival in relapsed/refractory patients with chronic lymphocytic leukaemia relative to lenalidomide monotherapy - the MD Anderson Cancer Center experience.26402369Todisco G, Manshouri T, Verstovsek S, Masarova L, Pierce SA, Keating MJ, Estrov ZLeukemia & lymphomaChronic lymphocytic leukemia and myeloproliferative neoplasms concurrently diagnosed: clinical and biological characteristics. Leuk Lymphoma. 2016 May; 57(5):1054-9.Leuk Lymphoma2015-10-19T00:00:002015Chronic lymphocytic leukemia and myeloproliferative neoplasms concurrently diagnosed: clinical and biological characteristics.26437693Jain P, Tang G, Konoplev SN, Kanagal-Shamanna R, Wang SA, Pemmaraju N, Daver N, Estrov ZAmerican journal of hematologySynchronous del5q myelodysplastic syndrome (del5qMDS) and adult B-cell acute lymphoblastic leukemia (B-ALL) with TET2 and TP53 mutations. Am J Hematol. 2016 Mar; 91(3):354-5.Am J Hematol2016-01-11T00:00:002016Synchronous del5q myelodysplastic syndrome (del5qMDS) and adult B-cell acute lymphoblastic leukemia (B-ALL) with TET2 and TP53 mutations.26700872Jain P, Verstovsek S, Wang W, Loghavi S, Torres HA, Estrov Z, Patel KP, Pemmaraju NLeukemia & lymphomaDNMT3A, TET2, and JAK2 mutations in polycythemia vera following long-term remission of secondary acute myeloid leukemia. Leuk Lymphoma. 2016 08; 57(8):1969-73.Leuk Lymphoma2015-12-24T00:00:002015DNMT3A, TET2, and JAK2 mutations in polycythemia vera following long-term remission of secondary acute myeloid leukemia.26752456Takahashi K, Kantarjian H, Garcia-Manero G, Borthakur G, Kadia T, DiNardo C, Jabbour E, Pierce S, Estrov Z, Konopleva M, Andreeff M, Ravandi F, Cortes JClinical lymphoma, myeloma & leukemiaClofarabine Plus Low-Dose Cytarabine Is as Effective as and Less Toxic Than Intensive Chemotherapy in Elderly AML Patients. Clin Lymphoma Myeloma Leuk. 2016 Mar; 16(3):163-8.e1-2.Clin Lymphoma Myeloma Leuk2015-11-24T00:00:002015Clofarabine Plus Low-Dose Cytarabine Is as Effective as and Less Toxic Than Intensive Chemotherapy in Elderly AML Patients.27013651Vitale C, Ahn IE, Sivina M, Ferrajoli A, Wierda WG, Estrov Z, Konoplev SN, Jain N, O'Brien S, Farooqui M, Keating MJ, Wiestner A, Burger JAHaematologicaAutoimmune cytopenias in patients with chronic lymphocytic leukemia treated with ibrutinib. Haematologica. 2016 06; 101(6):e254-8.Haematologica2016-03-24T00:00:002016Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with ibrutinib.27076684Rozovski U, Harris DM, Li P, Liu Z, Wu JY, Grgurevic S, Faderl S, Ferrajoli A, Wierda WG, Martinez M, Verstovsek S, Keating MJ, Estrov ZJournal of immunology (Baltimore, Md. : 1950)At High Levels, Constitutively Activated STAT3 Induces Apoptosis of Chronic Lymphocytic Leukemia Cells. J Immunol. 2016 05 15; 196(10):4400-9.J Immunol2016-04-13T00:00:002016At High Levels, Constitutively Activated STAT3 Induces Apoptosis of Chronic Lymphocytic Leukemia Cells.26588193Thompson PA, O'Brien SM, Xiao L, Wang X, Burger JA, Jain N, Ferrajoli A, Estrov Z, Keating MJ, Wierda WGCancer?2 -microglobulin normalization within 6 months of ibrutinib-based treatment is associated with superior progression-free survival in patients with chronic lymphocytic leukemia. Cancer. 2016 Feb 15; 122(4):565-73.Cancer2015-11-20T00:00:002015?2 -microglobulin normalization within 6 months of ibrutinib-based treatment is associated with superior progression-free survival in patients with chronic lymphocytic leukemia.26729897Jain P, Kantarjian H, Patel KP, Gonzalez GN, Luthra R, Kanagal Shamanna R, Sasaki K, Jabbour E, Romo CG, Kadia TM, Pemmaraju N, Daver N, Borthakur G, Estrov Z, Ravandi F, O'Brien S, Cortes JBloodImpact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors. Blood. 2016 Mar 10; 127(10):1269-75.Blood2016-01-04T00:00:002016Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors.26799924Jain P, Tang G, Huh YO, Yin CC, Zuo Z, Pemmaraju N, Estrov Z, Daver NAmerican journal of hematologyPhiladelphia-positive dimorphic blasts in mixed-phenotype acute leukemia with TET2 mutation. Am J Hematol. 2016 06; 91(6):647-8.Am J Hematol2016-02-09T00:00:002016Philadelphia-positive dimorphic blasts in mixed-phenotype acute leukemia with TET2 mutation.26871476Takahashi K, Patel K, Bueso-Ramos C, Zhang J, Gumbs C, Jabbour E, Kadia T, Andreff M, Konopleva M, DiNardo C, Daver N, Cortes J, Estrov Z, Futreal A, Kantarjian H, Garcia-Manero GOncotargetClinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents. Oncotarget. 2016 Mar 22; 7(12):14172-87.Oncotarget2016-03-22T00:00:002016Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents.26643954Rozovski U, Hazan-Halevy I, Barzilai M, Keating MJ, Estrov ZLeukemia & lymphomaMetabolism pathways in chronic lymphocytic leukemia. Leuk Lymphoma. 2016; 57(4):758-65.Leuk Lymphoma2015-12-08T00:00:002015Metabolism pathways in chronic lymphocytic leukemia.27463065Kadia TM, Jain P, Ravandi F, Garcia-Manero G, Andreef M, Takahashi K, Borthakur G, Jabbour E, Konopleva M, Daver NG, Dinardo C, Pierce S, Kanagal-Shamanna R, Patel K, Estrov Z, Cortes J, Kantarjian HMCancerTP53 mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes. Cancer. 2016 Nov 15; 122(22):3484-3491.Cancer2016-07-26T00:00:002016TP53 mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes.27065330Liu PP, Liu J, Jiang WQ, Carew JS, Ogasawara MA, Pelicano H, Croce CM, Estrov Z, Xu RH, Keating MJ, Huang POncogeneElimination of chronic lymphocytic leukemia cells in stromal microenvironment by targeting CPT with an antiangina drug perhexiline. Oncogene. 2016 10 27; 35(43):5663-5673.Oncogene2016-04-11T00:00:002016Elimination of chronic lymphocytic leukemia cells in stromal microenvironment by targeting CPT with an antiangina drug perhexiline.27341356Rozovski U, Hazan-Halevy I, Calin G, Harris D, Li P, Liu Z, Keating MJ, Estrov ZJournal of visualized experiments : JoVEDescribing a Transcription Factor Dependent Regulation of the MicroRNA Transcriptome. J Vis Exp. 2016 06 15; (112).J Vis Exp2016-06-15T00:00:002016Describing a Transcription Factor Dependent Regulation of the MicroRNA Transcriptome.27468087Jain P, Kanagal-Shamanna R, Wierda W, Keating M, Sarwari N, Rozovski U, Thompson P, Burger J, Kantarjian H, Patel KP, Medeiros LJ, Luthra R, Estrov ZAmerican journal of hematologyClinical and molecular characteristics of XPO1 mutations in patients with chronic lymphocytic leukemia. Am J Hematol. 2016 11; 91(11):E478-E479.Am J Hematol2016-08-22T00:00:002016Clinical and molecular characteristics of XPO1 mutations in patients with chronic lymphocytic leukemia.27657543Ravandi F, Jorgensen J, Borthakur G, Jabbour E, Kadia T, Pierce S, Brandt M, Wang S, Konoplev S, Wang X, Huang X, Daver N, DiNardo C, Andreeff M, Konopleva M, Estrov Z, Garcia-Manero G, Cortes J, Kantarjian HCancerPersistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia. Cancer. 2017 02 01; 123(3):426-435.Cancer2016-09-22T00:00:002016Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia.27879987Ohanian M, Pemmaraju N, Rozovski U, Alattar ML, Estrov Z, Kundra V, Tung C, Ravandi F, Manning J, Abruzzo LVBritish journal of haematologyOcular extramedullary myeloid leukaemia. Br J Haematol. 2018 03; 180(5):738-740.Br J Haematol2016-11-23T00:00:002016Ocular extramedullary myeloid leukaemia.28070498Shah AR, Muzzafar T, Assi R, Schellingerhout D, Estrov Z, Tamamyan G, Kantarjian H, Daver NBBA clinicalHemophagocytic lymphohistiocytosis in adults: An under recognized entity. BBA Clin. 2017 Jun; 7:36-40.BBA Clin2016-12-20T00:00:002016Hemophagocytic lymphohistiocytosis in adults: An under recognized entity.28076892Jabbour E, Strati P, Cabrero M, O'Brien S, Ravandi F, Bueso-Ramos C, Wei Q, Hu J, Abi Aad S, Short NJ, Dinardo C, Daver N, Kadia T, Wierda W, Wei Y, Colla S, Borthakur G, Cortes J, Estrov Z, Kantarjian H, Garcia-Manero GAmerican journal of hematologyImpact of achievement of complete cytogenetic response on outcome in patients with myelodysplastic syndromes treated with hypomethylating agents. Am J Hematol. 2017 Apr; 92(4):351-358.Am J Hematol2017-02-13T00:00:002017Impact of achievement of complete cytogenetic response on outcome in patients with myelodysplastic syndromes treated with hypomethylating agents.28077600Yin Q, Sivina M, Robins H, Yusko E, Vignali M, O'Brien S, Keating MJ, Ferrajoli A, Estrov Z, Jain N, Wierda WG, Burger JAJournal of immunology (Baltimore, Md. : 1950)Ibrutinib Therapy Increases T Cell Repertoire Diversity in Patients with Chronic Lymphocytic Leukemia. J Immunol. 2017 02 15; 198(4):1740-1747.J Immunol2017-01-11T00:00:002017Ibrutinib Therapy Increases T Cell Repertoire Diversity in Patients with Chronic Lymphocytic Leukemia.27797975Jain P, Keating MJ, Wierda WG, Sivina M, Thompson PA, Ferrajoli A, Estrov Z, Kantarjian H, O'Brien S, Burger JAClinical cancer research : an official journal of the American Association for Cancer ResearchLong-term Follow-up of Treatment with Ibrutinib and Rituximab in Patients with High-Risk Chronic Lymphocytic Leukemia. Clin Cancer Res. 2017 May 01; 23(9):2154-2158.Clin Cancer Res2016-10-19T00:00:002016Long-term Follow-up of Treatment with Ibrutinib and Rituximab in Patients with High-Risk Chronic Lymphocytic Leukemia.28130399Rozovski U, Harris DM, Li P, Liu Z, Jain P, Veletic I, Ferrajoli A, Burger J, O'Brien S, Bose P, Thompson P, Jain N, Wierda W, Keating MJ, Estrov ZMolecular cancer research : MCRConstitutive Phosphorylation of STAT3 by the CK2-BLNK-CD5 Complex. Mol Cancer Res. 2017 05; 15(5):610-618.Mol Cancer Res2017-01-27T00:00:002017Constitutive Phosphorylation of STAT3 by the CK2-BLNK-CD5 Complex.27534555Ten Hacken E, Sivina M, Kim E, O'Brien S, Wierda WG, Ferrajoli A, Estrov Z, Keating MJ, Oellerich T, Scielzo C, Ghia P, Caligaris-Cappio F, Burger JAJournal of immunology (Baltimore, Md. : 1950)Functional Differences between IgM and IgD Signaling in Chronic Lymphocytic Leukemia. J Immunol. 2016 09 15; 197(6):2522-31.J Immunol2016-08-17T00:00:002016Functional Differences between IgM and IgD Signaling in Chronic Lymphocytic Leukemia.27677095Pemmaraju N, Jain P, Medeiros LJ, Jorgenson JL, Jain N, Willis J, Kontoyiannis DP, Estrov Z, Wierda WGAmerican journal of hematologyPET-positive lymphadenopathy in CLL-Not always Richter transformation. Am J Hematol. 2017 04; 92(4):405-406.Am J Hematol2017-02-07T00:00:002017PET-positive lymphadenopathy in CLL-Not always Richter transformation.27686378Rozovski U, Verstovsek S, Manshouri T, Dembitz V, Bozinovic K, Newberry K, Zhang Y, Bove JE, Pierce S, Kantarjian H, Estrov ZHaematologicaAn accurate, simple prognostic model consisting of age, JAK2, CALR, and MPL mutation status for patients with primary myelofibrosis. Haematologica. 2017 01; 102(1):79-84.Haematologica2016-09-29T00:00:002016An accurate, simple prognostic model consisting of age, JAK2, CALR, and MPL mutation status for patients with primary myelofibrosis.27763690Koller PB, Kantarjian HM, Nogueras-Gonzalez GM, Jabbour E, Verstovsek S, Borthakur G, Estrov Z, Wierda WG, Garcia-Manero G, Ferrajoli A, Ravandi F, O'Brien SM, Cortes JECancerChronic myeloid leukemia among patients with a history of prior malignancies: A tale of dual survivorship. Cancer. 2017 02 15; 123(4):609-616.Cancer2016-10-20T00:00:002016Chronic myeloid leukemia among patients with a history of prior malignancies: A tale of dual survivorship.28003274Abaza Y, Kantarjian H, Garcia-Manero G, Estey E, Borthakur G, Jabbour E, Faderl S, O'Brien S, Wierda W, Pierce S, Brandt M, McCue D, Luthra R, Patel K, Kornblau S, Kadia T, Daver N, DiNardo C, Jain N, Verstovsek S, Ferrajoli A, Andreeff M, Konopleva M, Estrov Z, Foudray M, McCue D, Cortes J, Ravandi FBloodLong-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab. Blood. 2017 03 09; 129(10):1275-1283.Blood2016-12-21T00:00:002016Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab.28089238Jain P, Keating M, Renner S, Cleeland C, Xuelin H, Gonzalez GN, Harris D, Li P, Liu Z, Veletic I, Rozovski U, Jain N, Thompson P, Bose P, DiNardo C, Ferrajoli A, O'Brien S, Burger J, Wierda W, Verstovsek S, Kantarjian H, Estrov ZThe Lancet. HaematologyRuxolitinib for symptom control in patients with chronic lymphocytic leukaemia: a single-group, phase 2 trial. Lancet Haematol. 2017 Feb; 4(2):e67-e74.Lancet Haematol2017-01-12T00:00:002017Ruxolitinib for symptom control in patients with chronic lymphocytic leukaemia: a single-group, phase 2 trial.28278723Maiti A, Cortes J, Ferrajoli A, Estrov Z, Borthakur G, Garcia-Manero G, Jabbour E, Ravandi F, O'Brien S, Kantarjian HLeukemia & lymphomaPhase II trial of homoharringtonine with imatinib in chronic, accelerated, and blast phase chronic myeloid leukemia. Leuk Lymphoma. 2017 09; 58(9):1-6.Leuk Lymphoma2017-02-09T00:00:002017Phase II trial of homoharringtonine with imatinib in chronic, accelerated, and blast phase chronic myeloid leukemia.28291640Masarova L, Patel KP, Newberry KJ, Cortes J, Borthakur G, Konopleva M, Estrov Z, Kantarjian H, Verstovsek SThe Lancet. HaematologyPegylated interferon alfa-2a in patients with essential thrombocythaemia or polycythaemia vera: a post-hoc, median 83 month follow-up of an open-label, phase 2 trial. Lancet Haematol. 2017 Apr; 4(4):e165-e175.Lancet Haematol2017-03-11T00:00:002017Pegylated interferon alfa-2a in patients with essential thrombocythaemia or polycythaemia vera: a post-hoc, median 83 month follow-up of an open-label, phase 2 trial.28295181Thompson PA, Stingo F, Keating MJ, Wierda WG, O'Brien SM, Estrov Z, Ledesma C, Rezvani K, Qazilbash M, Shah N, Parmar S, Popat U, Anderlini P, Yago N, Ciurea SO, Kebriaei P, Champlin R, Shpall EJ, Hosing CMBritish journal of haematologyLong-term follow-up of patients receiving allogeneic stem cell transplant for chronic lymphocytic leukaemia: mixed T-cell chimerism is associated with high relapse risk and inferior survival. Br J Haematol. 2017 05; 177(4):567-577.Br J Haematol2017-03-14T00:00:002017Long-term follow-up of patients receiving allogeneic stem cell transplant for chronic lymphocytic leukaemia: mixed T-cell chimerism is associated with high relapse risk and inferior survival.28370097Alfonso A, Montalban-Bravo G, Takahashi K, Jabbour EJ, Kadia T, Ravandi F, Cortes J, Estrov Z, Borthakur G, Pemmaraju N, Konopleva M, Bueso-Ramos C, Pierce S, Kantarjian H, Garcia-Manero GAmerican journal of hematologyNatural history of chronic myelomonocytic leukemia treated with hypomethylating agents. Am J Hematol. 2017 Jul; 92(7):599-606.Am J Hematol2017-05-26T00:00:002017Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents.28370157Daher M, Hidalgo Lopez JE, Randhawa JK, Jabbar KJ, Wei Y, Pemmaraju N, Borthakur G, Kadia T, Konopleva M, Kantarjian HM, Hearn K, Estrov Z, Reyes S, Bueso-Ramos CE, Garcia-Manero GAmerican journal of hematologyAn exploratory clinical trial of bortezomib in patients with lower risk myelodysplastic syndromes. Am J Hematol. 2017 Jul; 92(7):674-682.Am J Hematol2017-06-09T00:00:002017An exploratory clinical trial of bortezomib in patients with lower risk myelodysplastic syndromes.28379307Jain P, Aoki E, Keating M, Wierda WG, O'Brien S, Gonzalez GN, Ferrajoli A, Jain N, Thompson PA, Jabbour E, Kanagal-Shamanna R, Pierce S, Alousi A, Hosing C, Khouri I, Estrov Z, Cortes J, Kantarjian H, Ravandi F, Kadia TMAnnals of oncology : official journal of the European Society for Medical OncologyCharacteristics, outcomes, prognostic factors and treatment of patients with T-cell prolymphocytic leukemia (T-PLL). Ann Oncol. 2017 Jul 01; 28(7):1554-1559.Ann Oncol2017-07-01T00:00:002017Characteristics, outcomes, prognostic factors and treatment of patients with T-cell prolymphocytic leukemia (T-PLL).28556489Jabbour E, Guastad Daver N, Short NJ, Huang X, Chen HC, Maiti A, Ravandi F, Cortes J, Abi Aad S, Garcia-Manero G, Estrov Z, Kadia T, O'Brien S, Dabaja B, Bueso-Ramos C, Strati P, Bivins C, Pierce S, Kantarjian HAmerican journal of hematologyFactors associated with risk of central nervous system relapse in patients with non-core binding factor acute myeloid leukemia. Am J Hematol. 2017 Sep; 92(9):924-928.Am J Hematol2017-07-19T00:00:002017Factors associated with risk of central nervous system relapse in patients with non-core binding factor acute myeloid leukemia.28608976Kanagal-Shamanna R, Jain P, Takahashi K, Short NJ, Tang G, Issa GC, Ravandi F, Garcia-Manero G, Yin CC, Luthra R, Patel KP, Khoury JD, Montalban-Bravo G, Sasaki K, Kadia TM, Borthakur G, Konopleva M, Jain N, Garris R, Pierce S, Wierda W, Estrov Z, Cortes J, O'Brien S, Kantarjian HM, Jabbour ECancerTP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper-CVAD-based regimens. Cancer. 2017 Oct 01; 123(19):3717-3724.Cancer2017-06-13T00:00:002017TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper-CVAD-based regimens.28596259Hidalgo-L?pez JE, Kanagal-Shamanna R, Medeiros LJ, Estrov Z, Yin CC, Verstovsek S, Konoplev S, Jorgensen JL, Mohammad MM, Miranda RN, Zhao C, Lee J, Zuo Z, Bueso-Ramos CEJournal of the National Comprehensive Cancer Network : JNCCNMorphologic and Molecular Characteristics of De Novo AML With JAK2 V617F Mutation. J Natl Compr Canc Netw. 2017 06; 15(6):790-796.J Natl Compr Canc Netw2017-06-01T00:00:002017Morphologic and Molecular Characteristics of De Novo AML With JAK2 V617F Mutation.28718728Short NJ, Kantarjian H, Ravandi F, Huang X, Xiao L, Garcia-Manero G, Plunkett W, Gandhi V, Sasaki K, Pemmaraju N, Daver NG, Borthakur G, Jain N, Konopleva M, Estrov Z, Kadia TM, Wierda WG, DiNardo CD, Brandt M, O'Brien SM, Cortes JE, Jabbour ELeukemia & lymphomaA phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia. Leuk Lymphoma. 2018 04; 59(4):813-820.Leuk Lymphoma2017-07-18T00:00:002017A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia.28722170Rozovski U, Harris DM, Li P, Liu Z, Jain P, Veletic I, Ferrajoli A, Burger J, Thompson P, Jain N, Wierda W, Keating MJ, Estrov ZInternational journal of cancerActivation of the B-cell receptor successively activates NF-?B and STAT3 in chronic lymphocytic leukemia cells. Int J Cancer. 2017 11 15; 141(10):2076-2081.Int J Cancer2017-08-04T00:00:002017Activation of the B-cell receptor successively activates NF-?B and STAT3 in chronic lymphocytic leukemia cells.28401108Jain P, Wang SA, Yin CC, Abaza Y, Verstovsek S, Estrov ZBlood researchA case of lymphocytic variant hypereosinophilic syndrome with sub-diagnostic systemic mastocytosis. Blood Res. 2017 Mar; 52(1):71-73.Blood Res2017-03-27T00:00:002017A case of lymphocytic variant hypereosinophilic syndrome with sub-diagnostic systemic mastocytosis.28646517Jain P, Kantarjian H, Jain N, Short NJ, Yin CC, Kanagal-Shamanna R, Khoury J, Konopleva M, Sasaki K, Kadia TM, Garris R, Pierce S, Estrov Z, Wierda W, Cortes J, O'Brien S, Ravandi F, Jabbour EAmerican journal of hematologyClinical characteristics and outcomes of previously untreated patients with adult onset T-acute lymphoblastic leukemia and T-lymphoblastic lymphoma with hyper-CVAD based regimens. Am J Hematol. 2017 10; 92(10):E595-E597.Am J Hematol2017-07-29T00:00:002017Clinical characteristics and outcomes of previously untreated patients with adult onset T-acute lymphoblastic leukemia and T-lymphoblastic lymphoma with hyper-CVAD based regimens.28171709Jain P, Thompson PA, Keating M, Estrov Z, Ferrajoli A, Jain N, Kantarjian H, Burger JA, O'Brien S, Wierda WGCancerLong-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib. Cancer. 2017 Jun 15; 123(12):2268-2273.Cancer2017-02-07T00:00:002017Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib.28295472Short NJ, Kantarjian HM, Ko H, Khoury JD, Ravandi F, Thomas DA, Garcia-Manero G, Khouri M, Cortes JE, Wierda WG, Verstovsek S, Estrov Z, Ferrajoli A, Thompson PA, Pierce S, O'Brien SM, Jabbour EAmerican journal of hematologyOutcomes of adults with relapsed or refractory Burkitt and high-grade B-cell leukemia/lymphoma. Am J Hematol. 2017 06; 92(6):E114-E117.Am J Hematol2017-04-18T00:00:002017Outcomes of adults with relapsed or refractory Burkitt and high-grade B-cell leukemia/lymphoma.28743165Jain P, Kantarjian HM, Ghorab A, Sasaki K, Jabbour EJ, Nogueras Gonzalez G, Kanagal-Shamanna R, Issa GC, Garcia-Manero G, Kc D, Dellasala S, Pierce S, Konopleva M, Wierda WG, Verstovsek S, Daver NG, Kadia TM, Borthakur G, O'Brien S, Estrov Z, Ravandi F, Cortes JECancerPrognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients. Cancer. 2017 Nov 15; 123(22):4391-4402.Cancer2017-07-25T00:00:002017Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients.28798068Strati P, Keating MJ, Burger JA, O'Brien SM, Wierda WG, Estrov Z, Zacharian G, Ferrajoli AHaematologicaConsolidation treatment with lenalidomide following front-line or salvage chemoimmunotherapy in chronic lymphocytic leukemia. Haematologica. 2017 12; 102(12):e494-e496.Haematologica2017-08-10T00:00:002017Consolidation treatment with lenalidomide following front-line or salvage chemoimmunotherapy in chronic lymphocytic leukemia.28859185Jabbour E, Ravandi F, Kebriaei P, Huang X, Short NJ, Thomas D, Sasaki K, Rytting M, Jain N, Konopleva M, Garcia-Manero G, Champlin R, Marin D, Kadia T, Cortes J, Estrov Z, Takahashi K, Patel Y, Khouri MR, Jacob J, Garris R, O'Brien S, Kantarjian HJAMA oncologySalvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Clinical Trial. JAMA Oncol. 2018 Feb 01; 4(2):230-234.JAMA Oncol2018-02-01T00:00:002018Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Clinical Trial.29134664Assi R, Kantarjian HM, Garcia-Manero G, Cortes JE, Pemmaraju N, Wang X, Nogueras-Gonzalez G, Jabbour E, Bose P, Kadia T, Dinardo CD, Patel K, Bueso-Ramos C, Zhou L, Pierce S, Gergis R, Tuttle C, Borthakur G, Estrov Z, Luthra R, Hidalgo-Lopez J, Verstovsek S, Daver NAmerican journal of hematologyA phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms. Am J Hematol. 2018 02; 93(2):277-285.Am J Hematol2017-11-27T00:00:002017A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms.28841236Abaza YM, Kadia TM, Jabbour EJ, Konopleva MY, Borthakur G, Ferrajoli A, Estrov Z, Wierda WG, Alfonso A, Chong TH, Chuah C, Koh LP, Goh BC, Chang JE, Durkes DE, Foudray MC, Kantarjian HM, Dong XQ, Garcia-Manero GCancerPhase 1 dose escalation multicenter trial of pracinostat alone and in combination with azacitidine in patients with advanced hematologic malignancies. Cancer. 2017 Dec 15; 123(24):4851-4859.Cancer2017-08-25T00:00:002017Phase 1 dose escalation multicenter trial of pracinostat alone and in combination with azacitidine in patients with advanced hematologic malignancies.28972595Kondo K, Shaim H, Thompson PA, Burger JA, Keating M, Estrov Z, Harris D, Kim E, Ferrajoli A, Daher M, Basar R, Muftuoglu M, Imahashi N, Alsuliman A, Sobieski C, Gokdemir E, Wierda W, Jain N, Liu E, Shpall EJ, Rezvani KLeukemiaIbrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD-1/PD-L1 pathway. Leukemia. 2018 04; 32(4):960-970.Leukemia2017-10-03T00:00:002017Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD-1/PD-L1 pathway.28708931Jabbour E, Short NJ, Ravandi F, Huang X, Xiao L, Garcia-Manero G, Plunkett W, Gandhi V, Sasaki K, Pemmaraju N, Daver NG, Borthakur G, Jain N, Konopleva M, Estrov Z, Kadia TM, Wierda WG, DiNardo CD, Brandt M, O'Brien SM, Cortes JE, Kantarjian HCancerA randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia. Cancer. 2017 Nov 15; 123(22):4430-4439.Cancer2017-07-14T00:00:002017A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia.28774880Jabbour E, Short NJ, Montalban-Bravo G, Huang X, Bueso-Ramos C, Qiao W, Yang H, Zhao C, Kadia T, Borthakur G, Pemmaraju N, Sasaki K, Estrov Z, Cortes J, Ravandi F, Alvarado Y, Komrokji R, Sekeres MA, Steensma DP, DeZern A, Roboz G, Kantarjian H, Garcia-Manero GBloodRandomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN. Blood. 2017 09 28; 130(13):1514-1522.Blood2017-08-03T00:00:002017Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN.29164608Jain P, Nogueras Gonz?lez GM, Kanagal-Shamanna R, Rozovski U, Sarwari N, Tam C, Wierda WG, Thompson PA, Jain N, Luthra R, Quesada A, Sanchez-Petitto G, Ferrajoli A, Burger J, Kantarjian H, Cortes J, O'Brien S, Keating MJ, Estrov ZBritish journal of haematologyThe absolute percent deviation of IGHV mutation rather than a 98% cut-off predicts survival of chronic lymphocytic leukaemia patients treated with fludarabine, cyclophosphamide and rituximab. Br J Haematol. 2018 01; 180(1):33-40.Br J Haematol2017-11-21T00:00:002017The absolute percent deviation of IGHV mutation rather than a 98% cut-off predicts survival of chronic lymphocytic leukaemia patients treated with fludarabine, cyclophosphamide and rituximab.28751563ten Hacken E, Gounari M, Back JW, Shimanovskaya E, Scarf? L, Kim E, Burks J, Ponzoni M, Ramirez GA, Wierda WG, Estrov Z, Keating MJ, Ferrajoli A, Stamatopoulos K, Ghia P, Burger JAHaematologicaCalreticulin as a novel B-cell receptor antigen in chronic lymphocytic leukemia. Haematologica. 2017 10; 102(10):e394-e396.Haematologica2017-07-27T00:00:002017Calreticulin as a novel B-cell receptor antigen in chronic lymphocytic leukemia.29465264Rozovski U, Harris DM, Li P, Liu Z, Jain P, Ferrajoli A, Burger J, Thompson P, Jain N, Wierda W, Keating MJ, Estrov ZLeukemia & lymphomaIbrutinib inhibits free fatty acid metabolism in chronic lymphocytic leukemia. Leuk Lymphoma. 2018 11; 59(11):2686-2691.Leuk Lymphoma2018-02-21T00:00:002018Ibrutinib inhibits free fatty acid metabolism in chronic lymphocytic leukemia.29479067Strati P, Ferrajoli A, Wierda WG, Jain N, Thompson PA, O'Brien SM, Rezvani K, Kantarjian HM, Burger JA, Hinojosa CO, Keating MJ, Estrov ZLeukemiaSustained long-lasting responses after lenalidomide discontinuation in patients with chronic lymphocytic leukemia. Leukemia. 2018 10; 32(10):2278-2281.Leukemia2018-02-20T00:00:002018Sustained long-lasting responses after lenalidomide discontinuation in patients with chronic lymphocytic leukemia.29296729Masarova L, Todisco G, Manshouri T, Newberry KJ, Cortes JE, Kantarjian HM, Estrov Z, Verstovsek SBlood advancesTherapy-related myelofibrosis does not appear to exist. Blood Adv. 2017 Jun 13; 1(14):863-866.Blood Adv2017-05-26T00:00:002017Therapy-related myelofibrosis does not appear to exist.29296774Boddu P, Kantarjian HM, Garcia-Manero G, Ravandi F, Verstovsek S, Jabbour E, Borthakur G, Konopleva M, Bhalla KN, Daver N, DiNardo CD, Benton CB, Takahashi K, Estrov Z, Pierce SR, Andreeff M, Cortes JE, Kadia TMBlood advancesTreated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis. Blood Adv. 2017 Jul 25; 1(17):1312-1323.Blood Adv2017-07-19T00:00:002017Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis.29379494Shaim H, Estrov Z, Harris D, Hernandez Sanabria M, Liu Z, Ruvolo P, Thompson PA, Ferrajoli A, Daher M, Burger J, Muftuoglu M, Imahashi N, Li L, Liu E, Alsuliman AS, Basar R, Nassif Kerbauy L, Sobieski C, Gokdemir E, Kondo K, Wierda W, Keating M, Shpall EJ, Rezvani KFrontiers in immunologyThe CXCR4-STAT3-IL-10 Pathway Controls the Immunoregulatory Function of Chronic Lymphocytic Leukemia and Is Modulated by Lenalidomide. Front Immunol. 2017; 8:1773.Front Immunol2018-01-15T00:00:002018The CXCR4-STAT3-IL-10 Pathway Controls the Immunoregulatory Function of Chronic Lymphocytic Leukemia and Is Modulated by Lenalidomide.29741984Ohanian M, Rozovski U, Kanagal-Shamanna R, Abruzzo LV, Loghavi S, Kadia T, Futreal A, Bhalla K, Zuo Z, Huh YO, Post SM, Ruvolo P, Garcia-Manero G, Andreeff M, Kornblau S, Borthakur G, Hu P, Medeiros LJ, Takahashi K, Hornbaker MJ, Zhang J, Nogueras-Gonz?lez GM, Huang X, Verstovsek S, Estrov Z, Pierce S, Ravandi F, Kantarjian HM, Bueso-Ramos CE, Cortes JELeukemia & lymphomaMYC protein expression is an important prognostic factor in acute myeloid leukemia. Leuk Lymphoma. 2019 01; 60(1):37-48.Leuk Lymphoma2018-05-09T00:00:002018MYC protein expression is an important prognostic factor in acute myeloid leukemia.29358183Takahashi K, Hu B, Wang F, Yan Y, Kim E, Vitale C, Patel KP, Strati P, Gumbs C, Little L, Tippen S, Song X, Zhang J, Jain N, Thompson P, Garcia-Manero G, Kantarjian H, Estrov Z, Do KA, Keating M, Burger JA, Wierda WG, Futreal PA, Ferrajoli ABloodClinical implications of cancer gene mutations in patients with chronic lymphocytic leukemia treated with lenalidomide. Blood. 2018 04 19; 131(16):1820-1832.Blood2018-01-22T00:00:002018Clinical implications of cancer gene mutations in patients with chronic lymphocytic leukemia treated with lenalidomide.29515765Montalban-Bravo G, Takahashi K, Patel K, Wang F, Xingzhi S, Nogueras GM, Huang X, Pierola AA, Jabbour E, Colla S, Ga?an-Gomez I, Borthakur G, Daver N, Estrov Z, Kadia T, Pemmaraju N, Ravandi F, Bueso-Ramos C, Chamseddine A, Konopleva M, Zhang J, Kantarjian H, Futreal A, Garcia-Manero GOncotargetImpact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms. Oncotarget. 2018 Feb 09; 9(11):9714-9727.Oncotarget2018-01-03T00:00:002018Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms.29660836Assi R, Kantarjian HM, Kadia TM, Pemmaraju N, Jabbour E, Jain N, Daver N, Estrov Z, Uehara T, Owa T, Cortes JE, Borthakur GCancerFinal results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome. Cancer. 2018 07 01; 124(13):2758-2765.Cancer2018-04-16T00:00:002018Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome.29723397Naqvi K, Jabbour E, Skinner J, Yilmaz M, Ferrajoli A, Bose P, Thompson P, Alvarado Y, Jain N, Takahashi K, Burger J, Estrov Z, Borthakur G, Pemmaraju N, Paul S, Cortes J, Kantarjian HMCancerEarly results of lower dose dasatinib (50?mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia. Cancer. 2018 07 01; 124(13):2740-2747.Cancer2018-05-03T00:00:002018Early results of lower dose dasatinib (50?mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia.29143068Boddu P, Masarova L, Verstovsek S, Strati P, Kantarjian H, Cortes J, Estrov Z, Pierce S, Pemmaraju NAnnals of hematologyPatient characteristics and outcomes in adolescents and young adults with classical Philadelphia chromosome-negative myeloproliferative neoplasms. Ann Hematol. 2018 Jan; 97(1):109-121.Ann Hematol2017-11-15T00:00:002017Patient characteristics and outcomes in adolescents and young adults with classical Philadelphia chromosome-negative myeloproliferative neoplasms.29557496Khan M, Muzzafar T, Kantarjian H, Badar I, Short N, Wang X, Chamoun K, Jain P, DiNardo C, Pemmaraju N, Bose P, Borthakur G, Cortes J, Verstovsek S, Garcia-Manero G, Estrov ZAnnals of hematologyAssociation of bone marrow fibrosis with inferior survival outcomes in chronic myelomonocytic leukemia. Ann Hematol. 2018 Jul; 97(7):1183-1191.Ann Hematol2018-03-20T00:00:002018Association of bone marrow fibrosis with inferior survival outcomes in chronic myelomonocytic leukemia.29632735Schliffke S, Sivina M, Kim E, von Wenserski L, Thiele B, Aky?z N, Falker-Gieske C, Statovci D, Oberle A, Thenhausen T, Krohn-Grimberghe A, Bokemeyer C, Jain N, Estrov Z, Ferrajoli A, Wierda W, Keating M, Burger JA, Binder MOncoimmunologyDynamic changes of the normal B lymphocyte repertoire in CLL in response to ibrutinib or FCR chemo-immunotherapy. Oncoimmunology. 2018; 7(4):e1417720.Oncoimmunology2018-01-15T00:00:002018Dynamic changes of the normal B lymphocyte repertoire in CLL in response to ibrutinib or FCR chemo-immunotherapy.30071517Abou Dalle I, Cortes JE, Pinnamaneni P, Lamothe B, Diaz Duque A, Randhawa J, Pemmaraju N, Jabbour E, Ferrajoli A, Wierda WG, Estrov Z, Konopleva M, Ravandi F, Alvarado Y, Borthakur G, Gandhi V, Kantarjian HMActa haematologicaA Pilot Phase II Study of Erlotinib for the Treatment of Patients with Relapsed/Refractory Acute Myeloid Leukemia. Acta Haematol. 2018; 140(1):30-39.Acta Haematol2018-08-02T00:00:002018A Pilot Phase II Study of Erlotinib for the Treatment of Patients with Relapsed/Refractory Acute Myeloid Leukemia.30074241Veletic I, Manshouri T, Newberry KJ, Garnett J, Verstovsek S, Estrov ZBritish journal of haematologyPentraxin-3 plasma levels correlate with tumour burden and overall survival in patients with primary myelofibrosis. Br J Haematol. 2019 04; 185(2):382-386.Br J Haematol2018-08-03T00:00:002018Pentraxin-3 plasma levels correlate with tumour burden and overall survival in patients with primary myelofibrosis.30263097Rozovski U, Harris DM, Li P, Liu Z, Jain P, Ferrajoli A, Burger J, Thompson P, Jain N, Wierda W, Keating MJ, Estrov ZOncotargetSTAT3 is constitutively acetylated on lysine 685 residues in chronic lymphocytic leukemia cells. Oncotarget. 2018 Sep 14; 9(72):33710-33718.Oncotarget2018-09-14T00:00:002018STAT3 is constitutively acetylated on lysine 685 residues in chronic lymphocytic leukemia cells.30328139Short NJ, Jabbour E, Naqvi K, Patel A, Ning J, Sasaki K, Nogueras-Gonzalez GM, Bose P, Kornblau SM, Takahashi K, Andreeff M, Sanchez-Petitto G, Estrov Z, Dinardo CD, Montalban-Bravo G, Konopleva M, Alvarado Y, Bhalla KN, Fiskus W, Khouri M, Islam R, Kantarjian H, Garcia-Manero GAmerican journal of hematologyA phase II study of omacetaxine mepesuccinate for patients with higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agents. Am J Hematol. 2019 01; 94(1):74-79.Am J Hematol2018-11-15T00:00:002018A phase II study of omacetaxine mepesuccinate for patients with higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agents.30114695Rozovski U, Keating MJ, Estrov ZActa haematologicaWhy Is the Immunoglobulin Heavy Chain Gene Mutation Status a Prognostic Indicator in Chronic Lymphocytic Leukemia? Acta Haematol. 2018; 140(1):51-54.Acta Haematol2018-08-16T00:00:002018Why Is the Immunoglobulin Heavy Chain Gene Mutation Status a Prognostic Indicator in Chronic Lymphocytic Leukemia?30115541Kadia TM, Cortes J, Ravandi F, Jabbour E, Konopleva M, Benton CB, Burger J, Sasaki K, Borthakur G, DiNardo CD, Pemmaraju N, Daver N, Ferrajoli A, Wang X, Patel K, Jorgensen JL, Wang S, O'Brien S, Pierce S, Tuttle C, Estrov Z, Verstovsek S, Garcia-Manero G, Kantarjian HThe Lancet. HaematologyCladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial. Lancet Haematol. 2018 Sep; 5(9):e411-e421.Lancet Haematol2018-08-13T00:00:002018Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial.30245189Abaza Y, Hidalgo-Lopez JE, Verstovsek S, Jabbour E, Ravandi F, Borthakur G, Estrov Z, Alvarado Y, Burger J, Schneider H, Soltysiak KA, Wei Y, Kantarjian HM, Bueso-Ramos CE, Garcia-Manero GLeukemia researchPhase I study of ruxolitinib in previously treated patients with low or intermediate-1 risk myelodysplastic syndrome with evidence of NF-kB activation. Leuk Res. 2018 10; 73:78-85.Leuk Res2018-09-14T00:00:002018Phase I study of ruxolitinib in previously treated patients with low or intermediate-1 risk myelodysplastic syndrome with evidence of NF-kB activation.30307606Assi R, Garcia-Manero G, Ravandi F, Borthakur G, Daver NG, Jabbour E, Burger J, Estrov Z, Dinardo CD, Alvarado Y, Hendrickson S, Ferrajoli A, Wierda W, Cortes J, Kantarjian H, Kadia TMCancerAddition of eltrombopag to immunosuppressive therapy in patients with newly diagnosed aplastic anemia. Cancer. 2018 11 01; 124(21):4192-4201.Cancer2018-10-11T00:00:002018Addition of eltrombopag to immunosuppressive therapy in patients with newly diagnosed aplastic anemia.30318751Zulbaran-Rojas A, Lin HK, Shi Q, Williams LA, George B, Garcia-Manero G, Jabbour E, O'Brien S, Ravandi F, Wierda W, Estrov Z, Borthakur G, Kadia T, Cleeland C, Cortes JE, Kantarjian HCancer medicineA prospective analysis of symptom burden for patients with chronic myeloid leukemia in chronic phase treated with frontline second- and third-generation tyrosine kinase inhibitors. Cancer Med. 2018 11; 7(11):5457-5469.Cancer Med2018-10-14T00:00:002018A prospective analysis of symptom burden for patients with chronic myeloid leukemia in chronic phase treated with frontline second- and third-generation tyrosine kinase inhibitors.30319961Boddu P, Borthakur G, Koneru M, Huang X, Naqvi K, Wierda W, Bose P, Jabbour E, Estrov Z, Burger J, Alvarado Y, Deshmukh A, Patel A, Cavazos A, Han L, Cortes JE, Kantarjian H, Andreeff M, Konopleva MFrontiers in oncologyInitial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia. Front Oncol. 2018; 8:369.Front Oncol2018-09-24T00:00:002018Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia.29765537Rozovski U, Harris DM, Li P, Liu Z, Jain P, Ferrajoli A, Burger J, Thompson P, Jain N, Wierda W, Keating MJ, Estrov ZOncotargetSTAT3-activated CD36 facilitates fatty acid uptake in chronic lymphocytic leukemia cells. Oncotarget. 2018 Apr 20; 9(30):21268-21280.Oncotarget2018-04-20T00:00:002018STAT3-activated CD36 facilitates fatty acid uptake in chronic lymphocytic leukemia cells.29769624Thompson PA, Peterson CB, Strati P, Jorgensen J, Keating MJ, O'Brien SM, Ferrajoli A, Burger JA, Estrov Z, Jain N, Kadia TM, Borthakur G, DiNardo CD, Daver N, Jabbour E, Wierda WGLeukemiaSerial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategies. Leukemia. 2018 11; 32(11):2388-2398.Leukemia2018-04-17T00:00:002018Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategies.30028037Ohanian M, Garcia-Manero G, Levis M, Jabbour E, Daver N, Borthakur G, Kadia T, Pierce S, Burger J, Richie MA, Patel K, Andreeff M, Estrov Z, Cortes J, Kantarjian H, Ravandi FAmerican journal of hematologySorafenib Combined with 5-azacytidine in Older Patients with Untreated FLT3-ITD Mutated Acute Myeloid Leukemia. Am J Hematol. 2018 09; 93(9):1136-1141.Am J Hematol2018-08-31T00:00:002018Sorafenib Combined with 5-azacytidine in Older Patients with Untreated FLT3-ITD Mutated Acute Myeloid Leukemia.30152528Jain P, Kanagal-Shamanna R, Konoplev S, Zuo Z, Estrov ZAmerican journal of hematologyBiclonal IGHV-4-34 hairy cell leukemia variant and CLL - successful treatment with ibrutinib and venetoclax. Am J Hematol. 2018 12; 93(12):1568-1569.Am J Hematol2018-10-02T00:00:002018Biclonal IGHV-4-34 hairy cell leukemia variant and CLL - successful treatment with ibrutinib and venetoclax.30745304Veletic I, Manshouri T, Multani AS, Yin CC, Chen L, Verstovsek S, Estrov ZBloodMyelofibrosis osteoclasts are clonal and functionally impaired. Blood. 2019 05 23; 133(21):2320-2324.Blood2019-02-11T00:00:002019Myelofibrosis osteoclasts are clonal and functionally impaired.30508305Kanagal-Shamanna R, Jain P, Patel KP, Routbort M, Bueso-Ramos C, Alhalouli T, Khoury JD, Luthra R, Ferrajoli A, Keating M, Jain N, Burger J, Estrov Z, Wierda W, Kantarjian HM, Medeiros LJCancerTargeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation. Cancer. 2019 02 15; 125(4):559-574.Cancer2018-12-03T00:00:002018Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation.30651532Yilmaz M, Wang F, Loghavi S, Bueso-Ramos C, Gumbs C, Little L, Song X, Zhang J, Kadia T, Borthakur G, Jabbour E, Pemmaraju N, Short N, Garcia-Manero G, Estrov Z, Kantarjian H, Futreal A, Takahashi K, Ravandi FBlood cancer journalLate relapse in acute myeloid leukemia (AML): clonal evolution or therapy-related leukemia? Blood Cancer J. 2019 01 16; 9(2):7.Blood Cancer J2019-01-16T00:00:002019Late relapse in acute myeloid leukemia (AML): clonal evolution or therapy-related leukemia?30530801Burger JA, Sivina M, Jain N, Kim E, Kadia T, Estrov Z, Nogueras-Gonzalez GM, Huang X, Jorgensen J, Li J, Cheng M, Clow F, Ohanian M, Andreeff M, Mathew T, Thompson P, Kantarjian H, O'Brien S, Wierda WG, Ferrajoli A, Keating MJBloodRandomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia. Blood. 2019 03 07; 133(10):1011-1019.Blood2018-12-07T00:00:002018Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia.30545576Short NJ, Kantarjian HM, Loghavi S, Huang X, Qiao W, Borthakur G, Kadia TM, Daver N, Ohanian M, Dinardo CD, Estrov Z, Kanagal-Shamanna R, Maiti A, Benton CB, Bose P, Alvarado Y, Jabbour E, Kornblau SM, Pemmaraju N, Jain N, Gasior Y, Richie MA, Pierce S, Cortes J, Konopleva M, Garcia-Manero G, Ravandi FThe Lancet. HaematologyTreatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial. Lancet Haematol. 2019 Jan; 6(1):e29-e37.Lancet Haematol2018-12-10T00:00:002018Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial.D015451Disorders29023900.403303Leukemia, Lymphocytic, Chronic, B-CellAuthorship 94312921Authorship 9431671230885996Jain P, Kantarjian H, Boddu PC, Nogueras-Gonz?lez GM, Verstovsek S, Garcia-Manero G, Borthakur G, Sasaki K, Kadia TM, Sam P, Ahaneku H, O'Brien S, Estrov Z, Ravandi F, Jabbour E, Cortes JEBlood advancesAnalysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs. Blood Adv. 2019 03 26; 3(6):851-861.Blood Adv2019-03-26T00:00:002019Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs.30924136Hu B, Patel KP, Chen HC, Wang X, Wang F, Luthra R, Routbort MJ, Kanagal-Shamanna R, Medeiros LJ, Yin CC, Zuo Z, Ok CY, Loghavi S, Tang G, Tambaro FP, Thompson P, Burger J, Jain N, Ferrajoli A, Bose P, Estrov Z, Keating MJ, Wierda WGBritish journal of haematologyRoutine sequencing in CLL has prognostic implications and provides new insight into pathogenesis and targeted treatments. Br J Haematol. 2019 06; 185(5):852-864.Br J Haematol2019-03-28T00:00:002019Routine sequencing in CLL has prognostic implications and provides new insight into pathogenesis and targeted treatments.Authorship 944111630185431Masarova L, Verstovsek S, Hidalgo-Lopez JE, Pemmaraju N, Bose P, Estrov Z, Jabbour EJ, Ravandi-Kashani F, Takahashi K, Cortes JE, Ning J, Ohanian M, Alvarado Y, Zhou L, Pierce S, Gergis R, Patel KP, Luthra R, Kadia TM, DiNardo CD, Borthakur G, Bhalla K, Garcia-Manero G, Bueso-Ramos CE, Kantarjian HM, Daver NBloodA phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis. Blood. 2018 10 18; 132(16):1664-1674.Blood2018-09-05T00:00:002018A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis.Authorship 946805931076409Strati P, Takahashi K, Peterson CB, Keating MJ, Thompson PA, Daver NG, Jain N, Burger JA, Estrov Z, O'Brien SM, Kantarjian HM, Wierda WG, Futreal PA, Ferrajoli ABlood advancesEfficacy and predictors of response of lenalidomide and rituximab in patients with treatment-naive and relapsed CLL. Blood Adv. 2019 05 14; 3(9):1533-1539.Blood Adv2019-05-14T00:00:002019Efficacy and predictors of response of lenalidomide and rituximab in patients with treatment-naive and relapsed CLL.19762485Kurtova AV, Balakrishnan K, Chen R, Ding W, Schnabl S, Quiroga MP, Sivina M, Wierda WG, Estrov Z, Keating MJ, Shehata M, J?ger U, Gandhi V, Kay NE, Plunkett W, Burger JABloodDiverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance. Blood. 2009 Nov 12; 114(20):4441-50.Blood2009-09-17T00:00:002009Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance.Authorship 947952831141631Jain N, Keating M, Thompson P, Ferrajoli A, Burger J, Borthakur G, Takahashi K, Estrov Z, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Sasaki K, Kanagal-Shamanna R, Patel K, Jorgensen J, Garg N, Wang X, Sondermann K, Cruz N, Wei C, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda WThe New England journal of medicineIbrutinib and Venetoclax for First-Line Treatment of CLL. N Engl J Med. 2019 05 30; 380(22):2095-2103.N Engl J Med2019-05-30T00:00:002019Ibrutinib and Venetoclax for First-Line Treatment of CLL.Authorship 9506972031243771Hu B, Patel KP, Chen HC, Wang X, Luthra R, Routbort MJ, Kanagal-Shamanna R, Medeiros LJ, Yin CC, Zuo Z, Ok CY, Loghavi S, Tang G, Tambaro FP, Thompson P, Burger J, Jain N, Ferrajoli A, Bose P, Estrov Z, Keating M, Wierda WGBritish journal of haematologyAssociation of gene mutations with time-to-first treatment in 384 treatment-naive chronic lymphocytic leukaemia patients. Br J Haematol. 2019 11; 187(3):307-318.Br J Haematol2019-06-26T00:00:002019Association of gene mutations with time-to-first treatment in 384 treatment-naive chronic lymphocytic leukaemia patients.Authorship 952605931344256Strati P, Wang F, Tambaro FP, Thompson PA, Burger JA, Jain N, Ferrajoli A, Bose P, Estrov Z, Keating MJ, Futreal A, Takahashi K, Wierda WGBritish journal of haematologyThe landscape of genetic mutations in patients with chronic lymphocytic leukaemia and complex karyotype. Br J Haematol. 2019 10; 187(1):e1-e4.Br J Haematol2019-07-25T00:00:002019The landscape of genetic mutations in patients with chronic lymphocytic leukaemia and complex karyotype.Authorship 9536471431400961Ravandi F, Assi R, Daver N, Benton CB, Kadia T, Thompson PA, Borthakur G, Alvarado Y, Jabbour EJ, Konopleva M, Takahashi K, Kornblau S, DiNardo CD, Estrov Z, Flores W, Basu S, Allison J, Sharma P, Pierce S, Pike A, Cortes JE, Garcia-Manero G, Kantarjian HMThe Lancet. HaematologyIdarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study. Lancet Haematol. 2019 Sep; 6(9):e480-e488.Lancet Haematol2019-08-07T00:00:002019Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study.Authorship 955254431502383Abou Dalle I, Kantarjian H, Burger J, Estrov Z, Ohanian M, Verstovsek S, Ravandi F, Borthakur G, Garcia-Manero G, Jabbour E, Cortes JCancer medicineEfficacy and safety of generic imatinib after switching from original imatinib in patients treated for chronic myeloid leukemia in the United States. Cancer Med. 2019 11; 8(15):6559-6565.Cancer Med2019-09-10T00:00:002019Efficacy and safety of generic imatinib after switching from original imatinib in patients treated for chronic myeloid leukemia in the United States.Authorship 9557771131537528Thompson PA, Srivastava J, Peterson C, Strati P, Jorgensen JL, Hether T, Keating MJ, O'Brien SM, Ferrajoli A, Burger JA, Estrov Z, Jain N, Wierda WGBloodMinimal residual disease undetectable by next-generation sequencing predicts improved outcome in CLL after chemoimmunotherapy. Blood. 2019 11 28; 134(22):1951-1959.Blood2019-11-28T00:00:002019Minimal residual disease undetectable by next-generation sequencing predicts improved outcome in CLL after chemoimmunotherapy.Authorship 9559931431553487Naqvi K, Jabbour E, Skinner J, Anderson K, Dellasala S, Yilmaz M, Ferrajoli A, Bose P, Thompson P, Alvarado Y, Jain N, Takahashi K, Burger J, Estrov Z, Borthakur G, Pemmaraju N, Paul S, Cortes J, Kantarjian HMCancerLong-term follow-up of lower dose dasatinib (50?mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia. Cancer. 2020 01 01; 126(1):67-75.Cancer2019-09-25T00:00:002019Long-term follow-up of lower dose dasatinib (50?mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia.Authorship 956220831569199Manshouri T, Verstovsek S, Harris DM, Veletic I, Zhang X, Post SM, Bueso-Ramos CE, Estrov ZPloS onePrimary myelofibrosis marrow-derived CD14+/CD34- monocytes induce myelofibrosis-like phenotype in immunodeficient mice and give rise to megakaryocytes. PLoS One. 2019; 14(9):e0222912.PLoS One2019-09-30T00:00:002019Primary myelofibrosis marrow-derived CD14+/CD34- monocytes induce myelofibrosis-like phenotype in immunodeficient mice and give rise to megakaryocytes.Authorship 9577631431645416Rozovski U, Harris DM, Li P, Liu Z, Jain P, Ferrajoli A, Burger JA, Bose P, Thompson PA, Jain N, Wierda WG, Uziel O, Keating MJ, Estrov ZJournal of immunology (Baltimore, Md. : 1950)STAT3-Induced Wnt5a Provides Chronic Lymphocytic Leukemia Cells with Survival Advantage. J Immunol. 2019 12 01; 203(11):3078-3085.J Immunol2019-10-23T00:00:002019STAT3-Induced Wnt5a Provides Chronic Lymphocytic Leukemia Cells with Survival Advantage.Authorship 9604561831682008Yilmaz M, Kantarjian H, Wang X, Khoury JD, Ravandi F, Jorgensen J, Short NJ, Loghavi S, Cortes J, Garcia-Manero G, Kadia T, Sasaki K, Konopleva M, Takahashi K, Wierda W, Jain N, Verstovsek S, Estrov Z, Bose P, Pierce S, Garris R, O'Brien S, Jabbour EAmerican journal of hematologyThe early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia-negative B-cell acute lymphoblastic leukemia is a strong predictor for survival. Am J Hematol. 2020 02; 95(2):144-150.Am J Hematol2019-11-19T00:00:002019The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia-negative B-cell acute lymphoblastic leukemia is a strong predictor for survival.Authorship 962945831862959Kim E, Ten Hacken E, Sivina M, Clarke A, Thompson PA, Jain N, Ferrajoli A, Estrov Z, Keating MJ, Wierda WG, Bhalla KN, Burger JALeukemiaThe BET inhibitor GS-5829 targets chronic lymphocytic leukemia cells and their supportive microenvironment. Leukemia. 2020 06; 34(6):1588-1598.Leukemia2019-12-20T00:00:002019The BET inhibitor GS-5829 targets chronic lymphocytic leukemia cells and their supportive microenvironment.Authorship 9750921131895947Strati P, Schlette EJ, Solis Soto LM, Duenas DE, Sivina M, Kim E, Keating MJ, Wierda WG, Ferrajoli A, Kantarjian H, Estrov Z, Jain N, Thompson PA, Wistuba II, Burger JABloodAchieving complete remission in CLL patients treated with ibrutinib: clinical significance and predictive factors. Blood. 2020 02 13; 135(7):510-513.Blood2020-02-13T00:00:002020Achieving complete remission in CLL patients treated with ibrutinib: clinical significance and predictive factors.Authorship 9758502631941838Fuentes-Mattei E, Bayraktar R, Manshouri T, Silva AM, Ivan C, Gulei D, Fabris L, Soares do Amaral N, Mur P, Perez C, Torres-Claudio E, Dragomir MP, Badillo-Perez A, Knutsen E, Narayanan P, Golfman L, Shimizu M, Zhang X, Zhao W, Ho WT, Estecio MR, Bartholomeusz G, Tomuleasa C, Berindan-Neagoe I, Zweidler-McKay PA, Estrov Z, Zhao ZJ, Verstovsek S, Calin GA, Redis RSJCI insightmiR-543 regulates the epigenetic landscape of myelofibrosis by targeting TET1 and TET2. JCI Insight. 2020 01 16; 5(1).JCI Insight2020-01-16T00:00:002020miR-543 regulates the epigenetic landscape of myelofibrosis by targeting TET1 and TET2.Authorship 9767279Authorship 9767371431999839Maiti A, Cortes JE, Patel KP, Masarova L, Borthakur G, Ravandi F, Verstovsek S, Ferrajoli A, Estrov Z, Garcia-Manero G, Kadia TM, Nogueras-Gonz?lez GM, Skinner J, Poku R, DellaSala S, Luthra R, Jabbour EJ, O'Brien S, Kantarjian HMCancerLong-term results of frontline dasatinib in chronic myeloid leukemia. Cancer. 2020 04 01; 126(7):1502-1511.Cancer2020-01-30T00:00:002020Long-term results of frontline dasatinib in chronic myeloid leukemia.31999850Masarova L, Cortes JE, Patel KP, O'Brien S, Nogueras-Gonzalez GM, Konopleva M, Verstovsek S, Garcia-Manero G, Ferrajoli A, Kadia TM, Ravandi-Kashani F, Borthakur G, DellaSala S, Estrov Z, Jabbour EJ, Kantarjian HMCancerLong-term results of a phase 2 trial of nilotinib 400?mg twice daily in newly diagnosed patients with chronic-phase chronic myeloid leukemia. Cancer. 2020 04 01; 126(7):1448-1459.Cancer2020-01-30T00:00:002020Long-term results of a phase 2 trial of nilotinib 400?mg twice daily in newly diagnosed patients with chronic-phase chronic myeloid leukemia.Authorship 978511832099037Bose P, Verstovsek S, Cortes JE, Tse S, Gasior Y, Jain N, Jabbour EJ, Estrov Z, Alvarado Y, DiNardo CD, Pemmaraju N, Kornblau SM, Kadia TM, Daver NG, Naqvi K, Short NJ, Masarova L, Villareal J, Pierce SA, Nogueras-Gonzalez G, Huang X, Garcia-Manero G, Kantarjian HM, Ravandi FLeukemiaA phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia. Leukemia. 2020 09; 34(9):2489-2492.Leukemia2020-02-25T00:00:002020A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia.Authorship 979034532157815Hu Z, Wang W, Thakral B, Chen Z, Estrov Z, Bueso-Ramos CE, Verstovsek S, Medeiros LJ, Wang SACytometry. Part B, Clinical cytometryLymphocytic variant of hypereosinophilic syndrome: A report of seven cases from a single institution. Cytometry B Clin Cytom. 2021 05; 100(3):352-360.Cytometry B Clin Cytom2020-03-11T00:00:002020Lymphocytic variant of hypereosinophilic syndrome: A report of seven cases from a single institution.32236406Bose P, McCue D, Wurster S, Wiederhold NP, Konopleva M, Kadia TM, Borthakur G, Ravandi F, Masarova L, Takahashi K, Estrov Z, Yilmaz M, Daver N, Pemmaraju N, Naqvi K, Rausch CR, Marx KR, Qiao W, Huang X, Bivins CA, Pierce SA, Kantarjian HM, Kontoyiannis DPClinical infectious diseases : an official publication of the Infectious Diseases Society of AmericaIsavuconazole as Primary Antifungal Prophylaxis in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-label, Prospective, Phase 2 Study. Clin Infect Dis. 2021 05 18; 72(10):1755-1763.Clin Infect Dis2021-05-18T00:00:002021Isavuconazole as Primary Antifungal Prophylaxis in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-label, Prospective, Phase 2 Study.Authorship 9879051932324887Short NJ, Patel KP, Albitar M, Franquiz M, Luthra R, Kanagal-Shamanna R, Wang F, Assi R, Montalban-Bravo G, Matthews J, Ma W, Loghavi S, Takahashi K, Issa GC, Kornblau SM, Jabbour E, Garcia-Manero G, Kantarjian HM, Estrov Z, Ravandi FBlood advancesTargeted next-generation sequencing of circulating cell-free DNA vs bone marrow in patients with acute myeloid leukemia. Blood Adv. 2020 04 28; 4(8):1670-1677.Blood Adv2020-04-28T00:00:002020Targeted next-generation sequencing of circulating cell-free DNA vs bone marrow in patients with acute myeloid leukemia.Authorship 9920081932546726Issa GC, Kantarjian HM, Xiao L, Ning J, Alvarado Y, Borthakur G, Daver N, DiNardo CD, Jabbour E, Bose P, Jain N, Kadia TM, Naqvi K, Pemmaraju N, Takahashi K, Verstovsek S, Andreeff M, Kornblau SM, Estrov Z, Ferrajoli A, Garcia-Manero G, Ohanian M, Wierda WG, Ravandi F, Cortes JELeukemiaPhase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality. Leukemia. 2020 11; 34(11):2914-2924.Leukemia2020-06-16T00:00:002020Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality.Authorship 9946351232681739Abaza Y, Kantarjian H, Alwash Y, Borthakur G, Champlin R, Kadia T, Garcia-Manero G, Daver N, Ravandi F, Verstovsek S, Burger J, Estrov Z, Ohanian M, Lim M, Pemmaraju N, Jabbour E, Cortes JAmerican journal of hematologyPhase I/II study of dasatinib in combination with decitabine in patients with accelerated or blast phase chronic myeloid leukemia. Am J Hematol. 2020 11; 95(11):1288-1295.Am J Hematol2020-08-12T00:00:002020Phase I/II study of dasatinib in combination with decitabine in patients with accelerated or blast phase chronic myeloid leukemia.Authorship 9950299Authorship 995753632697338Masarova L, Bose P, Pemmaraju N, Daver NG, Zhou L, Pierce S, Sasaki K, Kantarjian HM, Estrov Z, Verstovsek SCancerPrognostic value of blasts in peripheral blood in myelofibrosis in the ruxolitinib era. Cancer. 2020 10 01; 126(19):4322-4331.Cancer2020-07-22T00:00:002020Prognostic value of blasts in peripheral blood in myelofibrosis in the ruxolitinib era.32732359Veletic I, Prijic S, Manshouri T, Nogueras-Gonzalez GM, Verstovsek S, Estrov ZHaematologicaAltered T-cell subset repertoire affects treatment outcome of patients with myelofibrosis. Haematologica. 2021 09 01; 106(9):2384-2396.Haematologica2021-09-01T00:00:002021Altered T-cell subset repertoire affects treatment outcome of patients with myelofibrosis.Authorship 9991302332896301DiNardo CD, Maiti A, Rausch CR, Pemmaraju N, Naqvi K, Daver NG, Kadia TM, Borthakur G, Ohanian M, Alvarado Y, Issa GC, Montalban-Bravo G, Short NJ, Yilmaz M, Bose P, Jabbour EJ, Takahashi K, Burger JA, Garcia-Manero G, Jain N, Kornblau SM, Thompson PA, Estrov Z, Masarova L, Sasaki K, Verstovsek S, Ferrajoli A, Weirda WG, Wang SA, Konoplev S, Chen Z, Pierce SA, Ning J, Qiao W, Ravandi F, Andreeff M, Welch JS, Kantarjian HM, Konopleva MYThe Lancet. Haematology10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. Lancet Haematol. 2020 Oct; 7(10):e724-e736.Lancet Haematol2020-09-05T00:00:00202010-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.Authorship 9998291632955970Yilmaz M, Kantarjian HM, Toruner G, Yin CC, Kanagal-Shamanna R, Cortes JE, Issa G, Short NJ, Khoury JD, Garcia-Manero G, Ravandi F, Kadia T, Konopleva M, Wierda WG, Jain N, Estrov Z, Sasaki K, Pierce S, O'Brien SM, Jabbour EJLeukemia & lymphomaTranslocation t(1;19)(q23;p13) in adult acute lymphoblastic leukemia - a distinct subtype with favorable prognosis. Leuk Lymphoma. 2021 01; 62(1):224-228.Leuk Lymphoma2020-09-21T00:00:002020Translocation t(1;19)(q23;p13) in adult acute lymphoblastic leukemia - a distinct subtype with favorable prognosis.Authorship 1003309833087831Sivina M, Xiao L, Kim E, Vaca A, Chen SS, Keating MJ, Ferrajoli A, Estrov Z, Jain N, Wierda WG, Huang X, Chiorazzi N, Burger JALeukemiaCXCL13 plasma levels function as a biomarker for disease activity in patients with chronic lymphocytic leukemia. Leukemia. 2021 06; 35(6):1610-1620.Leukemia2020-10-21T00:00:002020CXCL13 plasma levels function as a biomarker for disease activity in patients with chronic lymphocytic leukemia.Authorship 10045991833156969Montalban-Bravo G, Kanagal-Shamanna R, Guerra V, Ramos-Perez J, Hammond D, Shilpa P, Naqvi K, Sasaki K, Jabbour E, DiNardo C, Takahashi K, Konopleva M, Pemmaraju N, Kadia T, Ravandi F, Daver N, Borthakur G, Estrov Z, Khoury JD, Loghavi S, Pierce S, Bueso-Ramos C, Patel K, Kantarjian H, Garcia-Manero GAmerican journal of hematologyClinical outcomes and influence of mutation clonal dominance in oligomonocytic and classical chronic myelomonocytic leukemia. Am J Hematol. 2021 02 01; 96(2):E50-E53.Am J Hematol2020-11-21T00:00:002020Clinical outcomes and influence of mutation clonal dominance in oligomonocytic and classical chronic myelomonocytic leukemia.Authorship 1008866733449377Abou Dalle I, Kantarjian HM, Ravandi F, Daver N, Wang X, Jabbour E, Estrov Z, DiNardo CD, Pemmaraju N, Ferrajoli A, Jain N, Wang SA, Jammal N, Borthakur G, Naqvi K, Pelletier S, Pierce S, Andreeff M, Garcia-Manero G, Cortes JE, Kadia TMCancerPhase 2 study of lenalidomide maintenance for patients with high-risk acute myeloid leukemia in remission. Cancer. 2021 06 01; 127(11):1894-1900.Cancer2021-01-15T00:00:002021Phase 2 study of lenalidomide maintenance for patients with high-risk acute myeloid leukemia in remission.Authorship 1010863833551345Masarova L, Bose P, Pemmaraju N, Daver N, Zhou L, Pierce S, Kantarjian H, Estrov Z, Verstovsek SClinical lymphoma, myeloma & leukemiaClinical Significance of Bone Marrow Blast Percentage in Patients With Myelofibrosis and the Effect of Ruxolitinib Therapy. Clin Lymphoma Myeloma Leuk. 2021 05; 21(5):318-327.e6.Clin Lymphoma Myeloma Leuk2021-01-06T00:00:002021Clinical Significance of Bone Marrow Blast Percentage in Patients With Myelofibrosis and the Effect of Ruxolitinib Therapy.Authorship 10143011533747356Rozovski U, Harris DM, Li P, Liu Z, Jain P, Manshouri T, Veletic I, Ferrajoli A, Bose P, Thompson P, Jain N, Verstovsek S, Wierda W, Keating MJ, Estrov ZOncotargetSTAT3 induces the expression of GLI1 in chronic lymphocytic leukemia cells. Oncotarget. 2021 Mar 02; 12(5):401-411.Oncotarget2021-03-02T00:00:002021STAT3 induces the expression of GLI1 in chronic lymphocytic leukemia cells.Authorship 101620817Authorship 10163171733846541Montalban-Bravo G, Hammond D, DiNardo CD, Konopleva M, Borthakur G, Short NJ, Ramos-Perez J, Guerra V, Kanagal-Shamanna R, Naqvi K, Sasaki K, Jabbour E, Pemmaraju N, Kadia TM, Ravandi F, Daver N, Estrov Z, Pierce S, Kantarjian H, Garcia-Manero GLeukemiaActivity of venetoclax-based therapy in chronic myelomonocytic leukemia. Leukemia. 2021 05; 35(5):1494-1499.Leukemia2021-04-12T00:00:002021Activity of venetoclax-based therapy in chronic myelomonocytic leukemia.33853292Swaminathan M, Kantarjian HM, Levis M, Guerra V, Borthakur G, Alvarado Y, DiNardo CD, Kadia T, Garcia-Manero G, Ohanian M, Daver N, Konopleva M, Pemmaraju N, Ferrajoli A, Andreeff M, Jain N, Estrov Z, Jabbour EJ, Wierda WG, Pierce S, Pinsoy MR, Xiao L, Ravandi F, Cortes JEHaematologicaA phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Haematologica. 2021 08 01; 106(8):2121-2130.Haematologica2021-08-01T00:00:002021A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome.Authorship 10167991033885751Masarova L, DiNardo CD, Bose P, Pemmaraju N, Daver NG, Kadia TM, Chifotides HT, Zhou L, Borthakur G, Estrov Z, Konopleva M, Verstovsek SBlood advancesSingle-center experience with venetoclax combinations in patients with newly diagnosed and relapsed AML evolving from MPNs. Blood Adv. 2021 04 27; 5(8):2156-2164.Blood Adv2021-04-27T00:00:002021Single-center experience with venetoclax combinations in patients with newly diagnosed and relapsed AML evolving from MPNs.Authorship 101707717Authorship 10172601533901324Kadia TM, Ravandi F, Borthakur G, Konopleva M, DiNardo CD, Daver N, Pemmaraju N, Kanagal-Shamanna R, Wang X, Huang X, Pierce S, Rausch C, Burger J, Ferrajoli A, Jain N, Popat U, Estrov Z, Verstovsek S, Jabbour E, Garcia-Manero G, Kantarjian HAmerican journal of hematologyLong-term results of low-intensity chemotherapy with clofarabine or cladribine combined with low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia. Am J Hematol. 2021 08 01; 96(8):914-924.Am J Hematol2021-05-26T00:00:002021Long-term results of low-intensity chemotherapy with clofarabine or cladribine combined with low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia.33914911Montalban-Bravo G, Kanagal-Shamanna R, Sasaki K, Masarova L, Naqvi K, Jabbour E, DiNardo CD, Takahashi K, Konopleva M, Pemmaraju N, Kadia TM, Ravandi F, Daver N, Borthakur G, Estrov Z, Khoury JD, Loghavi S, Soltysiak KA, Pierce S, Bueso-Ramos C, Patel KP, Verstovsek S, Kantarjian HM, Bose P, Garcia-Manero GCancerClinicopathologic correlates and natural history of atypical chronic myeloid leukemia. Cancer. 2021 09 01; 127(17):3113-3124.Cancer2021-04-29T00:00:002021Clinicopathologic correlates and natural history of atypical chronic myeloid leukemia.Authorship 1018242933973230Cherng HJ, Jammal N, Paul S, Wang X, Sasaki K, Thompson P, Burger J, Ferrajoli A, Estrov Z, O'Brien S, Keating M, Wierda WG, Jain NBritish journal of haematologyClinical and molecular characteristics and treatment patterns of adolescent and young adult patients with chronic lymphocytic leukaemia. Br J Haematol. 2021 07; 194(1):61-68.Br J Haematol2021-05-10T00:00:002021Clinical and molecular characteristics and treatment patterns of adolescent and young adult patients with chronic lymphocytic leukaemia.Authorship 101862611Authorship 1018875634007049Jain N, Thompson P, Burger J, Ferrajoli A, Takahashi K, Estrov Z, Borthakur G, Bose P, Kadia T, Pemmaraju N, Sasaki K, Konopleva M, Jabbour E, Garg N, Wang X, Kanagal-Shamanna R, Patel K, Wang W, Jorgensen J, Wang S, Lopez W, Ayala A, Plunkett W, Gandhi V, Kantarjian H, O'Brien S, Keating M, Wierda WGLeukemiaIbrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations. Leukemia. 2021 12; 35(12):3421-3429.Leukemia2021-05-18T00:00:002021Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations.Authorship 1020762834110383Jain N, Keating M, Thompson P, Ferrajoli A, Burger JA, Borthakur G, Takahashi K, Estrov Z, Sasaki K, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Kanagal-Shamanna R, Patel K, Wang W, Jorgensen J, Wang SA, Garg N, Wang X, Wei C, Cruz N, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda WGJAMA oncologyIbrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial. JAMA Oncol. 2021 Aug 01; 7(8):1213-1219.JAMA Oncol2021-08-01T00:00:002021Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial.Authorship 10282201534424319Pemmaraju N, Carter BZ, Bose P, Jain N, Kadia TM, Garcia-Manero G, Bueso-Ramos CE, DiNardo CD, Bledsoe S, Daver NG, Popat U, Konopleva MY, Zhou L, Pierce S, Estrov ZE, Borthakur GM, Ohanian M, Qiao W, Masarova L, Wang X, Mak PY, Cortes J, Jabbour E, Verstovsek SBlood advancesFinal results of a phase 2 clinical trial of LCL161, an oral SMAC mimetic for patients with myelofibrosis. Blood Adv. 2021 08 24; 5(16):3163-3173.Blood Adv2021-08-24T00:00:002021Final results of a phase 2 clinical trial of LCL161, an oral SMAC mimetic for patients with myelofibrosis.Authorship 103977710Authorship 1040515935077575Masarova L, Bose P, Pemmaraju N, Daver NG, Sasaki K, Chifotides HT, Zhou L, Kantarjian HM, Estrov Z, Verstovsek SCancerImproved survival of patients with myelofibrosis in the last decade: Single-center experience. Cancer. 2022 04 15; 128(8):1658-1665.Cancer2022-01-25T00:00:002022Improved survival of patients with myelofibrosis in the last decade: Single-center experience.35149845Vaca AM, Ioannou N, Sivina M, Vlachonikola E, Clise-Dwyer K, Kim E, Li D, Ma Q, Ferrajoli A, Estrov Z, Wierda WG, Patten PEM, Ramsay AG, Burger JALeukemiaActivation and expansion of T-follicular helper cells in chronic lymphocytic leukemia nurselike cell co-cultures. Leukemia. 2022 05; 36(5):1324-1335.Leukemia2022-02-11T00:00:002022Activation and expansion of T-follicular helper cells in chronic lymphocytic leukemia nurselike cell co-cultures.Authorship 10441741535442137Short NJ, Borthakur G, Pemmaraju N, Dinardo CD, Kadia TM, Jabbour E, Konopleva M, Macaron W, Ning J, Ma J, Pierce S, Alvarado Y, Sasaki K, Takahashi K, Estrov Z, Masarova L, Issa GC, Montalban-Bravo G, Andreeff M, Burger JA, Miller D, Alexander L, Naing A, Garcia-Manero G, Ravandi F, Daver NLeukemia & lymphomaA multi-arm phase Ib/II study designed for rapid, parallel evaluation of novel immunotherapy combinations in relapsed/refractory acute myeloid leukemia. Leuk Lymphoma. 2022 09; 63(9):2161-2170.Leuk Lymphoma2022-04-20T00:00:002022A multi-arm phase Ib/II study designed for rapid, parallel evaluation of novel immunotherapy combinations in relapsed/refractory acute myeloid leukemia.21868570Naqvi K, Jabbour E, Bueso-Ramos C, Pierce S, Borthakur G, Estrov Z, Ravandi F, Faderl S, Kantarjian H, Garcia-Manero GBloodImplications of discrepancy in morphologic diagnosis of myelodysplastic syndrome between referral and tertiary care centers. Blood. 2011 Oct 27; 118(17):4690-3.Blood2011-08-25T00:00:002011Implications of discrepancy in morphologic diagnosis of myelodysplastic syndrome between referral and tertiary care centers.16078266Verstovsek S, Golemovic M, Kantarjian H, Manshouri T, Estrov Z, Manley P, Sun T, Arlinghaus RB, Alland L, Dugan M, Cortes J, Giles F, Beran MCancerAMN107, a novel aminopyrimidine inhibitor of p190 Bcr-Abl activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cells. Cancer. 2005 Sep 15; 104(6):1230-6.Cancer2005-09-15T00:00:002005AMN107, a novel aminopyrimidine inhibitor of p190 Bcr-Abl activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cells.Authorship 10459398Authorship 104627916Authorship 1046287735595309Rozovski U, Veletic I, Harris DM, Li P, Liu Z, Jain P, Manshouri T, Ferrajoli A, Burger JA, Bose P, Thompson PA, Jain N, Wierda WG, Verstovsek S, Keating MJ, Estrov ZJournal of immunology (Baltimore, Md. : 1950)STAT3 Activates the Pentraxin 3 Gene in Chronic Lymphocytic Leukemia Cells. J Immunol. 2022 06 15; 208(12):2847-2855.J Immunol2022-05-20T00:00:002022STAT3 Activates the Pentraxin 3 Gene in Chronic Lymphocytic Leukemia Cells.35595725Manshouri T, Veletic I, Li P, Yin CC, Post SM, Verstovsek S, Estrov ZCell death & diseaseGLI1 activates pro-fibrotic pathways in myelofibrosis fibrocytes. Cell Death Dis. 2022 May 20; 13(5):481.Cell Death Dis2022-05-20T00:00:002022GLI1 activates pro-fibrotic pathways in myelofibrosis fibrocytes.35567779Cherng HJ, Khwaja R, Kanagal-Shamanna R, Tang G, Burger J, Thompson P, Ferrajoli A, Estrov Z, Sasaki K, Sampath D, Wang X, Kantarjian H, Keating M, Wierda WG, Jain NAmerican journal of hematologyTP53-altered chronic lymphocytic leukemia treated with firstline Bruton's tyrosine kinase inhibitor-based therapy: A retrospective analysis. Am J Hematol. 2022 08; 97(8):1005-1012.Am J Hematol2022-05-30T00:00:002022TP53-altered chronic lymphocytic leukemia treated with firstline Bruton's tyrosine kinase inhibitor-based therapy: A retrospective analysis.Authorship 1073408937243913Masarova L, Bose P, Pemmaraju N, Daver NG, Sasaki K, Chifotides HT, Zhou L, Kantarjian HM, Estrov Z, Verstovsek SCancerThe role of therapy in the outcome of patients with myelofibrosis. Cancer. 2023 09 15; 129(18):2828-2835.Cancer2023-05-27T00:00:002023The role of therapy in the outcome of patients with myelofibrosis.Authorship 1079062637699357Masarova L, Bose P, Pemmaraju N, Zhou L, Pierce S, Estrov Z, Kantarjian H, Verstovsek SActa haematologicaRelevant Clinical Factors in Patients with Myelofibrosis on Ruxolitinib for 5 or More Years. Acta Haematol. 2023; 146(6):522-529.Acta Haematol2023-09-12T00:00:002023Relevant Clinical Factors in Patients with Myelofibrosis on Ruxolitinib for 5 or More Years.Authorship 10886322638329131Fuentes-Mattei E, Bayraktar R, Manshouri T, Silva AM, Ivan C, Gulei D, Fabris L, Soares do Amaral N, Mur P, Perez C, Torres-Claudio E, Dragomir MP, Badillo-Perez A, Knutsen E, Narayanan P, Golfman L, Shimizu M, Zhang X, Zhao W, Ho WT, Estecio MR, Bartholomeusz G, Tomuleasa C, Berindan-Neagoe I, Zweidler-McKay PA, Estrov Z, Zhao ZJ, Verstovsek S, Calin GA, Redis RSJCI insightmiR-543 regulates the epigenetic landscape of myelofibrosis by targeting TET1 and TET2. JCI Insight. 2024 Feb 08; 9(3).JCI Insight2024-02-08T00:00:002024miR-543 regulates the epigenetic landscape of myelofibrosis by targeting TET1 and TET2.true1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessor23829280Jain P, Baez-Vallecillo L, Huh YO, Benjamini O, Abruzzo L, O'Brien S, Pemmaraju N, Keating M, Gagel RF, Estrov ZLeukemia & lymphomaAtypical chronic lymphocytic leukemia with polyglandular autoimmune endocrinopathy type II: a complex profile. Leuk Lymphoma. 2014 Apr; 55(4):944-6.Leuk Lymphoma2014-01-24T00:00:002014Atypical chronic lymphocytic leukemia with polyglandular autoimmune endocrinopathy type II: a complex profile.24487412Ravandi F, Arana Yi C, Cortes JE, Levis M, Faderl S, Garcia-Manero G, Jabbour E, Konopleva M, O'Brien S, Estrov Z, Borthakur G, Thomas D, Pierce S, Brandt M, Pratz K, Luthra R, Andreeff M, Kantarjian HLeukemiaFinal report of phase II study of sorafenib, cytarabine and idarubicin for initial therapy in younger patients with acute myeloid leukemia. Leukemia. 2014 Jul; 28(7):1543-5.Leukemia2014-02-03T00:00:002014Final report of phase II study of sorafenib, cytarabine and idarubicin for initial therapy in younger patients with acute myeloid leukemia.